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  Abstract	  
Cardiac	  Resynchronisation	   therapy	   (CRT)	   is	   an	   established	   treatment	   for	   heart	  failure	  patients	  with	   severe	   left	   ventricular	   (LV)	  dysfunction	   and	  widened	  QRS	  duration.	  Response	  to	  CRT	  remains	  variable.	  Up	  to	  30%	  of	  patients	  do	  not	  gain	  symptomatic	  benefit	  with	  numbers	  that	  fail	  to	  reverse	  remodel	  (RR)	  even	  higher.	  Strategies	  to	  improve	  response	  rates	  have	  focused	  on	  pre-­‐implant	  dyssynchrony	  following	   assumption	   that	   electrical	   dyssynchrony	   translates	   into	   mechanical	  dyssynchrony.	  Other	   factors	   that	   influence	  outcome	  are	  presence	  of	  myocardial	  scar	  and	  LV	  lead	  position.	  	  	  Cardiac	   magnetic	   resonance	   (CMR)	   imaging	   can	   quantify	   global	   myocardial	  dyssynchrony	   in	   different	   modalities;	   volume	   change,	   muscle	   thickening	   and	  strain.	  Understanding	  how	  these	  measures	  of	  dyssynchrony	  relate	  to	  each	  other	  is	  important	  when	  considering	  how	  they	  can	  assist	  patient	  selection.	  In	  addition	  the	  role	  of	  CMR	  to	  assess	  cardiac	  anatomy	  and	  scar	  means	  that	  it	  is	  ideally	  placed	  as	   an	   imaging	   modality	   to	   provide	   comprehensive	   evaluation	   of	   heart	   failure	  patients	  prior	  to	  CRT.	  	  This	   thesis	  aims	   to	  explore	   the	   feasibility	  of	  using	  CMR	   imaging	  as	  an	   inclusive	  imaging	  method	  to	  assess	  patients	  for	  CRT.	  	  	  Forty-­‐eight	   patients	   fulfilling	   the	   criteria	   for	   CRT	   were	   recruited	   (43	   male,	  63.8±13.9	   years).	   25	   had	   dilated	   cardiomyopathy	   (DCM)	   and	   23	   ischaemic	  cardiomyopathy	   (ICM).	   All	   patients	   underwent	   a	   CMR	   and	   echocardiographic	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assessment	  prior	  to	  CRT	  implantation	  and	  were	  followed	  up	  six	  months	  later	  to	  assess	   clinical	   response	   and	   RR	   (reduction	   of	   greater	   than	   15%	   end	   systolic	  volume	   (ESV)	   on	   echocardiography).	   A	   sub	   group	   of	   the	   patients	   had	   invasive	  measurements	  during	  the	  CRT	  implant	  with	  a	  pressure	  wire	  in	  the	  LV	  measuring	  LV-­‐dP/dtmax	  and	  a	  further	  sub	  group	  had	  non-­‐contact	  mapping	  (NCM)	  performed	  to	  assess	  the	  electrical	  activation	  patterns	  to	  different	  pacing	  modes.	  	  	  A	  CMR	  examination	  framework	  allowing	  global	  assessment	  of	  dyssynchrony	  for	  volume	  change,	  muscle	   thickening	  and	  strain	  as	  well	  as	  coronary	  vein	  anatomy	  and	  myocardial	   scar	  was	  used.	  Developments	   in	   image	   segmentation	   tools	   and	  registration	  allowed	  the	  information	  from	  the	  CMR	  anatomy,	  scar	  and	  motion	  to	  be	  used	  during	  the	  implantation	  of	  the	  CRT	  devices.	  	  	  I	   found	   volume	   derived	   systolic	   dyssynchrony	   index	   (SDI)	   predicted	   an	   acute	  haemodynamic	   response	   (AHR)	   (P=0.008)	   and	   strongly	   predicted	   RR	  (P<0.0001).	   Receiver	   operator	   characteristics	   (ROC)	   analysis	   showed	   a	   SDI	   of	  ≥10%	   was	   highly	   sensitive	   (0.94)	   and	   specific	   (0.87)	   for	   predicting	   which	  patients	   are	   likely	   to	   RR.	   SDI	   from	   volume	   dyssynchrony	   was	   superior	   to	  measures	   of	   myocardial	   strain	   and	   muscle	   thickening	   at	   predicting	   acute	  response	  to	  CRT	  and	  RR.	  Further	  more	  I	   found	  that	  ≥	  10%	  raise	  in	  LV-­‐dP/dtmax	  predicted	  RR	   for	  DDDLV	  pacing	   (p<0.001).	  AHR predicted RR in both	  DCM and 
ICM (P=0.01 & P=0.006).	  
  Thirteen	   patients	   underwent	   pre-­‐implant	   NCM.	   Abnormal	   septal	  motion	   called	  the	   septal	   flash	   (SF)	  was	   defined	   from	   echo	   images	   both	   visually	   and	  with	  M-­‐
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mode	  and	  fused	  with	  NCM	  bull’s	  eye	  plots	  of	  endocardial	  activation	  patterns.	  Five	  patients	  had	  a	  large	  SF,	  four	  small	  SF	  and	  four	  no	  SF.	  Patients	  with	  large	  SF	  had	  areas	  of	  conduction	  block	  in	  non-­‐infarcted	  regions	  whereas	  those	  with	  small	  or	  no	   SF	   did	   not.	   Patients	   with	   large	   SF	   had	   greater	   acute	   response	   to	   LV	   and	  biventricular	  pacing	  versus	   those	  with	  small/no	  SF	  (%	   increase	  dP/dt	  28±14%	  vs	  11±19%	  for	  LV	  pacing	  and	  42±28%	  vs	  22±21%	  for	  BIV	  pacing).	  The	  lines	  of	  conduction	  block	  disappeared	  after	  LV	  and	  BIV	  pacing,	  while	  remaining	  present	  with	  RV	  pacing.	  	  	  With	   the	   development	   of	   the	   CMR	   protocols	   I	   showed	   it	   is	   feasible	   to	   image	  coronary	  sinus	  (CS),	  coronary	  veins	  and	  scar	  in	  a	  single	  CMR	  examination.	  Using	  experimental	   image	   registration	   and	   segmentation	   software	   12	   patients	   had	  anatomical	  models	  of	   the	   cardiac	   chambers,	  CS	  and	  branches	  overlaid	  onto	   the	  live	  fluoroscopy	  using	  a	  prototype	  version	  of	  the	  Philips	  EP	  Navigator	  software	  to	  guide	   lead	   implantation.	   I	   achieved	   high	   fidelity	   segmentations	   of	   cardiac	  chambers,	   CS	   anatomy	   and	   accurate	   registration	   between	   the	   3D	   anatomical	  models	  and	  the	  live	  fluoroscopy	  in	  all	  12	  patients	  confirmed	  by	  balloon	  occlusion	  angiography.	  The	  CS	  was	  cannulated	  successfully	  in	  every	  patient,	  and	  in	  all	  but	  one	  an	  LV	  lead	  was	  implanted	  successfully.	  (one	  patient	  had	  no	  acceptable	   lead	  values	  due	  to	  extensive	  myocardial	  scar).	  	  This	   thesis	   shows	   it	   is	   feasible	   to	   use	   CMR	   as	   an	   inclusive	   imaging	  method	   to	  assess	   myocardial	   motion,	   coronary	   vein	   anatomy	   and	   scar,	   and	   thus	   has	  significant	  clinical	  benefits	  when	  assessing	  which	  patients	  will	  RR	  post	  CRT.	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Table	  20	  	   Acute	  haemodynamic	  response	  with	  different	  pacing	  modes	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Chapter	  1	  
Summary	  of	  Thesis	  
	  
Introduction	  Cardiac	   resynchronisation	   therapy	   offers	   reduction	   in	  morbidity	   and	  mortality	  for	  patients	  with	  significant	  LV	  dysfunction,	  advanced	  symptomatic	  heart	  failure	  and	  conduction	  delay	  on	  the	  surface	  ECG.	  Under	  current	  selection	  criteria	  there	  unfortunately	   remain	   a	   significant	   proportion	   of	   patients	   that	   do	   not	   derive	  clinical	  benefit,	  and	  the	  numbers	  that	  do	  not	  RR	  are	  even	  higher.	  	  This	   has	   led	   to	   a	   large	   amount	   of	   research	   to	   develop	   strategies	   that	   improve	  patient	   selection.	  Much	  of	   this	  work	  has	   focused	  on	  measures	  of	  dyssynchrony	  derived	  from	  echocardiography.	  Although	  single	  centre	  trials	  have	  been	  positive	  these	  findings	  have	  not	  been	  reproduced	  in	  large	  multicentre	  trials.	  The	  reasons	  that	   echocardiographic	  measures	   of	   dyssynchrony	   do	   not	   aid	   patient	   selection	  include	  poor	  reproducibility	  of	  techniques	  as	  well	  as	  over	  simplifying	  assessment	  of	  myocardial	  motion.	  	  	  Furthermore	  the	  relationship	  between	  electrical	  and	  mechanical	  dyssynchrony	  is	  not	   fully	   understood,	   along	   with	   the	   relationship	   between	   dyssynchrony	   and	  cardiac	  motion.	  In	  addition	  echocardiography	  does	  not	  take	  into	  account	  cardiac	  anatomy,	   in	   particular	   that	   of	   the	   coronary	   veins,	   myocardial	   scar	   and	   their	  relationship	  with	  each	  other.	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  Developments	   in	  CMR	   imaging	  have	   led	   to	   it	  becoming	  an	   increasingly	   integral	  imaging	  modality	  in	  the	  assessment	  of	  heart	  failure.	  The	  superior	  image	  quality	  means	   that	   CMR	   has	   the	   potential	   to	   answer	   many	   of	   the	   questions	   left	  unanswered	   by	   echocardiographic	   studies.	   With	   this	   comes	   the	   potential	   to	  improve	  patient	  selection	  and	  improve	  response	  rates	  to	  CRT.	  	  
Methods	  Patients	  with	   heart	   failure	   fulfilling	   the	   criteria	   for	   CRT	  were	   recruited	   (NYHA	  class	  III	  or	  IV,	  EF	  <	  35%,	  QRS	  duration	  >	  120ms).	  All	  patients	  were	  assessed	  pre	  CRT	  implantion	  using	  the	  Minnesota	   living	  with	  heart	  failure	  questionnaire	  and	  six-­‐minute	  walk.	  A	  full	  echo	  study	  was	  performed	  including	  TDI,	  speckle	  tracking	  and	   3D	   SDI.	   Patients	   were	   then	   followed	   up	   at	   six	   months	   with	   the	   same	  assessments.	  	  All	  patients	  underwent	  a	  CMR	  on	  a	  1.5T	  MR-­‐scanner	  (Achieva,	  Philips	  Healthcare,	  Best,	   Netherlands)	   with	   a	   32-­‐element	   cardiac	   coil	   or	   a	   5-­‐element	   cardiac	   coil	  (large	   or	   claustrophobia	   patients).	   An	   all-­‐inclusive	   CMR	   examination	   was	  developed	  for	  this	  project	  that	  included	  anatomical	  (coronary	  veins),	  functional,	  motion	  and	  scar	  assessment.	  	  	  During	   implantation	   acute	   response	   to	   CRT	   was	   determined	   using	   a	   pressure	  wire	  within	   the	  LV,	   and	   long-­‐term	   response	  was	  measured	  by	   improvement	   in	  clinical	  indices	  and	  RR	  governed	  by	  reduction	  in	  ESV	  at	  six	  months.	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  CMR	   images	   were	   post-­‐processed	   with	   respect	   to	   anatomical	   assessment	   of	  coronary	   veins	   and	   relationship	   to	   late	   gadolinium	   enhancement.	   Motion	   and	  dyssynchrony	  assessment	  was	  performed	  semi	  automotively	  using	  both	  cine	  and	  tagged	   imaging.	   Various	   indices	   of	   myocardial	   motion	   were	   measured	   and	  compared	   including	   endocardial	   volume	   change,	   muscle	   thickening,	   and	   strain	  (longitudinal,	   circumferential,	   radial	   and	   combined).	   These	   indices	   were	   then	  used	   to	   understand	   the	   relationship	  with	   each	   other	   and	   how	   they	  may	   aid	   in	  improving	  patient	  selection	  to	  CRT.	  	  In	   order	   to	   study	   the	   relationship	   between	   electrical	   and	   mechanical	  dyssynchrony	  a	  small	  group	  of	  patients	  underwent	  non-­‐contact	  mapping	  which	  was	  compared	  to	  the	  echocardiographic	  mechanical	  motion.	  
Results	  A	   protocol	   was	   developed	   that	   allowed	   assessment	   of	   myocardial	  motion/dyssynchrony	  and	  cardiac	  anatomy	  (including	  scar	  and	  coronary	  veins)	  in	  a	  single	  CMR	  examination.	  	  Relating	   non-­‐contact	  mapping	   to	   echocardiography	   and	  CMR	   images	   allowed	   a	  relationship	   between	   the	   electrical	   activation	   patterns	   of	   the	   left	   ventricle	   and	  septal	  motion	  to	  be	  demonstrated.	  	  I	   demonstrated	   volume-­‐derived	   measures	   of	   dyssynchrony.	   The	   systolic	  dyssynchrony	  index	  strongly	  predicted	  both	  an	  acute	  response	  to	  LV	  pacing,	  and	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RR	  at	  six	  months	  (≥	  10%	  rise	  in	  LV-­‐dP/dtmax	  from	  baseline	  pacing	  with	  LV	  pacing	  was	  highly	  predictive	  of	  RR	  at	  six	  months).	  	  	  Using	  novel	  image	  segmentation	  and	  registration	  tools	  I	  showed	  it	   is	  feasible	  to	  incorporate	  the	   information	  from	  CMR	  with	  regards	  to	  myocardial	  motion,	  scar	  and	  vein	  anatomy	  during	  the	  CRT	  implantation	  procedure	  to	  aid	  LV	  lead	  position.	  
Conclusions	  The	  work	  in	  this	  thesis	  shows	  how	  CMR	  can	  be	  used	  as	  an	  all-­‐inclusive	  imaging	  technique	   to	   improve	   patient	   selection	   for	   CRT.	   By	   developing	   new	   image	  processing	  techniques	  it	   is	  possible	  to	  explain	  the	  relationship	  between	  various	  indices	   of	   dyssynchrony	   and	   which	   are	   likely	   to	   be	   helpful	   in	   assessing	   and	  improving	   patient	   selection	   pre	   CRT.	   It	   is	   also	   feasible	   to	   use	   the	   information	  about	   anatomy	   and	   motion	   to	   aid	   in	   the	   CRT	   implantation	   with	   novel	   image	  segmentation	  and	  registration	  tools.	  
Key	  words	  Cardiac	   resynchronisation	   therapy,	   Heart	   failure,	   Dyssynchrony,	   Left	   ventricle,	  Myocardial	  scar.	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Aims	  of	  Thesis	  The	   aim	   of	   the	   work	   in	   this	   thesis	   is	   to	   demonstrate	   the	   feasibility	   of	   using	  cardiac	  magnetic	  resonance	  imaging	  as	  comprehensive	  imaging	  method	  to	  assess	  patients	  for	  cardiac	  resynchronisation	  therapy.	  	  	  The	  thesis	  focuses	  on	  a	  number	  of	  key	  areas;	  	  1. Using	  CMR	  to	  measure	  myocardial	  motion/dyssynchrony	  and	  explain	  how	  these	  measures	  related	  to	  each	  other,	  and	  the	  potential	  of	  using	  them	  to	  predict	  which	  patients	  are	  likely	  to	  respond	  to	  CRT.	  2. The	  relationship	  between	  electrical	  and	  mechanical	  dyssynchrony.	  3. The	  relationship	  between	  acute	  and	  chronic	  response	  to	  CRT.	  4. The	  development	  of	  a	  comprehensive	  CMR	  examination	  to	  image	  cardiac	  anatomy	  of	  the	  coronary	  veins	  and	  myocardial	  scar	  as	  well	  as	  mechanical	  motion	  in	  a	  single	  examination.	  5. The	  potential	  to	  register	  CMR	  information	  on	  coronary	  vein	  anatomy,	  scar	  position	   and	  mechanical	   motion	   during	   a	   real	   time	   implant	   to	   improve	  procedure	  success	  rates	  and	  overall	  long-­‐term	  response.	  	  
Ethics	  All	  studies	  in	  this	  thesis	  complied	  with	  the	  local	  ethics	  committees	  and	  informed	  consent	  was	  obtained	  from	  each	  patient.	  See	  appendix	  2.	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Contribution	  of	  Candidate	  and	  Colleagues	  By	  its	  nature,	  this	  work	  could	  not	  have	  been	  done	  without	  the	  involvement	  of	  a	  large	  number	  of	  basic	  scientists	  and	  clinical	  colleagues.	  This	  section	  describes	  my	  contribution	  and	   the	   contribution	  of	  my	  many	  colleagues	  who	  were	   involved.	   I	  had	  a	  key	  scientific	  contribution	  in	  all	  of	  the	  work	  in	  this	  thesis	  and	  none	  of	  the	  work	  would	  have	  happened	  without	  my	  input.	  
Setting	  up	  the	  Program	  The	   Imaging	   Sciences	   department	   is	   a	  multidisciplinary	   collaboration	   between	  basic	  and	  clinical	  scientists.	  This	  work	  would	  not	  have	  been	  possible	  without	  the	  contributions	   from	   all	   of	   these	   skill	   bases.	   Professor	   Razavi	   proposed	   and	  acquired	  the	  grant	  that	  funded	  this	  work.	  I	  wrote	  and	  submitted	  the	  ethics.	  With	  the	   help	   of	   Professor	   Razavi,	   Professor	   Schaeffter	   and	   Dr	   Carr-­‐White	   we	  developed	   an	   all-­‐inclusive	   imaging	   protocol	   and	   CRT	   assessment	   for	   patients	  recruited	  into	  the	  research.	  I	  was	  instrumental	  in	  setting	  up	  an	  assessment	  clinic	  for	  patients	  pre	  and	  post	  CRT	  to	  enable	  appropriate	  assessment	  and	  follow	  up	  of	  all	  patients	  with	  CRT	  implants.	  	  Dr	  Aldo	  Rinaldi	  was	   instrumental	   in	  development	  of	   some	  of	   the	  methodology,	  particularly	  with	   respect	   to	   acute	  haemodynamic	   response	  and	  overlay	   studies	  where	  he	  was	  the	  main	  implanter.	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Clinical	  Data	  Acquisition	  Several	   researchers	  working	   in	   this	  group	  contributed	   to	   the	  work	  described.	   I	  was	   involved	   in	   all	   parts	   of	   this	   work	   from	   patient	   recruitment	   to	   data	  acquisition	  and	  analysis.	  	  Dr	   Matthew	   Ginks	   and	   Dr	   Anoop	   Shetty,	   clinical	   research	   fellows	   working	   in	  imaging	  sciences,	  helped	  with	  patient	  recruitment	  and	  data	  acquisition.	  	  	  Eliane	   Cuncliffe	   and	  Hollie	   Butler,	   echocardiography	   technicians,	   helped	   in	   the	  acquisition	  of	  the	  echo	  data.	  Stephen	  Sinclair	  and	  John	  Totman,	  CMR	  technicians,	  helped	   in	   the	   acquisition	   of	   the	   MRI	   data.	   Julian	   Bostock,	   electrophysiologist,	  helped	  in	  the	  acquisition	  of	  pressure	  wire	  and	  Ensite	  mapping	  data.	  
Data	  Analysis	  Dr	   Amedeo	   Chiribiri,	   a	   clinical	   research	   fellow,	   helped	   with	   CMR	   analysis,	  particularly	  of	  the	  coronary	  veins.	  	  Benjamin	   Knowles,	   YingLiang	   Ma	   and	   Xiahai	   Zhung,	   post-­‐doctoral	   research	  fellows,	  helped	  with	  the	  segmentation	  and	  registration	  of	  CMR	  images.	  Dr	  Kawal	  Rhodes,	   lecturer	   in	   Rayne	   Institute,	   helped	   with	   image	   registration.	   Dr	   Phani	  Chinchapatnam,	  post-­‐doctoral	  research	  fellow,	  helped	  with	  analysis	  of	  the	  Ensite	  data.	  Dr	  Oscar	  Camara,	  post-­‐doctoral	  research	  fellow,	  aided	  with	  the	  registration	  of	   Ensite	   data	   to	   motion	   maps.	   Dr	   Stam	   Kapetanakis,	   consultant	   cardiologist,	  helped	  with	  3D	  echocardiographic	  acquisition,	  analysis	  of	  the	  echo	  dyssynchrony	  and	  advice	  on	  statistical	  analysis.	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Overview	  of	  Thesis	  	  
Description	  of	  chapters	  
Chapter	  2:	  Review	  of	  Current	  Practice	  and	  Concepts	  in	  CRT	  and	  Related	  Imaging	  and	  
Physiology	  This	  is	  an	  overview	  of	  major	  issues	  surrounding	  CRT	  and	  an	  in-­‐depth	  description	  of	  the	  place	  of	  CMR	  in	  heart	  failure	  assessment	  and	  the	  potential	  of	  this	  imaging	  technique	  to	  aid	  in	  our	  understanding.	  	  
Chapter	   3:	  Methods	   of	   Measuring	   Mechanical	   Dyssynchrony	   and	   Effectiveness	   in	  
Predicting	  Acute	  and	  Chronic	  Response	  in	  CRT	  This	  chapter	  describes	  the	  methods	  we	  used	  to	  measure	  myocardial	  motion	  and	  the	   relationship	   between	   the	   different	  measurements,	   and	   the	   use	   of	   different	  indices	  of	  dyssynchrony	  to	  predict	  acute	  and	  chronic	  response	  to	  CRT	  
Chapter	  4:	  Relationship	  Between	  Acute	  and	  Chronic	  Response	  to	  CRT	  This	   chapter	   explains	   how	   acute	   response	   to	   CRT	  was	  measured	   and	   how	   this	  relates	  to	  reverse	  remodelling.	  	  
Chapter	   5:	   Relationship	   Between	   Myocardial	   Electrical	   Activation	   and	   Motion	   in	  
Helping	  to	  Understand	  Response	  to	  CRT	  This	   chapter	   explains	   a	   method	   used	   to	   show	   the	   relationship	   between	  mechanical	  myocardial	  motion	  and	  electrical	  activation	  of	  the	  ventricle.	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Chapter	  6:	  A	  Method	  for	  Imaging	  Coronary	  Veins	  and	  Myocardial	  Scar	  during	  Single	  
CMR	  Acquisition	  This	   chapter	   explains	   a	  method	   used	   to	   image	   coronary	   veins	   and	  myocardial	  scar	   in	   a	   single	   CMR	   examination,	   and	   the	   ability	   to	   show	   the	   relationship	  between	  myocardial	  scar	  and	  position	  of	  coronary	  veins.	  
Chapter	  7:	  Image	  Guidance	  to	  Aid	  CRT	  Implantation	  This	   chapter	   describes	   how	   anatomical	   information	   about	   coronary	   veins	   and	  scar	  as	  well	  as	  motion	  information	  can	  be	  used	  to	  aid	  CRT	  implantation	  with	  the	  use	  of	  novel	  overlay	  techniques	  and	  its	  implementation	  into	  the	  clinical	  arena	  
Chapter	  8:	  Discussion	  and	  Personal	  Opinion	  This	   chapter	   is	   a	   discussion	   of	   the	   author’s	   views	   of	   the	   pros	   and	   cons	   of	   the	  techniques	  presented	  in	  the	  thesis,	  and	  their	  likely	  roles	  in	  the	  future.	  
Chapter	  9:	  General	  Conclusions	  Short	  conclusions	  of	  this	  thesis	  and	  future	  works	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Chapter	  2	  	  
Review	  of	  Current	  Practice	  and	  Concepts	  in	  CRT	  and	  
Related	  Imaging	  and	  Physiology	  
	  
Introduction	  There	  follows	  an	  introduction	  and	  review	  of	  the	  key	  issues	  around	  heart	  failure	  and	  cardiac	  resynchronisation	  therapy	  as	  well	  as	  the	  current	  techniques	  used	  to	  assess	  patients	  prior	  to	  CRT.	  	  
Heart	  failure:	  The	  size	  of	  the	  problem	  Diseases	   of	   the	   heart	   and	   circulatory	   system	   are	   the	   main	   cause	   of	   death	  worldwide,	  accounting	  for	  an	  estimated	  17.5	  million	  deaths	  in	  2005.	  Nearly	  half	  of	   all	   deaths	   from	   cardiovascular	   disease	   are	   attributed	   to	   coronary	   heart	  disease.	  The	  global	  prevalence	  of	  heart	   failure	   is	  approximately	  22.5	  million.	   In	  2004	   the	   incidence	   of	   heart	   failure	   worldwide	   was	   5.7	   million.	   With	  improvements	   in	   survival	   from	   coronary	   heart	   disease	   the	   prevalence	   of	   heart	  failure	  is	  likely	  to	  increase.	  	  In	   the	   UK	   alone,	   700,000	   people	   are	   living	   with	   heart	   failure.	   There	   are	  approximately	   63,500	   new	   cases	   of	   heart	   failure	   each	   year,	   and	   heart	   failure	  causes	   approximately	   4%	   of	   all	   deaths.	   1	   The	   in-­‐hospital	   mortality	   for	   heart	  failure	   admissions	   is	   15%	   2	   and	   the	   one-­‐year	   survival	   is	   62%.	   3	   The	   five-­‐year	  survival	  reported	  in	  the	  Framingham	  study	  has	  improved	  only	  slightly	  from	  30%	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to	  41%	  from	  the	  middle	  to	  the	  end	  of	  the	  20th	  century.	  4	  The	  incidence	  of	  heart	  failure	   increases	   with	   age	   (Figure	   1),	   with	   the	   consequence	   that	   heart	   failure	  patients	   are	   placing	   increasing	   demands	   on	   the	   NHS	   and	   represent	   a	   huge	  burden,	  with	  a	  cost	  of	  over	  £600	  million	  per	  year.	  	  
Figure	  1	  Incidence	  of	  heart	  failure	  by	  sex	  and	  age	  5	  
	  	  
Pathophysiology	  Patients	   are	   typically	   divided	   into	   ischaemic	   (ICM)	   or	   dilated	   cardiomyopathy	  (DCM)	   on	   the	   basis	   of	   the	   clinical	   history,	   examination,	   and	   subsequent	  investigations	  including	  12	  lead	  ECG,	  echocardiogram,	  coronary	  angiography	  and	  increasingly	  CMR.	  (Table	  1)	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  Left	  ventricular	  (LV)	  systolic	  dysfunction	  causes	  a	  fall	   in	  cardiac	  output,	   leading	  to	   activation	   of	   neurohormonal	   mechanisms	   aimed	   at	   improving	   tissue	   and	  organ	  perfusion.	  Activation	  of	  the	  sympathetic	  nervous	  system	  leads	  to	  increased	  circulating	   catcholamines,	   causing	   peripheral	   vasoconstriction,	   increased	   heart	  rate	  and	  increased	  myocardial	  contractility.	  Activation	  of	  the	  renin-­‐angiotensin-­‐aldosterone	  system	  also	  leads	  to	  increase	  in	  vascular	  tone	  as	  well	  as	  an	  increase	  in	   circulating	   blood	   volume	   resulting	   from	   salt	   and	   water	   retention.	   The	  physiological	   countering	   effect	   to	   this	   is	   the	   release	   predominantly	   of	   atrial	  natriuretic	   peptides	   and	   brain	   natriuretic	   peptides	   in	   response	   to	   myocardial	  stretch.	   These	   peptides	   lead	   to	   vasodilatation	   and	   promote	   renal	   sodium	   and	  water	  excretion.	  	  In	   the	   short	   term,	   these	  physiological	   responses	  act	   to	   increase	   cardiac	  output.	  However,	  the	  increases	  in	  pre	  and	  after	  load	  that	  result	  from	  fluid	  retention	  and	  increased	  vascular	  tone	  have	  adverse	  effects	  in	  the	  long	  term.	  In	  conjunction	  with	  chronic	  increases	  in	  sympathetic	  activation,	  they	  lead	  to	  adverse	  remodelling	  and	  deterioration	  in	  cardiac	  function.	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Table	  1	  Causes	  of	  heart	  failure	  
Anatomical	  
category	  
Aetiology	   Examples	   Approximate	  UK	  
prevalence	  (%)	  
Pericardial	   	   Constrictive	  pericarditis	   <1	  
Myocardial	   ICM	   Myocardial	  infarction	   50-­‐60	  DCM	  Idiopathic	  Infective	  Metabolic	  Toxin	  Deficiency	  Genetic	  Peripartum	  
	  	  Viral,	  Bacterial	  Thyroid	  disease	  Alcohol	  Thiamine	  Mitochondrial	  myopathy	  
10-­‐20	  
Hypertrophy	  Hypertensive	  Genetic	  defect	  
	   5	  
Restrictive	   Amyloidosis	  Haemochromatosis	   <1	  
Endocardial	   Valvular	  disease	   Aortic	  stenosis	   10	  
Arrhythmia	   	   Atrial	  fibrillation	   	  
High-­‐output	  states	   	   Paget’s	  disease	  Ateriovenous	  fistula	   5	  
Congenital	   	   Ventricular	  septal	  defect	   <1	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Medical	  Therapy	  for	  Heart	  Failure	  Advances	   in	   pharmacological	   treatment	   of	   heart	   failure	   have	   demonstrated	  prognostic	   benefits	   of	   cardio-­‐selective	   beta	   blockers,	   6	   angiotensin	   converting	  enzyme	   inhibitors,	   7	  angiotensin	  receptor	  antagonists	   8,	   9	  and	  spironolactone.	   10	  These	  drugs	  act	  by	  counteracting	  the	  pathophysiological	  mechanisms	  described	  earlier.	  Although	  advances	  in	  medical	  therapy	  have	  improved	  prognosis	  the	  long-­‐term	  survival	  from	  heart	  failure	  remains	  poor.	  4	  	  
Cardiac	  Resynchronisation	  Therapy	  
Rationale	  Heart	   failure	   patients	   frequently	   have	   abnormal	   ventricular	   conduction	  manifested	   on	   the	   surface	   ECG	   with	   broad	   QRS	   complexes	   often	   seen	   as	   left	  bundle	  branch	  block	   (LBBB)	   11	   (Figure	  2).	   	  This	   gives	   rise	   to	  delayed	  electrical	  stimulation	   and	   thus	   delayed	  mechanical	   activation	   of	   the	   lateral	   LV	   free	  wall,	  which	   contracts	   late	   relative	   to	   the	   inter	   ventricular	   septum.	   This	   loss	   of	  synchronous	   contraction	   disrupts	   mechanical	   efficiency,	   causing	   further	  impairment	  of	   the	   cardiac	  output.	  Furthermore	  QRS	  duration	   tends	   to	   increase	  with	  time	  and	  is	  associated	  with	  an	  adverse	  outcome.12	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Figure	  2	  ECG	  of	  heart	  failure	  patient	  with	  LBBB	  
	  	  The	  aim	  of	  CRT	  is	  to	  re-­‐coordinate	  the	  heart	  by	  artificially	  correcting	  the	  timing	  of	   electrical	   stimulation.	   This	   is	   achieved	   by	   pacing	   both	   the	   LV	   and	   right	  ventricles	   (RV)	   in	   conjunction	  with	   the	   right	   atrium	   (Figure	   3).	   The	   LV	   lead	   is	  generally	   empirically	   implanted	   in	   a	   lateral	   or	   posteriolateral	   vein,	   which	  appears	   to	   confer	   greater	   benefit	   than	   an	   anterior	   or	   anterolateral	   branch13	  although	  a	  recent	  study	  showed	  that	  LV	  lead	  placement	  is	  patient	  specific.	  14	  The	  correction	   of	   dyssynchrony	   with	   CRT	   is	   associated	   with	   improvements	   in	   LV	  systolic	   function15,	   myocardial	   oxygen	   consumption16,	   and	   reduction	   in	   mitral	  regurgitation17.	  
QRS	  Duration	  164ms 
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Figure	  3	  Explanation	  of	  normal	  cardiac	  conduction	  and	  abnormal	  conduction	  in	  CRT	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Evidence	  for	  CRT	  CRT	   has	   changed	   the	   management	   of	   patients	   in	   New	   York	   Heart	   Association	  (NYHA)	   class	   III	   and	   IV	   heart	   failure	   on	   maximum	   drug	   therapy.	   There	   are	  numerous	   multi-­‐centre	   trials	   (Table	   2)	   that	   have	   shown	   the	   benefits	   of	   CRT.	  Clinical	  studies	  have	  demonstrated	  acute	  haemodynamic	  benefit18,	  19,	  LV	  reverse	  remodeling	   (RR)	   20,	   21	   and	   improvements	   in	   symptoms	   incorporating	   exercise	  capacity,	   quality	   of	   life	   score	   (QOL)	   and	   NYHA	   class22-­‐24.	   In	   addition,	   large	  prospective	   randomized	   clinical	   trials	   have	   shown	   reductions	   in	   hospital	  admissions	  and	  mortality25,	  26.	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Table	  2	  Summary	  of	  studies	  showing	  benefit	  from	  CRT	  







PATH-­‐CHF27	   Crossover	   41	   6MWT	  Peak	  V02	   NYHA	  class	  QOL	  Hospitalizations	  
Improvement	  in	  6MWT	  NYHA	  class	  QOL	  Less	  hospitalizations	  
MUSTIC-­‐SR22	   Crossover	   58	   6MWT	   NYHA	  class	  QOL	  Peak	  V02	  LV	  volumes	  MR	  Hospitalizations	  Total	  mortality	  
Improvement	  in	  6MWT	  NYHA	  class	  QOL	  Peak	  V02	  LV	  volumes	  MR	  Less	  hospitalizations	  
MIRACLE28	   Parallel	  arms	   453	   6MWT	  NYHA	  class	  QOL	  
Peak	  V02	  LV	  EF	  LVEDD	  MR	  Clinical	  composite	  response	  
Improvements	  in	  6MWT	  NYHA	  class	  QOL	  LVEF	  LVEDD	  MR	  
MIRACLE-­‐
ICD24	  
Parallel	  arms	   555	   6MWT	  NYHA	  class	  QOL	  
Peak	  V02	  LV	  EF	  LVEDD	  MR	  Clinical	  composite	  response	  
Improvements	  in	  NYHA	  class	  QOL	  
COMPANION25	   Parallel	  arms	   1,520	   All-­‐cause	  mortality	  or	  hospitalizations	  
All-­‐cause	  mortality	  and	  cardiac	  morbidity	  	  
Reduced	  all-­‐cause	  mortality/hospitalization	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Trial	   Design	   Patient	  (no.)	   Primary	  end	  point	   Secondary	  end	  point	   Results	  summary	  
CARE-­‐HF29	   Open	  label,	  randomized	   814	   All-­‐cause	  mortality	   NYHA	  class	  QOL	  LVEF	  LVESV	  Hospitalization	  for	  heart	  failure	  
Reduced	  mortality/morbidity	  Improvement	  in	  NYHA	  class	  QOL	  LVEF	  LVESV	  PATH-­‐CHF	  II30	   Crossover	  (no	  pacing	  vs	  LV	  pacing)	  
86	   6MWT	  Peak	  02	   NYHA	  class	  QOL	   Improvement	  in	  6MWT	  QOL	  Peak	  V02	  CONTAK-­‐CD20	   Crossover,	  parallel	  controlled	   490	   6MWT	  NYHA	  class	  QOL	  
LVEF	  LV	  volumes	  Composite	  of	  mortality,	  Hospitalizations,	  VT/VF	  
Improvement	  in	  6MWT	  NYHA	  class	  QOL	  LVEF	  LV	  volumes	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Current	  Guidelines	  Current	   European	   Society	   of	   Cardiology	   guidelines	   recommend	   that	   CRT	   is	  indicated	   in	   patients	   in	   sinus	   rhythm	   with	   symptomatic	   severe	   heart	   failure	  despite	   optimal	   drug	   therapy,	   with	   evidence	   of	   dyssynchrony	   as	   defined	   by	  prolongation	   of	   the	   QRS	   complex	   on	   the	   surface	   ECG	   >120ms.	   However	   up	   to	  30%	  of	  patients	  do	  not	  derive	  significant	  clinical	  benefit	   from	  CRT	  and	  a	  higher	  percentage	  do	  not	  RR.	  29	  The	  reasons	  for	  this	  are	  multi	  factorial	  (Figure	  4).	  	  	  
Figure	  4	  Factors	  that	  affect	  response	  to	  CRT	  	  
	  	   	   !
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“Non-­‐response”	  to	  CRT	  The	  terms	  “responder”	  and	  “non	  responder”	  are	  frequently	  used	  although	  there	  is	  no	  clear	  consensus	  on	  what	  should	  be	  considered	  as	  response.	  31	  Some	  authors	  use	   clinical	   end	   point	   such	   as	   improvement	   in	  NYHA	   class	  whereas	   others	   use	  composite	  measures,	   such	  as	   freedom	   from	  hospitalisation	  or	  RR.	  Patients	   that	  do	  not	  derive	  clear	  benefit	  from	  CRT	  are	  labeled	  “non-­‐responders”,	  although	  this	  is	  a	  poor	  term	  as	  the	  response	  to	  treatment	  may	  be	  a	  lack	  of	  deterioration	  rather	  than	  clear	  improvement.	  In	  addition	  most	  clinical	  studies	  have	  not	  incorporated	  a	  placebo	  arm	  for	  comparison.	  	  	  There	   are	   various	   reasons	   for	   patients	   not	   improving	  with	   CRT	   (figure	   4).	  Not	  only	  does	  it	  depend	  on	  the	  definition	  of	  response,	  but	  also	  on	  the	  heterogeneity	  of	  the	  heart	  failure	  population.	  Patient	  specific	  factors	  include;	  aetiology,	  degree	  of	   dyssynchrony,	   burden	   and	   location	   of	   scar32,	   ischaemia,	   coronary	   vein	  anatomy33,	  arrhythmias,	  co-­‐morbidity,	  and	  baseline	  level	  of	  function.	  	  
	  
Areas	  where	  further	  work	  is	  required	  
• Defining	  and	  measuring	  response	  
• Improving	  patient	  selection	  
• Determining	   the	   optimal	   site	   and	  method	   to	   stimulate	   the	   left	   and	   right	  ventricle	  in	  order	  to	  maximise	  electromechanical	  recruitment	  	  
• Optimising	  device	  settings	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Improving	   our	   understanding	   of	   these	   key	   areas	   may	   enable	   us	   to	   improve	  patient	   selection,	   maximise	   the	   number	   of	   patients	   who	   are	   likely	   to	   derive	  benefit	  from	  CRT,	  and	  avoid	  potentially	  harmful	  procedures	  in	  those	  that	  will	  not.	  	  	  
Measuring	  Response	  Response	   to	   CRT	   can	   be	   measured	   in	   the	   acute	   setting	   by	   measuring	  haemodynamic	   parameters	   at	   the	   time	   of	   implant,	   and	   in	   the	   long-­‐term	   by	  looking	  at	  clinical	  or	  echocardiographic	  parameters	  (Figure	  5).	  	  
Acute	  Response	  
Evidence	  for	  LV-­‐dP/dtmax	  and	  response	  to	  CRT	  Several	   studies	   have	   used	   acute	   haemodynamic	   response	   (AHR)	   to	   determine	  lead	  position	   34,	   35	   and	   to	  optimise	  pacing	   settings	   36,	   37.	   Studies	  have	  evaluated	  the	  effect	  of	  LV	  pacing	  in	  the	  context	  of	  CRT	  using	  LV-­‐dP/dtmax	  as	  an	  end-­‐point	  34,	  
37-­‐39.	  LV-­‐dP/dtmax	  is	  a	  reproducible	  marker	  of	  LV	  contractility.	  The	  implication	  is	  that	   acute	   improvement	   in	   contractility	   translates	   into	   beneficial	   effects	   from	  CRT	  in	  the	  longer	  term.	  Whilst	  it	  is	  logical	  that	  energy,	  which	  is	  wasted	  as	  a	  result	  of	   LV	   dyssynchrony,	   may	   be	   “harnessed”	   by	   LV	   pacing	   in	   order	   to	   improve	  cardiac	  function,	  it	  is	  likely	  that	  there	  are	  more	  complex	  mechanisms	  involved	  in	  RR.	   Echocardiographic	   based	   assessments	   of	   AHR	   to	   CRT	   have	   shown	   it	   is	   a	  useful	  predictor	  of	  long-­‐term	  clinical	  outcome	  40,	  41	  (Figure	  6).	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Figure	  5	  Shows	  how	  response	  to	  CRT	  can	  be	  measured	  
	  MACE=Major	  adverse	  cardiac	  event	   !
	   42	  
Figure	  6	  Measurement	  of	  LV-­‐dP/dtmax	  as	  an	  indicator	  of	  LV	  performance	  derived	  from	  mitral	  regurgitation.	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However	   use	   of	   echocardiographic	   derived	   LV-­‐dP/dtmax	   is	   confined	   to	   patients	  with	   enough	   mitral	   regurgitation	   to	   obtain	   a	   clear	   signal	   and	   is	   difficult	   to	  measure	   during	   CRT	   implant.	   LV-­‐dP/dtmax	   can	   be	   measured	   invasively	   with	   a	  pressure	   wire	   in	   the	   LV	   (figure	   7	   and	   8).	   Although	   it	   has	   been	   shown	   with	  invasive	  measurement	   that	  AHR	   improves	  with	  CRT	   39	   it	   remains	  unclear	   if	   an	  AHR	  at	   the	  time	  of	  CRT	  equates	  to	  RR	  and	   improvement	  of	  clinical	  parameters.	  Furthermore,	  many	   of	   the	   studies	   have	   only	   used	   patients	  with	   non-­‐ischaemic	  cardiomyopathy34.	  	  	  There	  are	  many	  potential	  benefits	  to	  using	  AHR	  at	  the	  time	  of	  CRT	  implant.	  The	  current	  consensus	  to	  position	  the	  LV	  lead	  in	  a	  lateral	  or	  posterolateral	  branch	  of	  the	   coronary	   sinus	   (CS)	   15,	   42	   has	   recently	   been	   challenged	  by	   a	   study	   showing	  marked	  variation	  in	  haemodynamic	  response	  depending	  on	  LV	  pacing	  position.	  34	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Figure	  7	  Pressure	  wire	  
	  	  
Figure	  8	  Real-­‐time	  haemodynamic	  data	  from	  Physiomon	  software.	  Green	  trace:	  blood	  pressure;	  Blue	  trace:	  LV-­‐dP/dtmax	  
	  	   	  
!
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Issues	  with	  LV-­‐dP/dtmax	  Methods	  to	  assess	  acute	  response	  are	  not	  without	  problems	  and	  it	  is	  unclear	  how	  acute	   response	   equates	   to	   long-­‐term	   outcomes.	   During	   implants	   there	   are	  multiple	   factors	   that	  will	   affect	   the	  measurements,	   for	   example	  patient	   anxiety	  leading	  to	  elevated	  sympathetic	  drive,	  use	  of	  fluids	  and	  analgesia	  throughout	  the	  procedure,	  and	  cessation	  of	  medication	  prior	  to	  the	  implant.	  All	  of	  these	  factors	  affect	   the	   accuracy	   and	   relevance	   of	   measures	   of	   AHR	   in	   determining	   how	   a	  patient	  will	  respond	  in	  the	  long-­‐term.	  
Chronic	  Response	  
Defining	  chronic	  response	  to	  CRT	  	  The	  best	  measure	  for	  defining	  chronic	  response	  to	  CRT	  has	  not	  been	  established	  (table	   3).	   There	   is	   no	   universally	   accepted	   definition	   of	   response	   to	   CRT,	  although	   improvements	   in	   clinical	   criteria	   (NYHA	   class,	   peak	   oxygen	  consumption,	   exercise	   capacity,	   quality	   of	   life	   scores),	   echocardiographic	  parameters	   (ejection	   fraction,	   end-­‐systolic	   volume	   and	   severity	   of	   mitral	  regurgitation)	  and	  hard	  end-­‐points	  (hospitalisation	  due	  to	  heart	  failure	  or	  death)	  have	  been	  used.	  The	  measurement	  of	  brain	  naturetic	  peptide	  (BNP)	  is	  becoming	  more	  widely	  available	  and	  changes	  in	  levels	  are	  now	  being	  used.	  43	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markers	  NYHA	  class	  Quality	  of	  life	  score	  6	  minute	  walk	  distance	  Exercise	  capacity	  Peak	  V02	  max	  Hospitalisations	  (heart	  Failure)	  Mortality	  (cardiac)	  Psychological	  status	  
LV	  ejection	  fraction	  LV	  dimensions/volume	  Mitral	  regurgitation	  Inter	  ventricular	  synchronization	  Intra	  ventricular	  synchronization	  
Decrease	  in	  BNP	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Methods	  Used	  to	  Assess	  Chronic	  Response	  to	  CRT	  	  
Measuring	  clinical	  response	  There	  are	  many	  clinical	  measures	  that	  are	  considered	  for	  assessment	  of	  patient	  response	  post	  CRT.	  A	  major	   limitation	  with	  many	  of	   these	  methods	   is	   that	   they	  are	   subjective	   and	   can	   vary	  on	   a	  daily	   basis.	  What	   one	  doctor	   considers	  NYHA	  class	  3	  another	  would	  consider	  NYHA	  class	  2.	  Also	  patients’	  functional	  status	  can	  vary	  throughout	  the	  day.	  	  
Measuring	  reverse	  remodelling	  	  Echocardiographic	   measurements	   of	   LV	   dimensions	   and	   volume	   are	   normally	  used	   to	   define	   RR.	   44,	   45	   However	   a	   recent	   study	   comparing	   clinical	   and	  echocardiographic	  response	  to	  CRT	  demonstrated	  clinical	   improvement	   in	  70%	  of	  cases,	  but	  RR	  (defined	  as	   reduction	   in	  LV	  ESV	  ≥	  15%)	   in	  only	  56%.	   46	  When	  change	  in	  LV	  ESV	  was	  subdivided	  into	  quantiles	  of	  response,	  a	  clear	  relationship	  was	   seen	   between	   the	   percentage	   of	   clinical	   responders	   and	   degree	   of	   RR	  suggesting	  a	  spectrum	  rather	  than	  an	  absolute	  response/non-­‐response	  to	  CRT.	  47	  	  
Definition	  of	  reverse	  remodelling	  and	  clinical	  response	  in	  this	  work	  In	  this	  thesis	  patients	  were	  deemed	  to	  have	  RR	  if	  there	  was	  a	  ≥	  15%	  reduction	  in	  LV	   ESV	   as	   measured	   using	   Simpson’s	   modified	   biplane	   method	   on	   2D	   echo	  images.	   48,	   49	   Evaluation	   of	   symptomatic	   response	  was	  made	   using	  NYHA	   class	  and	  Minnesota	  living	  with	  heart	  failure	  questionnaire.	  50	  To	  assess	  sensitivity	  and	  specificity	   for	   LV-­‐dP/dtmax	   to	   predict	   RR,	   response	   was	   deemed	   acute	   if	   the	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percentage	   improvement	   in	   LV-­‐dP/dtmax	  was	   ≥	   10%	   compared	  with	   fixed	   rate	  atrial	   /	   RV	   pacing	   (baseline).	   This	   cut-­‐off	   value	   has	   been	   used	   in	   previous	  studies37,	  51.	  Patients	  were	  labeled	  clinical	  responders	  if	  the	  NYHA	  class	  fell	  by	  ≥	  1,	   if	   there	  was	  a	  ≥10%	  reduction	   in	  heart	   failure	  questionnaire	  score,	  or	  ≥10%	  improvement	  in	  six	  minute	  walk	  distance.	  	  
Understanding	  and	  Improving	  Patient	  Selection	  for	  CRT	  The	  significant	  number	  of	  patients	   failing	   to	  either	  RR	  or	  derive	  clinical	  benefit	  from	   CRT	   has	   led	   to	   extensive	   research	   into	   trying	   to	   understand	   why	   some	  groups	  of	  patients	  respond	  and	  others	  do	  not.	  	  	  Work	   has	   generally	   focused	   on	   two	   broad	   lines	   of	   investigation;	   either	  understanding	   the	   electrical	   activation,	   or	   mechanical	   myocardial	  motion/dyssynchrony	   (Figure	   9).	   The	   general	   concept	   is	   that	   CRT	   works	   by	  correcting	   electrical	   dyssynchrony	   within	   the	   heart	   that	   in	   turn	   leads	   to	  correction	  of	  mechanical	  dyssynchrony	  and	   improved	  myocardial	  performance.	  Therefore	   investigation	  of	   either	   the	   electrical	   activation	  or	  myocardial	  motion	  may	  give	  insight	  into	  likely	  patient	  response	  to	  CRT.	  It	  is	  important	  to	  recognise	  that	   the	   assumption	   that	   electrical	   dyssynchrony	   translates	   into	   mechanical	  dyssynchrony	  is	  not	  necessarily	  true.	  The	  most	  widely	  used	  marker	  of	  electrical	  dyssynchrony	  in	  CRT	  is	  the	  surface	  ECG.	  The	  QRS	  duration	  is	  used	  as	  an	  electrical	  surrogate	   measurement	   for	   LV	   dyssynchrony.	   However,	   this	   inadequately	  identifies	  mechanical	  dyssynchrony.	  52	  This,	  therefore,	  raises	  a	  further	  question:	  What	  is	  the	  relationship	  between	  electrical	  activation	  and	  mechanical	  motion?	  
	   49	  
	  
Figure	  9	  Methods	  for	  measuring	  electrical	  and	  mechanical	  dyssynchrony	  	  
	  	   	   !
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Understanding	  Electrical	  Myocardial	  Activation	  in	  CRT	  	  
Surface	  ECG	  The	  surface	  ECG	  is	  the	  most	  basic	  assessment	  of	  electrical	  activation.	  Patients	  for	  CRT	   are	   selected	   on	   the	   basis	   of	   QRS	   duration	   ≥120ms	   normally	   with	   LBBB	  morphology.	  It	  is	  assumed	  that	  the	  broader	  the	  QRS	  complex	  the	  more	  electrical	  dyssynchrony	   there	   is.	  However	   LBBB	   is	   a	   complex	   electrical	   disease	   resulting	  from	   conduction	   delay	   located	   at	   several	   anatomical	   levels	   of	   the	   activation	  sequence	   53	   and	   the	   surface	   ECG	   recordings	   are	   unable	   to	   characterise	   the	  location	  and	  extent	  of	  specific	  ventricular	  delays.54	  	  	  This	   inability	   of	   the	   surface	   ECG	   to	   adequately	   characterise	   the	   activation	  patterns	   of	   the	   myocardium	   has	   led	   to	   the	   use	   of	   more	   accurate	   but	   invasive	  methods	  such	  as	  non-­‐contact	  mapping	  (NCM).	  	  
Non-­‐contact	  mapping	  and	  heart	  failure	  NCM	   has	   been	   used	   in	   several	   studies	   of	   human	   patients	  with	   heart	   failure	   to	  characterise	   the	   LV	   endocardial	   activation	   pattern	   in	   patients	   with	   intra-­‐ventricular	   conduction	   delay.	   The	   concept	   of	   reconstructing	   intra-­‐cavity	  potentials	   mathematically	   without	   the	   need	   for	   contact	   with	   the	   walls	   of	   the	  chamber	  was	   introduced	  by	  Taccardi	  et	  al.	   55	  This	   technology	  has	  been	  refined,	  culminating	  in	  the	  development	  of	  the	  EnSite	  3000	  non-­‐contact	  mapping	  system.	  This	   consists	   of	   a	   multi-­‐electrode	   array	   (MEA):	   64	   laser-­‐etched	   electrodes	  mounted	   on	   a	   wire	   braid	   on	   a	   8mm	   balloon.	   This	   is	   seated	   on	   a	   9F	   catheter,	  
	   51	  
which	   allows	   introduction	   of	   the	   balloon	   to	   the	   chamber	   of	   interest	   (with	   the	  balloon	  deflated).	  	  The	   geometry	   of	   the	   chamber	   of	   interest	   can	   be	   reconstructed	   using	   a	   low	  current	  locator	  signal	  emitted	  from	  the	  tip	  of	  the	  MEA,	  at	  5.68Hz.	  This	  is	  sensed	  by	   two	   ring	   electrodes	   mounted	   on	   either	   side	   of	   the	   MEA	   balloon.	   With	   this	  system,	  other	  catheters	  can	  be	  localised	  in	  3D.	  A	  roving	  electro	  physiological	  (EP)	  catheter	   is	   moved	   around	   the	   chamber	   to	   define	   the	   location	   of	   the	   chamber	  walls	  in	  3D.	  	  	  The	   array	   then	   records	   intra-­‐cavity	   far-­‐field	   potentials	   that	   are	   sampled	   at	  1.2kHz	   and	   digitally	   filtered	   at	   0.1-­‐300Hz.	   The	   resulting	   signals	   are	   resolved	  using	   the	   inverse	   solution	   to	   Laplace’s	   equation	   by	   the	   boundary	   element	  method.	  This	  allows	  mathematical	   reconstruction	  of	  over	  3000	  virtual	  unipolar	  electrograms,	   which	   are	   superimposed	   on	   the	   chamber	   geometry.	   Both	  isopotential	  and	  isochronal	  maps	  can	  be	  generated,	  with	  colour	  coding	  to	  allow	  the	  endocardial	  activation	  pattern	  to	  be	  visualised.	  Data	  can	  be	  analysed	  off-­‐line	  in	  any	  orientation.	  	  Auricchio	  et	  al	  demonstrated	  the	  high	  prevalence	  of	   functional	   lines	  of	  block	   in	  patients	   with	   LBBB,	   often	   with	   the	   pattern	   of	   activation	   taking	   a	   “U-­‐shape”	  around	   the	   area	   of	   slow	   conduction.	   53	   Furthermore,	   areas	   of	   slow	   conduction	  could	   be	   defined	   by	   low	   voltage	   or	   fragmented	   electrograms.	   Conduction	  boundaries	   can	   be	   defined	   formally	   based	   on	   voltage	   distribution	   within	   the	  chamber,	  using	  an	  algorithm	  called	  dynamic	  substrate	  mapping.	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  Lambiase	  et	  al	  demonstrated	   that	  positioning	  of	   the	  LV	   lead	   in	  an	  area	  of	   slow	  conduction	  was	   associated	  with	   a	   significantly	   reduced	   haemodynamic	   benefit	  from	  CRT,	  when	  compared	  with	  pacing	  outside	  these	  areas.	  56	  Moreover,	  pacing	  in	  areas	  of	  slow	  conduction	  was	  associated	  with	  longer	  LV	  endocardial	  activation	  times,	  suggesting	  that	  correcting	  electrical	  delay	  was	  the	  underlying	  mechanism	  of	   haemodynamic	   benefit.	   Characterisation	   of	   the	   myocardial	   substrate	   was	  further	  advanced	  by	  Fung	  et	  al	  57	  who	  described	  two	  distinct	  types	  of	  activation	  pattern	  in	  patients	  with	  intra-­‐ventricular	  conduction	  delay.	  This	  work	  suggested	  that	  CRT	  response	  was	  higher	  in	  the	  patients	  with	  functional	  block	  as	  compared	  with	  a	  more	  homogeneous	  activation	  pattern.	  57	  	  Whilst	  non-­‐contact	  mapping	  can	  characterise	  areas	  of	  slow	  conduction	  and	  lines	  of	   block,	   it	   is	   important	   to	   realise	   that	   it	   remains	   unclear	   how	   the	   electrical	  activation	  corresponds	  to	  the	  myocardial	  motion/dyssynchrony.	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Understanding	  Myocardial	  Motion	  Prior	   to	   looking	   at	   how	   imaging	   techniques	   can	   be	   used	   to	   study	   myocardial	  motion	   and	   measure	   dyssynchrony	   it	   is	   important	   to	   understand	   the	  mechanisms	  behind	  ventricular	  systole	  and	  diastole	  and	  also	  the	  different	  ways	  these	  mechanisms	  can	  be	  investigated	  with	  various	  imaging	  modalities.	  	  	  
Defining	  myocardial	  dyssynchrony	  Myocardial	  dyssynchrony	  can	  be	  divided	  into	  three	  basic	  categories	  (figure	  10).	  1. Atrio-­‐Ventricular	   dyssynchrony	   (delay	   between	   the	   atria	   and	   the	  ventricles)	  2. Inter-­‐ventricular	   dyssynchrony	   (delay	   between	   the	   right	   and	   left	  ventricle)	  3. Intra-­‐ventricular	   dyssynchrony	   (delay	   between	   the	   walls	   of	   the	   left	  ventricle)	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Figure	  10	  Representations	  of	  how	  dyssynchrony	  can	  be	  defined.	  
!	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Atrio-­‐ventricular	   (AV)	   dyssynchrony	   is	   common	   in	   patients	   with	   heart	   failure	  and	  first-­‐degree	  heart	  block	  and	  was	  the	  first	  objective	  of	  CRT	  in	  the	  bicameral	  pacemaker	  in	  the	  early	  1990s.	  58	  AV	  dyssynchrony	  reduces	  the	  duration	  of	  filling,	  thus	   inducing	   diastolic	   and	   mitral	   regurgitation	   and	   reduced	   stroke	   volume.	  Heart	  failure	  patients	  often	  have	  abnormal	  filling	  patterns	  with	  either	  prolonged	  or	  shortened	  transmitral	  filling.	  59	  	  Inter-­‐ventricular	   dyssynchrony	   represents	   the	   discordance	   between	   the	   times	  for	  RV	  and	  LV	  contraction.	  	  	  Intra-­‐ventricular	  dyssynchrony	   is	  characterized	  by	  either	   the	  premature	  or	   late	  contraction	   of	   LV	   wall	   segments.	   Much	   of	   this	   thesis	   concentrates	   on	   ways	   to	  measure	  intra-­‐ventricular	  dyssynchrony.	  	  Patients	  with	   heart	   failure	   can	   have	   problems	  with	   any	   or	   all	   of	   these	   indices.	  CRT	  can	  affect	  all	  three	  of	  these,	  therefore	  it	  is	  important	  to	  understand	  how	  they	  are	  measured.	  	  
Myocardial	  myocyte	  anatomy	  Anatomical	   studies	   are	   important	   in	   explaining	   the	   complex	   structure	   of	   the	  myocardium	  and	  understanding	  how	   to	  measure	  myocardial	  motion.	  Anderson	  et	   al	   60	   showed	   that	   that	   myocytes	   aggregate	   together	   in	   a	   3D	  mesh	   within	   a	  supporting	  matrix	  of	  fibrous	  tissue.	  Within	  this	  mesh	  of	  aggregated	  myocytes,	  it	  is	   possible	   to	   recognise	   two	   populations	   depending	   on	   the	   orientation	   of	   their	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long	   axis.	   The	   first	   population	   is	   aligned	   with	   the	   long	   axis	   of	   the	   aggregated	  myocytes	   tangential	   to	   the	   epicardial	   and	   endocardial	   borders,	   albeit	   with	  marked	   variation	   in	   the	   angulations	   relative	   to	   the	   ventricular	   equator.	   The	  second	  population	  is	  aligned	  at	  angles	  of	  up	  to	  40	  degrees	  from	  the	  epicardium	  toward	  the	  endocardium	  (figure	  11).	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Figure	  11	  60	  
	  
A	  Porcine	  heart	  prepared	  by	  removing	  increasing	  layers	  from	  the	  wall	  of	  the	  LV,	  increasing	  the	  depth	  of	  dissection	  from	  base	  to	  apex.	  The	  overall	  alignment	  of	  the	  chains	  of	  myocytes	  can	  readily	  be	  distinguished,	  and	  their	  angulations	  relative	  to	  the	   equator	   can	   be	   seen	   to	   change	   with	   increasing	   depth	   within	   the	   wall.	   B	  Dissection	  of	  a	  human	  heart,	  viewed	  from	  the	  apex	  having	  separated	  and	  moved	  the	   left	   away	   from	   the	   RV,	   which	   is	   seen	   to	   the	   left	   hand	   supporting	   the	  pulmonary	  trunk	  on	  its	   infundibulum.	  The	  mass	  of	  myocytes	  aligned	  in	  circular	  fashion	  to	  make	  up	  the	  middle	  layers	  of	  the	  LV	  wall.	  	  	  	  When	  considering	  the	  mechanics	  of	  LV	  motion	  it	  is	  important	  to	  realise	  that	  the	  heart	  is	  made	  up	  of	  complex	  3D	  meshwork	  of	  myocytes	  formed	  into	  sheets	  set	  in	  a	   supporting	   fibrous	  matrix.	   Biomechanical	   studies	   have	   shown	   the	   pattern	   of	  wall	  thickening	  appears	  to	  be	  a	  function	  of	  the	  orientation	  of	  the	  laminar	  sheets,	  which	  vary	  regionally	  and	  tansmurally.	  61	  Within	  the	  meshwork	  of	  sheets	  are	  to	  be	  found	  populations	  of	  myocytes	  aligned,	  on	  the	  one	  hand,	  with	  their	  long	  axis	  tangential	  to	  the	  epicardial	  and	  endocardial	  surfaces,	  and	  on	  the	  other	  hand	  with	  
!
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angles	   of	   intrusion	   across	   the	   ventricular	   wall.	   Only	   by	   recognising	   the	  antagonistic	   roles	  of	   the	   two	  populations	   are	  we	  able	   to	  understand	   the	   forces	  involved	  during	  ventricular	  systolic	  emptying	  and	  diastolic	  filling.	  Understanding	  this	  allows	  better	  insight	  in	  to	  how	  imaging	  techniques	  can	  be	  used	  to	  investigate	  and	  quantify	  myocardial	  motion.	  These	  features,	  including	  changes	  in	  the	  fibrous	  matrix	   rather	   than	   the	   myocytes	   themselves,	   should	   be	   taken	   into	   account	   to	  fully	  understand	  the	  workings	  of	  the	  ventricular	  myocardium	  (figure	  12).	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Figure	  12	  Shows	   the	   three	   main	   directions	   that	   ventricular	   myocardial	   mass	   move	   in	  during	  systole	  and	  diastole.	  
	  	  
Techniques	  for	  measuring	  and	  assessing	  myocardial	  motion	  The	  measurement	  of	  myocardial	  motion	  can	  be	  undertaken	  in	  various	  ways	  with	  increasing	  complexity.	  	  
Volume	  change	  The	  simplest	  method	  is	  to	  assess	  the	  change	  in	  LV	  cavity	  volume.	  Measuring	  the	  LV	  cavity	  volume	  over	  the	  course	  of	  the	  cardiac	  cycle	  gives	  an	  indication	  of	  how	  coordinated	   the	   ventricular	   contraction	   is.	   However,	   this	   does	   not	   provide	  information	  on	  how	  the	  myocardial	  mass	   is	  working	   to	  bring	  about	  ventricular	  contraction.	  	  Methods	  using	  volume	  change	  over	  the	  cardiac	  cycle	  do	  not	  take	  into	  account	  the	  difference	   between	   active	   and	   passive	   motion	   and	   the	   magnitude	   of	   change	  within	  specific	  areas	  in	  the	  ventricle.	  Scarred	  and	  akinetic	  myocardial	  segments	  can	  be	  pulled	  or	  stretched	  by	  adjacent	  areas	  that	  can	  lead	  to	  change	  in	  volume.	  
!
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The	  importance	  of	  knowing	  these	  areas	  are	  working	  actively	  or	  moving	  passively	  is	  unclear	  and	  needs	  further	  investigation.	  	  
Muscle	  thickening/shortening	  To	   gain	   better	   understanding	   of	   the	   active	   processes	   involved	   in	   ventricular	  contraction,	   muscle	   thickening	   can	   be	   measured	   over	   the	   cardiac	   cycle.	   The	  assumption	   is	   that	   for	   the	   cardiac	  muscle	   fibers	   to	   contract	   they	  must	   thicken	  and	  shorten.	  This	  in	  turn	  must	  be	  an	  active	  process	  and	  would	  exclude	  areas	  of	  passive	   motion.	   During	   ventricular	   contraction	   there	   is	   radial	   thickening,	  longitudinal	   shortening	   and	   twisting	   of	   the	   ventricle	   (figure	   12).	   Simple	  measurement	   of	   the	   radial	   thickening	   and	   longitudinal	   shortening	   over	   the	  cardiac	  cycle	  may	  allow	  a	  better	  understanding	  of	   the	  mechanism	  that	   leads	   to	  active	  myocardial	  contraction	  and	  of	  active	  dyssynchrony.	  
Motion	  and	  deformation	  Assessing	   the	   change	   in	   position	   of	   particular	   anatomical	   points	   or	   structures	  allows	  the	  motion	  to	  be	  investigated	  during	  the	  cardiac	  cycle.	  More	  information	  can	   be	   gleaned	   by	   looking	   at	   the	   change	   from	   the	   normal	   size	   or	   shape	   of	   an	  anatomic	   structure	   due	   to	  mechanical	   forces	   that	   distort	   an	   otherwise	   normal	  structure,	   known	   as	   deformation.	   Myocardial	   deformation	   can	   be	   described	   in	  different	   ways.	   Mirsky	   et	   al	   62	   initially	   introduced	   the	   concept	   of	   strain	   to	  facilitate	   the	   understanding	   of	   elastic	   stiffness	   in	   heart	   muscle.	   They	   defined	  “strain”	  as	  a	  dimensionless	  quantity	   that	   represented	   the	  percentage	  change	   in	  dimension	   from	   a	   resting	   state	   to	   one	   achieved	   following	   application	   of	   force	  (stress).	   Therefore,	   strain	   is	   the	   relative	  deformation	  of	   tissue	   from	  an	   applied	  force,	  whereas	   strain	   rate	   is	   the	   rate	   of	   this	   deformation.	   Thus,	   negative	   strain	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would	  indicate	  compression	  or	  shortening	  and	  conversely	  positive	  strain	  would	  imply	  lengthening	  or	  expansion.	  63	  	  
Relationship	  Between	  Strain	  and	  Dyssynchrony	  The	  use	  of	   longitudinal	  and	  circumferential	  strain	  dyssynchrony	  measurements	  that	   align	   with	   the	   orientation	   of	   the	   helical	   cardiac	   microstructure	   64	   as	   sole	  metrics	  of	  cardiac	  function	  is	  fraught	  with	  physiological	  limitations.	  The	  intrinsic	  variation	  in	  the	  time	  taken	  for	  different	  regions	  of	  the	  heart	  to	  contract	  and	  reach	  their	   peak	   strain	   in	   the	   healthy	   heart	   obscures	   any	   changes	   in	   synchrony	   that	  may	  occur	  with	  heart	  failure.	  The	  timing	  of	  peak	  contraction	  in	  the	  heart	  varies	  transmurally	   65,	   circumferentially	   66	   and	   in	   the	   apex	   to	   base67	   directions.	   This	  variation	   is	  significant	  with	  an	  83ms	  65	  dispersion	   in	  time	  to	  peak	  strain	  across	  the	   heart	   wall	   in	   canines	   compared	   with	   a	   QRS	   duration	   of	   approximately	  60ms68,	  and	  the	  time	  to	  peak	  circumferential	  strain	  varies	  by	  121ms	  66	  in	  human	  LV,	  where	  the	  QRS	  duration	  is	  	  approximately	  80ms.	  69	  The	  distribution	  of	  timing	  of	  peak	  deformation	  is	  consistent	  with	  the	  distribution	  of	  electrical	  activation	  70-­‐
72	   only	   amplified.	   68	   This	   increased	   heterogeneity	   in	   the	   spatial	   variation	   in	  deformation	   is	   potentially	   facilitated	   by	   multiple	   factors	   including	   the	   non-­‐uniformity	  of	  fibre	  and	  sheet	  orientation	  73-­‐75,	  activation	  times	  72,	  regional	  cavity	  curvature	  76,	  contractile	  function	  77-­‐79,	  electrophysiology	  71	  and	  passive	  material	  properties.	  78,	  79	  	  The	  correlation	  between	  types	  of	  strain	  and	  predicting	  which	  patients	  are	  likely	  to	   respond	   to	   CRT	   is	   variable	   with	   some	   studies	   showing	   no	   correlation80	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whereas	  others	  do.	  81	  The	  apparent	  separation	  of	  radial	  from	  circumferential	  and	  axial	   strain	   seen	   in	   some	   studies	   correlates	   with	   the	   different	   mechanisms	  underpinning	   ejection	   due	   to	  wall	   thickening	   and	   apical-­‐basal	   shortening.	   In	   a	  normal	  subject,	  wall	  thickening	  contributes	  25-­‐48%	  of	  stroke	  volume	  82-­‐84	  and	  is	  the	  result	  of	  a	  combination	  of	  shearing	  and	  elongation	  along	  the	  laminar	  sheets	  that	   make	   up	   the	   myocardium	   85-­‐88	   and	   has	   a	   limited	   correlation	   with	   fibre	  shortening.	  89	  Furthermore,	  wall	  thickening	  is	  sensitive	  to	  both	  local	  perfusion	  90	  and	  metabolism	   91	   providing	   a	   potential	   indicator	   of	  metabolic	   heterogeneities	  and	  inefficiencies	  that	  are	  rectified	  in	  the	  case	  of	  CRT	  responders.	  92	  
Imaging	  in	  CRT	  and	  Techniques	  to	  Measure	  Dyssynchrony	  Imaging	   techniques	   in	   CRT	   are	   integral	   in	   determining	   function	   as	   well	   as	  response	  to	  therapy.	  The	  pursuit	  of	  improving	  patient	  selection	  has	  concentrated	  extensively	   on	   use	   of	   imaging	   methods,	   particularly	   transthoracic	  echocardiography	   (TTE),	   to	   develop	   measures	   of	   dyssynchrony	   that	   have	   the	  potential	   to	   improve	   CRT	   response	   rates.	   Although	   much	   of	   the	   work	   has	  concentrated	  on	  the	  use	  of	  echocardiography,	  similar	  comparable	  measures	  are	  being	  developed	  with	  CMR.	  Table	  4	  shows	  the	  comparison	  of	  echocardiography	  and	  CMR.	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Table	  4	  Comparisons	  of	  pros	  and	  cons	  of	  echocardiography	  and	  CMR	  	   Echocardiography	   	  	  	  	  	  	  	  	  CMR	  
Functional	  assessment	   ++	   +++	  
Dyssynchrony	   +++	   +++	  
Myocardial	  anatomy	   ++	   +++	  
Coronary	  vein	  anatomy	   	   +++	  
Myocardial	  scar	   	   +++	  
Inter	  procedural	  imaging	   ++	   +	  
Post	  procedural	  imaging	   +++	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Echocardiography	  in	  CRT	  TTE	   has	   a	   role	   in	   the	   routine	   evaluation	   of	   patients	   pre	   and	   post	   CRT	   for	  assessment	  of	  LV	   function,	   chamber	  dimensions	  and	  EF	  as	  well	   as	   exclusion	  of	  significant	   valvular	   disease	   and	   other	   cardiac	   pathology.	   Furthermore,	   TTE	   is	  required	  for	  the	  quantification	  of	  dyssynchrony	  as	  UK	  NICE	  guidelines	  stipulate	  that	  there	  must	  be	  echocardiographic	  evidence	  of	  dyssynchrony	  in	  patients	  with	  QRS	  duration	  between	  120	  and	  150ms	   in	  order	   for	  patients	   to	  qualify	   for	  CRT.	  There	   is	   worldwide	   interest	   in	   the	   potential	   of	   TTE	   to	   distinguish	   between	  responders	   and	   non-­‐responders	   to	   CRT	   due	   to	   the	   premise	   that	   electrical	  surrogate	   measurements	   for	   dyssynchrony	   (such	   as	   the	   QRS	   duration)	  inadequately	  identify	  mechanical	  dyssynchrony.	  	  
Assessment	  of	  Atrio-­‐Ventricular	  Dyssynchrony	  AV	  dyssynchrony	  is	  typically	  measured	  using	  pulsed	  wave	  Doppler	  recording	  of	  the	   transmitral	   inflow	  (figure	  13),	  which	   requires	   the	   sample	  volume	  placed	  at	  the	  tips	  of	  the	  mitral	  leaflets.	  93	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Figure	  13	  Mitral	  valve	  filling	  patterns	  for	  two	  patients	  with	  heart	  failure.	  
	  
A	   Shows	   clearly	   defined	   E/A	  waves	  whereas	  B	   there	   is	   clearly	   very	   abnormal	  filling	  with	  fused	  E/A	  waves.	  
Assessment	  of	  Inter-­‐ventricular	  Dyssynchrony	  Inter-­‐ventricular	   dyssynchrony	   is	   commonly	   assessed	   by	   using	   pulsed	   wave	  Doppler	  in	  the	  aorta	  and	  pulmonary	  artery,	  with	  the	  pre-­‐ejection	  periods	  (PEP)	  defined	  as	  time	  from	  the	  Q	  wave	  on	  the	  ECG	  to	  onset	  of	  flow	  on	  Doppler	  (figure	  15).	   Aortic	   pre-­‐ejection	   period	   ≥140ms	   and	   inter-­‐ventricular	   delay	   (IVMD)	  ≥40ms	  are	  considered	  to	  be	  pathological	  94	  and	  were	  two	  of	  the	  three	  criteria	  in	  the	   CARE-­‐HF	   study	   to	   define	   echocardiographic	   evidence	   of	   dyssynchrony.	  Alternatively,	   pulsed	   tissue	   Doppler	   can	   be	   used	   to	   determine	   IVMD	   by	  measuring	  the	  time	  from	  QRS	  onset	  to	  the	  peak	  myocardial	  systolic	  velocity	  (Sm)	  of	  the	  RV	  free	  wall	  versus	  the	  same	  time	  of	  the	  LV	  lateral	  wall	  in	  the	  apical	  four-­‐chamber	  view.	  44	  	  	   	  
!
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Figure	  14	  Calculation	  of	  inter-­‐ventricular	  mechanical	  delay.	  
	  	  
Assessment	  of	  intra-­‐ventricular	  Dyssynchrony	  The	   best	   TTE	   method	   for	   measuring	   intra-­‐ventricular	   dyssynchrony	   is	   not	  known.	   This	   has	   led	   to	   the	   development	   of	   multiple	   methods	   to	   assess	   intra-­‐ventricular	  dyssynchrony	  of	  varying	  complexity	  which	  are	  described	  below:	  
	  
M-­‐mode	  echocardiography	  The	   septal	   to	   posterior	   wall	   motion	   delay	   (the	   time	   difference	   between	   peak	  inward	   motion	   of	   the	   ventricular	   septum	   and	   the	   posterior	   wall)	   in	   the	  parasternal	   long	  axis	  view	  was	  described	  by	  Pitzalis	  et	  al.	   95	  A	  delay	  of	  >130ms	  was	   thought	   to	   predict	   reduction	   in	   ESV	   and	   improvement	   in	   LVEF	   as	  well	   as	  prognosis	   at	   six	  months.	   Limitations	   to	   this	   technique	   include	   the	   lack	   of	  wall	  thickening	   in	   infarcted	   regions	   as	   well	   as	   difficulty	   in	   aligning	   the	   ultrasound	  beam	   perpendicular	   to	   the	   ventricle	   in	   the	   case	   of	   off-­‐axis	   views.	   Subsequent	  studies	  did	  not	  confirm	  the	  initial	  findings.	  96,	  97	  
!
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Tissue	  velocity	  imaging	  This	  is	  performed	  using	  TDI	  in	  the	  apical	  views	  to	  identify	  peak	  systolic	  velocity	  in	  the	  longitudinal	  direction.	  Studies	  have	  varied	  in;	  	  1. Number	  of	  segments	  sampled	  	  2. Whether	   velocity	   peaks	   were	   measured	   during	   systole	   alone	   or	   also	  during	  the	  post-­‐ejection	  period	  	  3. Use	  of	  either	  time	  to	  peak	  velocity	  or	  time	  to	  onset	  of	  systolic	  velocity	  	  4. Whether	  the	  dyssynchrony	  index	  is	  derived	  from	  the	  maximum	  difference	  of	  timing	  intervals	  or	  the	  standard	  deviation	  of	  individual	  times	  	  5. Use	  of	  pulsed	  wave	  versus	  colour-­‐coded	  TDI.	  	  	  The	  latter	  is	  more	  robust	  as	  it	  allows	  simultaneous	  processing	  of	  multiple	  sample	  points	   on	   the	   same	   image.	   A	   basal	   septal-­‐lateral	   delay	   in	   time	   to	   peak	   systolic	  velocity	   of	   >60ms	   using	   this	   technique	   was	   reported	   by	   Bax	   et	   al	   to	   predict	  improvements	   in	   LVEF	   98	   and	   RR.	   49	   Yu,	   the	   other	   principal	   proponent	   of	   TDI,	  proposed	   a	   dyssynchrony	   index	   of	   standard	   deviation	   in	   time	   to	   peak	   systolic	  velocity	  between	  12	  basal	   and	  mid	   segments,	  which	  predicted	  RR	  after	  CRT.	   99	  Furthermore,	   this	   group	   demonstrated	   that	   RR	   rather	   than	   symptomatic	  improvement	  predicts	  long-­‐term	  survival	  after	  CRT.	  45	  	  There	   are	   several	   limitations	   to	   these	   techniques.	   Two	   distinct	   peaks	   of	   tissue	  velocity	   may	   be	   seen	   during	   systole,	   leading	   to	   difficulties	   in	   interval	  measurement.	  Peak	  velocities	  may	  occur	   after	   the	   end	  of	   systole,	   giving	   rise	   to	  uncertainty	  as	   to	  whether	   these	  should	  be	   included	   in	  analysis.	   In	  heart	   failure	  patients	   with	   LBBB,	   a	   rocking	   motion	   is	   frequently	   seen,	   but	   this	   may	   not	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represent	  dyssynchronous	  contraction	  and	  may	  be	  difficult	  to	  interpret	  with	  TDI.	  	  Therefore,	  differences	   in	   the	  timing	  and	  magnitude	  of	  regional	  contraction	  may	  be	  better	  evaluated	  in	  radial	  or	  circumferential	  planes.	  	  
	  
Strain	  imaging	  Strain	   can	   be	   measured	   using	   TDI	   or	   2D	   speckle	   tracking.	   Results	   using	   TDI-­‐derived	  strain	  have	  been	  mixed.	  Yu	  et	  al	   found	  that	   tissue	  Doppler	   longitudinal	  velocity,	   but	   not	   longitudinal	   strain,	   predicted	   RR	   after	   CRT.	   100	   2D	   speckle	  tracking	  has	  the	  advantage	  that	  it	   is	  angle	  independent,	  but	  at	  the	  cost	  of	   lower	  temporal	  resolution.	  Suffoletto	  et	  al	  demonstrated	  that	  radial	  strain	  assessed	  by	  speckle	  tracking	  was	  predictive	  of	  acute	  and	  chronic	  improvements	  in	  LVEF	  after	  CRT	  101	  with	  incremental	  benefit	  seen	  when	  the	  LV	  lead	  position	  was	  concordant	  with	   the	   site	   of	   latest	   mechanical	   activation.	   Ypenburg	   et	   al	   demonstrated	   a	  reduction	  in	  a	  combined	  endpoint	  of	  hospitalisation	  and	  death	  in	  cases	  where	  the	  LV	   lead	  was	  positioned	   in	   the	   site	   of	   latest	  mechanical	   activation	   corroborated	  these	  findings.	  14	  
Three-­‐dimensional	  echocardiography	  	  A	   single	   breath-­‐hold	   acquisition	   over	   several	   heartbeats	   gives	   the	   entire	  ventricular	   volume,	   which	   is	   subdivided	   into	   16	   pyramidal	   sub-­‐volumes.	   It	   is	  then	  possible	  to	  derive	  time-­‐volume	  data	  for	  the	  entire	  cardiac	  cycle	  and	  assess	  the	  time	  taken	  to	  reach	  the	  minimum	  systolic	  volume.	  The	  standard	  deviation	  of	  these	  values	  across	  16	  segments	  is	  expressed	  as	  a	  percentage	  of	  the	  cardiac	  cycle	  to	   give	   the	   systolic	   dyssynchrony	   index	   (SDI),	   which	   is	   a	  marker	   of	   the	   global	  dyssynchrony	  of	   the	  LV,	   first	  described	  by	  Kapetanakis	  et	   al.	   102	  Real-­‐time	  3DE	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(RT3DE)	  has	  been	  shown	  to	  predict	  acute	  response	  to	  CRT	  17	  although	  follow-­‐up	  data	  are	  limited.	  The	  large	  volume	  of	  acquisition	  of	  RT3DE	  gives	  rise	  to	  relatively	  poor	  temporal	  resolution	  compared	  with	  2D	  echo.	  This	  technique	  also	  relies	  on	  a	  regular	  RR	  interval	  thereby	  limiting	  its	  utility	  in	  patients	  with	  atrial	  fibrillation	  or	  frequent	  ectopy.	  	  
Current	  role	  of	  echocardiography	  Echocardiography	   is	   an	   essential	   tool	   for	   assessment	   of	   LV	   function,	   chamber	  dimensions	  and	  LV	  EF	  to	  identifying	  candidates	  for	  CRT.	  In	  light	  of	  the	  negative	  results	   of	   the	   PROSPECT	   study,	   which	   did	   not	   find	   any	   individual	  echocardiography	  criterion	  superior	  to	  QRS	  duration	  at	  predicting	  CRT	  response	  
103	   the	   assessment	   of	   dyssynchrony	   remains	   unclear	   when	   used	   to	   help	  determine	  which	   patients	  will	   do	  well	   from	   CRT.	   A	  major	   limitation	   to	   TTE	   is	  significant	  intra-­‐	  and	  inter-­‐observer	  variability,	  which	  was	  particularly	  marked	  in	  the	   PROSPECT	   trial.	   Reasons	   for	   the	   significant	   observer	   variability	   are	   multi	  factorial.	  	  1. Patients	  with	  heart	  failure	  often	  have	  poor	  acoustic	  windows.	  2. Difficulty	  breath	  holding	  leading	  to	  reduced	  image	  quality.	  3. Arrhythmias	   such	   as	   atrial	   fibrillation	   or	   ventricular	   ectopics	   affect	  measurement	  accuracy.	  	  Furthermore,	   there	  remains	  no	  clear	  consensus	  on	  which	  measure	  to	  use	  when	  assessing	  dyssynchrony.	  It	  therefore,	  remains	  unclear	  which	  TTE	  parameters	  of	  dyssynchrony	  should	  be	  used	  to	  determine	  which	  patients	  are	  likely	  to	  respond	  to	  CRT.	  However,	  the	  role	  of	  echocardiography	  in	  patients	  with	  intermediate	  QRS	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prolongation	   is	   currently	   mandated	   in	   the	   UK	   by	   the	   NICE	   guidelines.	   It	   is	  important	   to	   realise	   that	   newer	   techniques	   such	   as	   speckle	   tracking	   and	   3DE	  were	  not	  assessed	  in	  the	  PROSPECT	  study.	  The	  clinical	  usefulness	  of	  an	  imaging	  modality	  capable	  of	  predicting	  CRT	  response	  continues	  to	  drive	  forward	  research	  in	  this	  area.	  Overview	  of	  current	  echo	  acquisition	  and	  analysis	  methods	  is	  shown	  in	  figures	  15	  and	  16.	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Figure	  15	  Overview	  of	  echocardiography	  assessment	  of	  CRT	  patients	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Figure	  16	  Overview	  of	  analysis	  of	  echocardiography	  imaging	  in	  CRT	  patients	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Cardiac	  Magnetic	  Resonance	  Imaging	  	  
A	  brief	  history	  of	  magnetic	  resonance	  imaging	  	  Felix	   Bloch	   and	   Edward	   Purcell	   both	   described	   the	   phenomenon	   of	   nuclear	  magnetic	   resonance	   in	   the	   1940s	   independently.	   During	   the	   1950s	   and	   1960s	  this	  was	  widely	  used	  for	  the	  analysis	  of	  chemical	  compounds.	  Not	  until	  the	  1970s	  when	  Damadian	  applied	  MRI	  for	  tissue	  characterisation	  did	  the	  technique	  break	  into	  the	  clinical	  medicine	  arena.	  The	  application	  of	  imaging	  was	  developed	  when	  Lauterbur	   applied	   the	   idea	   of	   magnetic	   field	   gradients	   in	   3D	   to	   derive	   spatial	  orientation	  using	  MRI.	  Ernst	  developed	  the	  basis	  of	  modern	  MRI	  techniques	  with	  the	   introduction	   of	   phase	   and	   frequency	   encoding,	   and	   the	   Fourier	   transform.	  Mansfield	   developed	   echo-­‐planar	   imaging,	   with	   improvements	   in	   the	   use	   of	  gradients	  and	  signal	  analysis.	  
Basic	  principles	  of	  CMR	  The	  hydrogen	  atom	  consists	  of	  a	  positively	  charged	  proton	  and	  electrons	  and	  is	  abundant	  in	  the	  human	  body.	  This	  forms	  the	  basis	  for	  the	  use	  of	  MRI	  in	  medical	  imaging.	  The	  proton	  has	  an	  inherent	  nuclear	  spin,	  which	  creates	  a	  tiny	  magnetic	  field.	   In	   the	   tissues	  of	   the	  body,	   the	  magnetic	   fields	   resulting	   from	  each	  proton	  are	   randomly	   distributed.	   When	   the	   body	   is	   placed	   in	   a	   large	   and	   powerful	  magnet,	   these	   tiny	  magnetic	   fields	   align	  with	   the	   large	   external	  magnetic	   field	  and	  reach	  equilibrium.	  This	  equilibrium	  can	  be	  disturbed	  by	  applying	  energy	  to	  the	   body’s	   tissues	   (“excitation”).	   This	   is	   achieved	   using	   a	   radio-­‐frequency	   (RF)	  pulse,	  if	  the	  pulse	  is	  of	  the	  same	  resonance	  frequency	  as	  that	  of	  the	  protons.	  The	  result	   of	   the	   excitation	  with	   the	  RF	  pulse	   is	   a	   rotational	  movement	  of	   the	   total	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magnetisation,	   called	   precession.	   The	   frequency	   of	   precession	   for	   protons	   is	  proportional	  to	  the	  magnetic	  field	  strength	  and	  the	  strength	  of	  the	  magnetisation	  is	  dependent	  on	   the	  proton	  density	   in	   the	   tissue.	  The	  angle	  of	  magnetisation	   is	  moved	   to	   an	   angle	   away	   from	   the	   main	   magnetic	   field	   depending	   on	   the	  amplitude	   and	  duration	   of	   the	  RF	  pulse.	   The	  magnetisation	   rotates	   around	   the	  main	  axis	  of	  the	  magnetic	  field,	  resulting	  in	  a	  high	  frequency	  alternating	  magnetic	  field.	   This	   gives	   rise	   to	   a	   signal,	   which	   is	   a	   voltage	   that	   can	   be	  measured	   in	   a	  receiver	  coil.	  	  However,	  the	  signal	  is	  only	  transient,	  as	  the	  nuclei	  give	  off	  the	  energy	  they	  have	  acquired	   back	   to	   the	   surrounding	   tissues	   and	   the	   magnetisation	   becomes	  realigned	   in	   the	   longitudinal	   plane	   with	   the	   main	   magnetic	   field,	   at	   an	  exponential	  rate.	  This	  is	  known	  as	  longitudinal	  relaxation.	  The	  rate	  at	  which	  this	  happens	   depends	   on	   characteristics	   of	   the	   tissue	   and	   if	   the	   equilibrium	   is	  restored	  more	  quickly,	   the	   tissue	  has	   a	   short	  T1	   (longitudinal)	   relaxation	   time.	  The	  second	  aspect	  of	  restoring	  equilibrium	  is	  loss	  of	  the	  transverse	  component	  of	  the	  magnetisation,	  i.e.	  that	  which	  is	  in	  the	  plane	  perpendicular	  to	  the	  main	  axis	  of	  the	   magnetic	   field.	   This	   happens	   because	   of	   interaction	   between	   different	  protons	   causing	   inhomogeneities	   in	   the	  magnetic	   field.	   The	   rotating	   vectors	   of	  magnetisation	  are	  fanned	  out	  (“dephased”)	  such	  that	  they	  are	  not	  all	  pointing	  in	  the	  same	  direction,	  although	  they	  remain	  within	  the	  plane	  perpendicular	  to	  the	  main	  magnetic	  field.	  As	  a	  result,	  the	  sum	  of	  these	  rotating	  vectors	  is	  reduced	  and	  so	  is	  the	  signal.	  This	  is	  known	  as	  transverse	  relaxation.	  Again,	  the	  speed	  at	  which	  this	  occurs	  is	  dependent	  on	  tissue	  properties,	  which	  govern	  the	  T2	  (transverse)	  relaxation	  time.	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  Spatial	  orientation	  is	  necessary	  in	  order	  to	  create	  an	  image.	  This	  is	  made	  possible	  using	  gradient	  fields.	  In	  contrast	  to	  the	  static	  field	  of	  the	  magnet,	  gradient	  fields	  can	  be	  altered	  over	  time	  in	  all	   three	  dimensions.	   In	  this	  way,	  a	  2-­‐D	  slice	  can	  be	  selected	   by	   applying	   a	   gradient	   in	   the	   direction	   perpendicular	   to	   it,	   while	   the	  excitation	  RF	  pulse	  is	  transmitted.	  The	  pulse	  will	  only	  have	  an	  effect	  on	  the	  slice	  of	   tissue	   in	  which	   the	  protons	  have	   the	  same	  resonance	   frequency	  as	   the	  pulse	  itself.	  The	  signal	  induced	  in	  the	  detector	  coil	  is	  described	  by	  a	  sine	  function.	  The	  frequency	  and	  phase	  of	  this	  function	  are	  used	  to	  define	  spatial	  orientation.	  Phase	  differences	   result	   from	   the	   use	   of	   a	   gradient	   field	   in	   one	   direction	   (“phase	  encoding”)	   and	   frequency	   differences	   in	   the	   signal	   result	   from	   a	   gradient	   field	  applied	   in	   the	   other	   direction	   of	   the	   field	   of	   view	   (“frequency	   encoding”).	   This	  sampling	   process	   is	   repeated	   multiple	   times	   (this	   is	   the	   number	   of	   phase	  encoding	   steps)	   in	   order	   to	   acquire	   all	   of	   the	   spatial	   frequency	   components	  needed	   to	   make	   the	   image.	   The	   time	   between	   consecutive	   measurements	   is	  called	   the	   repetition	   time	   (“TR”).	  The	   image	  can	   then	  be	   calculated	  using	   these	  individual	   spatial	   frequency	   components	   using	   Fourier	   transformation.	   This	  gives	   a	   representation	   of	   the	   signals	   in	   the	   frequency	   domain.	   The	   digitized	  representations	  of	  these	  signals	  are	  converted	  into	  a	  data	  matrix	  called	  k-­‐space,	  which	   is	   derived	   on	   one	   axis	   from	   frequency	   encoding	   information	   and	   on	   the	  other	   from	   phase	   encoding	   information.	   Data	   in	   the	   centre	   of	   k-­‐space	   encodes	  contrast	  information	  as	  it	  has	  low	  spatial	  frequency	  but	  high	  amplitude,	  whereas	  data	  in	  the	  periphery	  of	  k-­‐space	  provides	  image	  sharpness,	  as	  it	  has	  high	  spatial	  frequency	  but	  low	  amplitude.	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Cardiac	  magnetic	  resonance	  imaging	  in	  CRT	  CMR	   has	   huge	   potential	   in	   the	   assessment	   and	   selection	   of	   patients	   for	   CRT.	  Although	  echocardiography	  remains	  the	  primary	  imaging	  modality	  in	  CRT,	  CMR	  has	  a	  number	  of	  advantages.	  The	  following	  can	  all	  be	  assessed	  with	  CMR.	  1. Cardiac	  function	  2. Myocardial	  scar	  3. Cardiac	  vein	  anatomy	  4. Ventricular	  motion/dyssynchrony	  CMR	  is	  the	  only	  imaging	  modality	  that	  is	  able	  to	  address	  all	  of	  these	  factors	  that	  have	  the	  potential	  to	   influence	  patient	  selection	  and	  thus	  improve	  the	  response	  to	  CRT.	  
Functional	  assessment	  The	   combination	   of	   an	   excellent	   spatial,	   contrast	   and	   temporal	   resolution,	  providing	  high-­‐quality	  morphological	  images	  of	  the	  heart	  throughout	  the	  cardiac	  cycle	   enables	   truly	   volumetric	   quantification	   and	   regional	   functional	   analysis.	  Velocity-­‐encoded	   CMR	   techniques	   allow	   assessment	   of	   flow	   profiles	   through	  cardiac	   valves	   and	   analysis	   of	   myocardial	   motion	   patterns.	   CMR	   myocardial	  tagging	  techniques	  offer	  unique	  information	  about	  myocardial	  wall	  deformation	  and	  the	  mechanisms	  of	  myocardial	  contraction.	  	  
Myocardial	  scar	  imaging	  Late	   gadolinium	  enhancement	   imaging	   is	   used	   to	   visualise	  myocardial	   damage,	  such	  as	   scar,	   fibrosis	  or	  oedema.	  Assessment	  of	   scar	   tissue	  not	  only	  helps	  with	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determining	  the	  aetiology	  of	  heart	  failure,	  but	  also	  can	  help	  in	  determining	  which	  patients	  are	  likely	  to	  respond	  to	  CRT.	  	  	  An	   intravenous	   contrast	   agent	   is	   administered,	   most	   frequently	   a	   chelate	   of	  gadolinium.	   This	   agent	   is	   extracellular,	   therefore	   is	   distributed	   into	   the	  intravascular	   and	   interstitial	   space,	   but	   does	   not	   penetrate	   healthy	  myocardial	  cells.	   Therefore,	   areas	   of	   acute	   or	   chronic	   infarction	   or	   oedema	   show	   higher	  signal	  than	  normal	  tissue.	  The	  inversion	  recovery	  technique	  104	  is	  used	  to	  null	  the	  healthy	  myocardium	  by	  suppressing	  the	  magnetisation,	  the	  tissue	  appears	  dark.	  The	  contrast	  agent	  accumulates	   in	  areas	  of	  damaged	  myocardium,	  and	  appears	  bright	  due	  to	  faster	  T1	  relaxation.	  The	  distribution	  and	  transmural	  extent	  of	  late	  gadolinium	  enhancement	  can	  be	  used	  to	  assess	  myocardial	  viability.	  105	  	  
Cardiac	  vein	  anatomy	  Knowledge	  of	  the	  cardiac	  anatomy	  particularly	  of	  the	  coronary	  veins	  is	  becoming	  increasingly	  important	  in	  CRT.	  In	  the	  vast	  majority	  of	  CRT	  procedures	  the	  LV	  lead	  is	  implanted	  transvenously	  through	  the	  coronary	  sinus	  into	  a	  lateral	  or	  posterior	  branch	  of	   the	  coronary	  sinus.	  There	   is	  marked	   individual	  variation	   in	   coronary	  venous	  anatomy,	  which	  can	  make	  it	  difficult	  to	  find	  a	  suitable	  position	  for	  the	  LV	  lead.	  106	  	  CMR	  can	  be	  used	  to	  assess	  coronary	  veins	  using	  an	  intravascular	  contrast	  107,	  108	  or	   without	   a	   contrast	   agent	   by	   employing	   an	  MTC-­‐prepulse.	   109	   The	   use	   of	   an	  intravascular	   contrast	   agent	   has	   been	   shown	   to	   give	   excellent	   CV	   anatomy.	   108	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The	   use	   of	   intravascular	   contrast	   agents	   means	   that	   limited	   information	   with	  respect	  to	  myocardial	  scar	  can	  be	  obtained.	  	  	  A	  recent	  retrospective	  study	  110	  evaluated	  CMR	  angiograms	  of	  31	  patients	  for	  the	  ability	   to	   visualize	   coronary	   venous	   anatomy	   using	   conventional	   extravascular	  contrast	  agent.	  This	  was	  part	  of	  a	  comprehensive	  research	  protocol	  for	  patients	  with	  suspected	  coronary	  disease.	  This	  study	  demonstrated	  the	  feasibility	  of	  using	  CMR	   for	   assessment	  of	   scar	   and	  venous	  anatomy.	  However	   the	   scans	  were	  not	  optimized	   for	   visualization	   of	   the	   venous	   system.	   Furthermore,	   the	   average	  ejection	  fraction	  in	  the	  patient	  group	  was	  over	  50%.	  The	  clinical	  relevance	  of	  this	  study	   is	   therefore	   limited	   as	   heart	   failure	  patients	   requiring	  CRT	  have	   ejection	  fractions	   of	   less	   than	   35%	   and	   often	   have	   fast	   irregular	   heat	   rhythms	   and	  irregular	  breathing	  patterns	  leading	  to	  technical	  challenges	  with	  respect	  to	  CMR	  image	  acquisition.	  	  	  Further	   work	   is	   required	   to	   enable	   visualization	   of	   coronary	   veins	   and	  myocardial	  scar	  in	  heart	  failure	  patients	  in	  a	  single	  CMR.	  	  
Assessing	  cardiac	  motion	  and	  dyssynchrony	  with	  CMR	  Using	   cine	   wall	   motion,	   myocardial	   tagging,	   tissue	   velocity	   mapping,	   or	  displacement	  imaging	  can	  quantify	  mechanical	  motion/dyssynchrony.	  However,	  no	   guidelines	   exist	   for	   the	   use	   of	   CMR	   derived	   measures	   of	   dyssynchrony	   for	  selection	  of	  patients	   for	  CRT.	  Therefore,	   the	  question	  remains	  how	  useful	   these	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measures	   of	   mechanical	   dyssynchrony	   are	   for	   indicating	   which	   patients	   will	  benefit	  from	  CRT.	  	  
Cine	  imaging	  and	  myocardial	  motion	  and	  dyssynchrony	  Cine	  anatomical	  images	  of	  the	  myocardium	  provide	  excellent	  information	  about	  both	   endocardial	   and	   epicardial	   borders.	   The	   images	   are	   normally	   acquired	   in	  the	   four-­‐chamber,	   three-­‐chamber,	   two-­‐chamber	   and	   short	   axis	   stack.	   Often	  mechanical	  dyssynchrony	  is	  apparent	  visually	  on	  these	  images.	  More	  quantative	  methods	   of	   identifying	   mechanical	   dyssynchrony	   have	   been	   developed.	   111-­‐113	  These	   methods	   utilize	   semi	   automated	   or	   automated	   border	   detection	   to	  compute	  myocardial	  wall	  motion,	  wall	   thickening	  or	  deformation.	  A	  method	  for	  quantification	  of	  myocardial	  dyssynchrony	  based	  on	  the	  amount	  of	  internal	  flow	  within	  the	  LV	  blood	  pool	  derived	  from	  the	  cine	  short-­‐axis	   images	  has	  also	  been	  proposed.	   114	   Issues	   with	   these	   techniques	   are	   that	   multiple	   breath	   holds	   are	  required,	  which	  lead	  to	  alignment	  errors	  between	  separate	  slices.	  The	  use	  of	  3D	  SSFP	  techniques	  either	  as	  breath	  holds	  or	  novel	  respiratory	  navigators	  115	  has	  the	  potential	   to	   overcome	   these	   problems.	   However,	   these	   techniques	   suffer	   from	  reduced	  blood	  pool	  contrast.	  	  The	   benefit	   of	   these	   techniques	   for	   predicting	   response	   to	   CRT	   is	   not	   clear.	  Studies	   have	   shown	   differences	   in	   systolic	   timings,	   112	   regional	   myocardial	  thickening,	   113	   maximal	   radial	   motion,	   116	   and	   internal	   flow	   fraction	   between	  normal	   volunteers	   and	   heart	   failure	   patients	   with	   QRS	   durations	   greater	   than	  120ms	   selected	   for	   CRT.	   A	   dyssynchrony	   index	   based	   on	   maximal	   radial	   wall	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motion	   deemed	   the	   “cardiovascular	   magnetic	   resonance	   tissue	   synchronization	  
index”	   (CMR-­‐TSI)	   was	   shown	   to	   be	   a	   predictor	   of	   all-­‐cause	   mortality	   and	   the	  hospitalizations	  related	  to	  heart	  failure	  after	  CRT.	  116	  	  	  
CMR	  tagging	  Myocardial	  tagging	  imposes	  a	  series	  of	  dark	  bands	  or	  grids	  across	  the	  image.	  This	  technique	   was	   devised	   to	   assess	   regional	   myocardial	   deformation.	   117	  Radiofrequency	  and	  gradient	  pulses	  are	  used	  to	  saturate	  lines	  in	  the	  myocardium	  in	   which	   the	   signal	   is	   destroyed,	   and	   the	   lines	   therefore	   appear	   black.	   	   This	  process	  is	  called	  spatial	  modulation	  of	  magnetization	  (“SPAMM”).	  The	  “tag”	  lines	  formed	   in	   this	   way	   produce	   a	   stripe	   or	   grid	   pattern.	   These	   are	   used	   as	   non-­‐invasive	   markers	   on	   the	   myocardium.	   The	   changes	   in	   these	   lines	   through	  multiple	   phases	   of	   the	   cardiac	   cycle	   can	   be	   used	   to	   derive	   regional	   changes	   in	  deformation	   (or	   strain).	   The	   tag	   lines	   do	   not	   persist	   indefinitely,	   as	   the	  magnetization	   recovers	   towards	   equilibrium.	   Complementary	   SPAMM	  (“CSPAMM”)	   improves	   the	  persistence	  of	   the	   tag	   lines	   in	  order	   to	   assess	   strain	  through	  the	  whole	  cardiac	  cycle.	  118	  	  Tagged	  images	  are	  usually	  analysed	  by	  tracking	  the	  location	  of	  the	  tag	  lines	  over	  time.	   This	   information	   is	   used	   to	   quantify	   regional	   deformation	   or	   compute	  regional	   strain.	   A	   variety	   of	   techniques	   are	   used	   for	   the	   analysis	   of	   tagged	  imaging.	   119	   120	  Most	  dyssynchrony	  measures	  reflect	   the	   temporal	  dispersion	  of	  cardiac	   events	   measured	   in	   terms	   of	   the	   absolute	   difference	   delay	   or	   the	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standard	  deviation	  of	  the	  time	  to	  onset	  or	  peak	  wall	  motion,	  deformation,	  strain	  or	  strain	  rate.	  	  The	  clinical	  usefulness	  of	  CMR	  tagging	  has	  been	   limited	  by	   the	   time-­‐consuming	  nature	  of	   the	  data	  analysis.	  Tagging	  has	  been	  used	   to	  quantify	   strain	   in	   animal	  models	  of	  ventricular	  pacing	  121	  and	  subsequently	  in	  humans	  with	  heart	  failure.	  
16	  Circumferential	  assessment	  of	  strain	  using	  CMR	  appears	  to	  be	  more	  sensitive	  to	  dyssynchrony	  when	  compared	  to	  longitudinal	  strain.	  81	  	  Harmonic	  phase	  (HARP)	  is	  a	  method	  of	  more	  rapid	  analysis	  of	  tagged	  MRI	  data,	  which	  measures	  motion	  by	   filtering	  out	  regions	   in	   the	   frequency	  domain	  of	   the	  images	   (harmonic	   peaks).	   122	   The	   harmonic	   magnitude	   and	   harmonic	   phase	  correspond	  to	  the	  anatomy	  and	  tag	  deformation	  of	  the	  resulting	  images,	  with	  the	  frequency	  of	   the	   tag	   lines	   reflecting	   local	  myocardial	   strain.	  This	   technique	  has	  been	  validated	  and	  applied	  in	  human	  studies	  to	  characterise	  regional	  function.	  123	  More	  recently	  this	  approach	  has	  been	  used	  to	  characterise	  regional	  strain	  in	  the	  assessment	  of	  patients	  for	  CRT	  using	  an	  index	  of	  circumferential	  strain	  (the	  CURE	  index).81	   The	  methodology	   used	   to	   derive	   the	   CURE	   index	   involves	   generating	  time	  plots	  of	  strain	  for	  each	  segment	  in	  each	  short	  axis	  slice.	  Each	  plot	  of	  strain	  versus	  myocardial	  location	  is	  submitted	  to	  Fourier	  analysis	  to	  yield	  zero	  to	  first	  order	   terms.	  Bichick	  et	  al	  showed	  that	  a	  CURE	  cut-­‐off	  of	  <0.75	  (0	  denotes	  pure	  dyssynchrony	   and	   1	   denotes	   perfect	   synchrony)	   predicted	   improvement	   in	  NYHA	  class	  post	  CRT	  with	  90%	  accuracy.	  124	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The	   various	   methods	   to	   analysis	   tagged	   data	   still	   suffer	   from	   the	   similar	  problems	  to	  TTE	  strain	  assessments	  in	  that	  motion	  analysis	  is	   limited	  to	  2D.	  As	  stated	  earlier	  the	  LV	  wall	  is	  a	  complex	  structure	  and	  a	  dyssynchrony	  assessment	  based	   on	   only	   one	   plane	   of	   motion	   is	   unlikely	   to	   reflect	   the	   extent	   of	   LV	  dyssynchrony.	  	  There	  have	  been	  developments	  in	  the	  3D	  CMR	  tagging.	  125	  This	  technique	  allows	  quantification	   of	   strain	   as	   well	   as	   direction	   of	   myocardial	   deformation	   and	  although	   it	   has	   only	   been	   applied	   to	   animals	   it	   may	   prove	   useful	   in	   the	  assessment	  of	  patients	  for	  CRT.	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Current	  Issues	  in	  CRT	  A	  lot	  of	  the	  research	  within	  CRT	  has	  been	  driven	  by	  the	  high	  non-­‐responder	  rate.	  There	  has	  been	  extensive	  work	  focusing	  on	  dyssynchrony	  measures	  to	  determine	  which	   patients	   are	   likely	   to	   respond.	   However,	   recent	  multi-­‐centre	   trials	   have	  shown	   echocardiography	   measures	   are	   no	   better	   than	   the	   QRS	   duration	   for	  predicting	  response.	  The	  reasons	  for	  this	  are	  multi	  factorial	  and	  need	  resolving.	  To	   fully	   understand	   this	   problem	   the	   measures	   of	   dyssynchrony	   need	   to	   be	  understood,	   in	  particular	  how	   they	  relate	   to	   the	  coordinated	  contraction	  of	   the	  ventricle	   and	   how	   these	   indices	   change	   within	   the	   failing	   heart.	  Echocardiography	  remains	  the	  key	  imaging	  modality	  in	  CRT.	  With	  CMR	  becoming	  widely	   available	   and	   the	   improvements	   in	   image	   processing	   there	   is	   huge	  potential	   to	   improve	  our	  understanding	  of	  how	  measures	  of	  dyssynchrony	  may	  aid	  patient	  selection	  for	  CRT.	  	  Currently	   QRS	   duration	   as	   a	   measure	   of	   electrical	   dyssynchrony	   is	   used	   as	   a	  surrogate	  for	  mechanical	  dyssynchrony.	  The	  relationship	  between	  electrical	  and	  mechanical	   activation	   remains	   unclear.	   Methods	   such	   as	   NCM	   allow	   accurate	  assessment	  of	  the	  activation	  patterns	  of	  the	  LV	  and	  image	  registration	  techniques	  allow	  these	  patterns	  to	  be	  compared	  to	  the	  ventricular	  motion.	  	  It	   is	   important	   to	   realise	   that	   although	   the	   aim	   of	   CRT	   is	   to	   synchronise	  ventricular	  contraction	  there	  are	  anatomical	  limitations	  particularly	  with	  respect	  to	  the	  coronary	  veins	  and	  position	  and	  extent	  of	  myocardial	  scar.	  It	  is	  known	  that	  the	  position	  and	  the	  extent	  of	  scar	  affect	  response	  to	  CRT.	  Most	  CRT	  devices	  are	  implanted	  using	  the	  coronary	  sinus.	  The	  relationship	  between	  scar	  and	  veins	  has	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the	   potential	   to	   aid	   implantation	   and	   improve	   response	   rates.	   Improvement	   in	  image	  registration	  tools	  within	  the	  interventional	  cardiac	  catheter	  laboratory	  has	  the	   potential	   to	   allow	   information	   about	   dyssynchrony,	   scar	   and	   veins	   to	   be	  registered	  real	  time	  and	  aid	  implantation.	  	  	  The	  concept	  of	  response	  to	  CRT	  remains	  unclear.	  There	  are	  no	  clear	  guidelines	  to	  determine	   what	   is	   acute	   or	   chronic	   response.	   Furthermore,	   the	   relationship	  between	   acute	   and	   chronic	   response	   is	   unclear	   as	   is	   the	   relationship	   between	  myocardial	   dyssynchrony	   and	   acute	   and	   chronic	   response.	   This	   remains	   an	  important	  issue	  that	  needs	  resolving.	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Chapter	  3	  	  
Methods	  of	  Measuring	  Mechanical	  Dyssynchrony	  and	  
Effectiveness	  in	  Predicting	  Acute	  and	  Chronic	  Response	  
to	  CRT	  
	  
Introduction	  What	  follows	  is	  the	  methodology,	  results	  and	  discussion	  for	  a	  study	  investigating	  global	  LV	  dyssynchrony	  with	  CMR.	  Using	  CMR	  cine	  and	  tagged	  images	  a	  method	  for	  assessing	  global	  myocardial	  muscle	  thickening	  and	  radial,	  circumferential	  and	  longitudinal	   strain	   was	   developed.	   Using	   this	   information	   a	   systolic	  dyssynchrony	   index	  (SDI)	  was	  derived	   for	  all	  parameters	   that	   is	  comparable	   to	  the	   previously	   described	   SDI	   for	   volume	   change.	   By	   developing	   comparable	  measures	  of	  myocardial	  dyssynchrony,	  which	  take	   into	  account	  both	  active	  and	  passive	   motion	   I	   aimed	   to	   evaluate	   how	   these	   techniques	   can	   aid	   in	   our	  understanding	  of	  myocardial	  dyssynchrony	  and	  in	  predicting	  which	  patients	  are	  likely	  to	  respond	  to	  CRT.	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Methods	  
	  
Study	  population	  Patients	  with	  severe	  heart	  failure	  fulfilling	  standard	  criteria	  for	  CRT	  (NYHA	  class	  III-­‐IV	   drug	   refractory	   heart	   failure,	   LVEF	   ≤35%,	   LV	   end-­‐diastolic	   diameter	  ≥55mm	  and	  prolonged	  QRS	  >	  120ms,	  or	  were	  going	  to	  be	  RV	  pacing	  dependent)	  were	  recruited.	  Clinical	  characteristics	  of	   the	  patients	  are	  presented	   in	  Table	  5.	  Patients	   had	   a	   quality-­‐of-­‐life	   questionnaire	   and	   six-­‐minute	   walk	   as	   well	   as	  standard	  2D	  and	  3D	  echocardiogram	  to	  assess	  LV	  volumes	  and	  dyssynchrony	  pre	  and	   six	  months	   post	   CRT.	   Acute	   haemodynamic	   response	  was	   evaluated	   in	   27	  patients	  using	  a	  pressure	  wire	  passed	  to	  the	  LV	  cavity	  at	  the	  time	  of	  CRT.	  Patients	  had	  a	  standard	  BIV	  pacemaker	  inserted	  (table	  6).	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Table	  5	  Patient	  characteristics	  






P	  value	  	  
Age	  (years)	   63.8±13.9	   63.3±16.3	   64.3±11.0	   0.4	  
Sex	  (male/female)	   43/5	   21/4	   22/1	   0.2	  
NYHA	  status	   2.9±0.5	   2.9±0.6	   2.8±0.4	   0.4	  
QOL	  score	  pre	  CRT	   51±24	   51±22	   51±27	   0.5	  
QRS	  duration	  (ms)	   154±24	   159±27	   149±19	   0.07	  
	   	   	   	   	  
Rhythm	   42	  SR	  6	  AF	   20	  SR	  5AF	   22SR	  1AF	   	  
6	  minute	  walk	  distance	  
(m)	  
255±112	   260±109	   248±118	   0.4	  
Ejection	  fraction	  (%)	   25±9	   25±10	   26±8	   0.6	  
End	  diastolic	  volume	  
(ml)	  
230±70	   234±75	   226±66	   0.4	  
End	  systolic	  volume	  
(ml)	  
175±67	   180±73	   170±61	   0.3	  
B	  Blockers	  (%)	   91	   95	   87	   	  
ACE/ARB	  (%)	   98	   100	   96	   	  
Diuretics	  (%)	   62	   76	   50	   	  
Aldosterone	  
antagonists	  (%)	  
38	   35	   40	   	  
ACE=Angiotensin	   II	   converting	   enzyme	   inhibitors,	   ARB=Angiotensin	   receptor	  blockers	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Table	  6	  Implant	  details	  	  	   Implant	  
Device	   13	  St	  Jude	  Promote	  Q	  CD3221	  	  14	  St	  Jude	  Promote	  RF	  3213-­‐36	  7	  St	  Jude	  Pacesetter	  Atlas	  II	  HF	  v-­‐367	  4	  St	  Jude	  Frontier	  II	  5596	  2	  Medtronic-­‐maximo	  II	  DR	  D284DRG	  1	  Medtronic-­‐syncra	  CRT-­‐P	  C2TR01	  2	  Medtronic	  concerto	  C174AWK	  3	  Medtronic-­‐Insync	  III	  8042	  1	  Biotronik-­‐Lumax	  340	  HF-­‐T	  1	  no	  device	  implanted	  
LV	  lead	  position	   2	  Posterior	  vein	  21	  Posteriolateral	  vein	  19	  Lateral	  vein	  2	  Middle	  cardiac	  vein	  3	  Anteriolateral	  vein	  1	  patient	  no	  implant	  
RV	  lead	  position	   28	  Septum	  19	  Apical	  
LV	  lead	  threshold	   1.3±0.7	  
RV	  lead	  threshold	   0.7±0.3	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Echocardiography	  Acquisition	  Prior	  to	  CRT,	  standard	  echocardiograms,	  with	  TDI,	  were	  acquired	  on	  a	  GE	  vivid	  7	  scanner	   (General	   Electric-­‐Vingmed,	   Milwaukee,	   Wisconsin).	   Analysis	   was	  performed	   using	   EchoPac	   version	   6.0.1	   (General	   Electric-­‐Vingmed).	   Ejection	  fractions	  and	  LV	  dimensions	  were	  measured	  using	  2D	  biplane	  Simpson’s	  method.	  Transmitral	  flow	  velocities	  were	  obtained	  from	  the	  apical-­‐4-­‐chamber	  view	  with	  pulsed-­‐wave	  Doppler	  positioned	  at	  the	  tip	  of	  the	   leaflets.	  End	  diastole	  (onset	  of	  isovolumic	  contraction)	  and	  end	  systole	  (aortic	  valve	  closure)	  were	  determined	  using	  transmitral	  and	  aortic	  Doppler	  profiles.	  	  
	  
Echocardiographic	  Assessment	  of	  Dyssynchrony	  	  The	  IVMD	  was	  calculated	  as	  the	  difference	  between	  the	  LV	  and	  RV	  pre-­‐ejection	  periods	   measured	   from	   the	   QRS	   to	   the	   onset	   of	   pulmonary	   and	   aortic	   flows	  respectively.	   126	   Intra-­‐ventricular	   dyssynchrony	   was	   assessed	   with	   TDI	   by	  measuring	  the	  difference	  between	  septal	  to	  lateral	  peak	  velocity	  within	  the	  aortic	  valve	   opening	   and	   closing	   times	   4,127	   Real-­‐time	   transthoracic	   3D	  echocardiography	  102	  was	  performed	  on	  all	  patients	  and	  volumes	  analysed	  with	  TomTec	   4D	   LV-­‐Analysis	   software	   (TomTec	   Imaging	   systems	   Inc,	   Munich,	  Germany).	  	  
CMR	  Imaging	  Acquisition	  The	  patients	  were	  scanned	  using	  1.5T	  MR-­‐scanner	  (Achieva,	  Philips	  Healthcare,	  Best,	   Netherlands)	   with	   a	   32-­‐element	   cardiac	   coil	   or	   a	   5-­‐element	   cardiac	   coil.	  Cardiac	  synchronisation	  was	  performed	  with	  vector	  electrocardiography	  (VECG).	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After	   localisation	   and	   a	   coil	   sensitivity	   reference	   scan	   an	   interactive	   real-­‐time	  scan	  was	  performed	  to	  determine	  the	  geometry	  of	  the	  short	  axis,	  four,	  three	  and	  two	   chamber.	   A	   multiple	   slice	   cine	   steady	   state	   free	   precession	   scan	   was	  performed	   in	   SA	   orientation	   to	   assess	   the	   ventricular	   function	   (FA=60°,	  TR/TE=2.9/1.5ms,	   resolution	   2.2x2.2x10mm,	   30	   heart	   phases).	   The	   4CH,	   3CH	  and	   2CH	   views	   were	   used	   to	   assess	   LV	   function	   for	   regional	   wall	   motion	  abnormalities.	  A	   short	   axis	   and	   longitudinal	   stack	  of	  breath	  hold	  ECG-­‐gated	  2D	  CSPAMM	  or	  3D	  CSPAMM	  128	  images	  were	  acquired	  of	  the	  whole	  LV.	  The	  change	  in	  acquisition	  was	  because	  of	  the	  availability	  of	  3D	  CSPAMM	  half	  way	  through	  the	  study	   which	   allowed	   a	   reduction	   in	   scan	   time	   and	   better	   alignment	   of	   slices.	  Delayed	   enhancement	   (DE-­‐MR)	   imaging	   was	   performed	   to	   assess	   myocardial	  scar.	   DE-­‐MR	   was	   performed	   15-­‐20mins	   following	   the	   administration	   of	   0.1-­‐0.2mmol/kg	  gadopentetate	  dimeglumine	  (Magnevist®,	  Bayer	  Healthcare,	  Dublin,	  Ireland)	  using	  conventional	  inversion	  recovery	  techniques.	  129	  	  
Methods	  for	  CMR	  Processing	  The	  SDI	  for	  change	  in	  LV	  cavity	  volume	  over	  the	  cardiac	  cycle	  was	  determined	  by	  using	  commercially	  available	  TomTec	  4D	  LV-­‐Analysis	  software	  (TomTec	  Imaging	  systems	   Inc,	   Munich,	   Germany).	   For	   myocardial	   strain	   and	   wall	   thickening,	   a	  framework130	   was	   developed	   (Figure	   17	   and	   18)	   which	   semi-­‐automatically	  computed	   these	   values	   at	   each	   phase	   across	   the	   cardiac	   cycle.	   The	   framework	  included	  three	  steps:	  (1)	  Manual	  slice	  by	  slice	  segmentation	  of	  the	  endo	  and	  epi-­‐cardial	  borders	  of	  the	  LV	  in	  the	  stack	  of	  SA	  and	  three	  long-­‐axis	  SSFP	  images	  in	  the	  first	   end	   diastolic	   (ED)	   cardiac	   phase;	   (2)	   detection	   of	   endo	   and	   epi-­‐cardial	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surfaces	   for	   wall	   thickening	   computation;	   and	   (3)	   extraction	   of	   deformation	  fields	  within	   the	  myocardium	  for	  myocardial	  motion	  and	  strain	  computation.	  A	  3D	  model	   of	   the	   heart	  was	   developed	   from	   the	   end	   diastolic	   slices	   and	   all	   the	  subsequent	   slices	   were	   registered	   to	   this	   to	   correct	   for	   slice	   misalignment.	  Myocardial	   surface	   detection	   and	   deformation	   fields	  were	   computed	   from	   cine	  and	  tagged	  CMR.	  The	  myocardial	  wall	  thickening	  value,	  and	  strain	  fields	  were	  all	  mapped	  onto	   the	  coordinate	  of	   the	  anatomical	  CMR,	  where	   the	  16	  segments	  of	  the	  LV	  myocardium	  (bulls-­‐eye)	  were	  defined	  from	  the	  segmentation	  results.	  	  
	  For	  each	  subject	  16	  segments	  of	   the	  LV	  myocardium	  were	  defined	  according	  to	  the	   same	   definition	   used	   by	   the	   Tomtec	   software.	   This	   was	   done	   by	   first	  manually	   labelling	  the	  myocardium	  of	   the	  LV	  at	   the	  end	  diastolic	  (ED)	  phase	  of	  the	   cine	   CMR.	   A	   pre-­‐constructed	   myocardium	   model	   which	   has	   16	   segments	  defined	   was	   then	   fitted	   onto	   the	   manually	   segmented	   myocardium	   using	  automatic	   image	   registration130.	   As	   corresponding	   16-­‐segment	   labelling	   of	   the	  myocardium	  at	  ED	  phase	  CMR	  for	  each	  subject	  was	  thus	  achieved.	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Figure	  17	  Workflow	   of	   how	   cine	   images	   are	   used	   to	   develop	   global	   motion	   and	  dyssynchrony	  assessment.	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Figure	  18	  Workflow	   of	   how	   tagged	   images	   are	   used	   to	   develop	   global	  motion	   and	   strain	  dyssynchrony	  assessment	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Myocardial	  Wall	  Thickening	  from	  Cine	  CMR	  Cine	  CMR	  provides	   good	   image	  quality,	   high	   signal	   and	   contrast	   to	   noise	   ratio.	  The	  endo-­‐	  and	  epi-­‐cardial	  surfaces	  of	  the	  LV	  for	  each	  phase	  of	  the	  cardiac	  cycle	  were	   segmented	   to	   achieve	   the	   segmentation	   of	   ED	   phase	   using	   manual	  delineation	  as	  described	  earlier.	  	  1) Other	  phases	  from	  the	  cine	  CMR	  were	  then	  extracted	  and	  the	  registration	  
and	   propagation	   procedure	   from	   the	   ED	   phase	   was	   applied	   to	   achieve	  automatic	  segmentation.	  In	  this	  procedure,	  the	  ED	  phase	  image	  is	  selected	  as	   the	   reference	   image.	  The	   reference	   image	   is	   then	   registered	   to	   all	   the	  other	   phases	   and	   the	   corresponding	   segmentation	   is	   propagated130.	   The	  serial	   propagation	   registration	  was	  used	   to	  model	   the	   large	  deformation	  field	   required	   for	   the	   registration	   between	   the	   phases	   that	   are	   far	   apart	  from	  the	  ED	  phase.	  In	  the	  serial	  propagation	  the	  neighbouring	  phase	  of	  the	  ED	   phase	   to	   the	   reference	   image	   is	   first	   registered,	   and	   the	   resulting	  transformation	  is	  used	  to	  initialize	  the	  registration	  of	  the	  next	  phase.	  This	  process	   continues	   until	   all	   the	   phases	   are	   registered	   with	   the	   reference	  image.	  2) Having	  achieved	  the	  segmentation	  of	  endo-­‐	  and	  epi-­‐cardial	  surfaces	  for	  all	  cardiac	   phases,	   the	   surface	   distance	   between	   the	   two	   surfaces	   was	  computed	  for	  each	  segment	  of	  the	  LV	  myocardium.	  	  	  	  
Myocardial	  Deformation	  from	  Cine	  and	  Tagged	  CMR	  Myocardial	   strain	   is	   computed	   from	   the	   deformation	   field	   of	   the	  myocardium,	  which	   is	   achieved	   by	   registering	   the	   ED	   phase	   CMR	   to	   all	   the	   other	   phases	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(Figure	  18).	  Having	  the	  deformation	  fields	  v(x,p)	  for	  voxel	  x,	  from	  the	  ED	  phase	  to	  phase	  p,	  the	  myocardial	  motion	  is	  computed	  as	  follows:	  m(x)	  =	  |v(x,p)|	  	  The	  term	  strain	  was	  defined	  as	  a	  material	  point	  with	  original	  volume	  V(sa,sl)	  and	  current	   volume	  V'(sa',sl')	  where	   sa	   is	   short-­‐axis	   area	   and	   sl	   is	   long-­‐axis	   length	  	  with	  the	  following	  equations:	  
S(x)	  =	  	   	  So	   that	   longitudinal	   strain	   is	   reverted	   so	   the	   strain	   term	   could	   represent	   the	  muscle	  function	  during	  the	  systolic	  cycle.	  	  
Systolic	  Dyssynchrony	  Index	  To	   assess	   global	   LV	   dyssynchrony	   the	   time	   taken	   to	   reach	   maximum	   muscle	  thickness	  or	  peak	  strain	   for	  16	  segments	  was	  calculated	  as	  a	  percentage	  of	   the	  cardiac	  cycle.	  A	  SDI	  was	  then	  defined	  as	  the	  standard	  deviation	  of	  these	  timings	  with	  a	  high	  SDI	  denoting	  more	  dyssynchrony.	  Expressing	  the	  SDI	  as	  a	  percentage	  of	   the	   cardiac	   cycle	   allows	   comparison	   between	   patients	   with	   different	   heart	  rates.	  	  Only	  segments	  that	  had	  ≥	  5%	  thickening	  defined	  from	  the	  diastolic	  wall	  thickness	  were	  included	  in	  the	  SDI	  for	  muscle	  thickening.	  	  Graphs	   with	   curves	   for	   each	   of	   the	   16	   segments	   for	   the	   change	   in	   volume,	  thickening	  and	  strain	  (radial,	   longitudinal	  and	  circumferential)	  over	  the	  cardiac	  
sa '∗ la
sa∗ la '
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cycle	  were	   formed	   for	  all	  patients	   to	  allow	  a	  visual	   representation	  of	  how	  each	  method	  compared	  during	  LV	  contraction.	  (Figure	  19)	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Figure	  19	  Curves	   for	   a	   volunteer	  with	   normal	   LV	   function	   representing	   the	   time	   to	   peak	  volume	  change	   (A)	   and	   time	   to	  peak	   strain	   for	   all	   16	  myocardial	   segments	   (B)	  Longitudinal	  strain,	  (C)	  Radial	  strain,	  (D)	  Circumferential	  strain.	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Implant	  and	  Acute	  Haemodynamic	  Measurements	  All	  patients	  had	  a	  standard	  CRT	  implant	  (Table	  6).	  During	  CRT	  implantation	  in	  27	  patients	   haemodynamic	   evaluation	   was	   performed	  with	   a	   0.014-­‐inch	   pressure	  sensor-­‐tipped	  percutaneous	  transluminal	  coronary	  angioplasty	  guide	  wire	  (Radi	  Medical	  Systems,	  Uppsal,	  Sweden)	  with	  a	  500-­‐Hz	  frequency	  response	  introduced	  into	  the	  LV	  through	  a	  4-­‐Fr	  multipurpose	  catheter	  from	  either	  a	  femoral	  or	  radial	  access	   site.	   131	   Subsequently	   the	   multi-­‐purpose	   catheter	   was	   removed	   or	  withdrawn	   into	   the	   aorta,	   leaving	   the	   soft	   tip	   of	   the	   pressure	  wire	   in	   a	   stable	  position	  within	  the	  LV	  cavity.	  Once	  venous	  access	  had	  been	  acquired	  for	  pacing	  lead	   implants,	   2500	   Units	   of	   heparin	   were	   given	   followed	   by	   saline	   flush.	   At	  steady-­‐state	   conditions	   LV-­‐dP/dtmax	   was	   calculated	   electronically	   from	   every	  heartbeat	  for	  a	  period	  of	  at	  least	  ten	  seconds.	  The	  results	  were	  averaged	  for	  the	  complete	  measurement	  period.	  A	  waiting	  period	  of	  at	   least	  twenty	  seconds	  was	  respected	  after	  any	  change	  in	  pacing	  settings	  or	  lead	  position	  in	  order	  to	  achieve	  haemodynamic	   stabilisation18,	   38.	   LV-­‐dP/dtmax	   was	   measured	   during	   intrinsic	  rhythm	  and	  atrial	  pacing	  (AAI	  10	  beats	  above	  intrinsic	  with	  consistent	  capture)	  and	  with	  LV	  CS	  pacing	  (DDLV	  (fixed	  AV	  delay	  100ms)	  or	  VVI	  (patients	   in	  atrial	  fibrillation	   (AF)),	   10	   beats	   above	   intrinsic).	   In	   patients	   with	   AF	   baseline	   was	  considered	   as	   RV	   pacing	   10	   beats	   above	   intrinsic	   rhythm.	   132	   Results	   were	  expressed	  as	   a	  percentage	  of	   variation	   from	   the	  baseline	   (AAI	  pacing,	  10	  beats	  above	  intrinsic).	  Baseline	  drift	  in	  LV-­‐dP/dtmax	  was	  determined	  by	  calculating	  the	  mean	  standard	  deviation	  over	  the	  course	  of	  the	  procedure.	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Classification	  of	  Acute	  Response	  Improvement	  in	  LV-­‐dP/dtmax	  ≥	  10%	  compared	  with	  fixed	  rate	  atrial	  /	  RV	  pacing	  (baseline)	  was	  used	  as	   the	   cut-­‐off	   for	   an	  acute	   response.	  This	   cut-­‐off	   value	  has	  been	  used	  in	  previous	  studies	  37,	  51.	  	  	  
Classification	  of	  Reverse	  Remodelling	  and	  Responders	  Patients	   were	   deemed	   to	   have	   RR	   if	   there	   was	   a	   ≥	   15%	   reduction	   in	   LV	   end-­‐systolic	  volume	  (ESV)	  as	  measured	  using	  modified	  Simpson’s	  biplane	  method	  on	  2D	  echo	  images48,	  49.	  Evaluation	  of	  symptomatic	  response	  was	  made	  using	  NYHA	  class,	   six-­‐minute	  walk	  distance	  and	  QOL	  score.	   50	  Patients	  were	   labeled	   clinical	  responders	  if	  the	  NYHA	  class	  fell	  by	  ≥	  1	  or	  if	  there	  was	  a	  ≥10%	  improvement	  in	  six	  minute	  walk	  distance	  or	  a	  ≥10%	  reduction	  in	  QOL	  score.	  	  
Comparison	  and	  Reproducibility	  of	  Methods	  Using	   the	   framework	   developed	   to	   assess	   strain	   and	   muscle	   thickening	   also	  allowed	   assessment	   of	   volume	   SDI	   comparable	   to	   the	   Tomtec	   method.	   To	  establish	  the	  agreement	  between	  the	  two	  methods	  statistical	  analysis	  proposed	  by	  Bland	  and	  Altman133	  was	  used.	  	  For	   volume	   SDI	   derived	   from	   TomTec	   4D	   LV-­‐Analysis	   software	   intra-­‐observer	  and	   inter-­‐observer	   agreements	   were	   assessed	   according	   to	   the	   statistical	  methods	   proposed	   by	   Bland	   and	   Altman.	   The	  measure	   of	   reproducibility	   used	  was	   two	   standard	   deviations	   (SD)	   of	   the	   intra-­‐observer	   and	   inter-­‐agreement	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indices.	  Therefore,	  the	  intra-­‐observer	  coefficient	  of	  variation	  (COV)	  was	  equal	  to	  two	  SD	  of	  	  
	  And	  the	  inter-­‐observer	  COV	  was	  equal	  to	  2	  SD	  of	  
	  The	   process	   to	   develop	   muscle	   thickening	   and	   strain	   SDI	   is	   an	   automotive	  process	  so	  intra-­‐observer	  or	  inter-­‐observer	  assessment	  is	  not	  appropriate.	  
Statistical	  Analysis	  Statistical	   analysis	   was	   performed	   using	   JMP	   software	   (version	   8.0.2,	   Marlow,	  Buckinghamshire,	   UK).	   A	   Shapiro-­‐Wilk	   test	  was	   used	   to	   ensure	   variables	  were	  normally	   distributed.	   Continuous	   variables	   were	   expressed	   as	   mean	   ±	   SD	   and	  compared	  with	   parametric	   (ANOVA)	   and	   non-­‐parametric	   (Wilcoxon	   rank	   sum)	  tests.	   Nominal	   variables	   are	   expressed	   as	   absolute	   count	   and	   percentages	   and	  compared	   with	   a	   Fisher’s	   exact	   test.	   Outcomes	   were	   assessed	   with	   logistic	  regression	   to	   create	   receiver-­‐operator	   characteristic	   (ROC)	   curves.	   P	   values	   of	  <0.05	  were	  considered	  statistically	  significant.	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Results	  Forty-­‐eight	   patients	   were	   recruited,	   (42	   male,	   63.8±13.9	   years),	   NYHA	   class	  2.8±0.5	   (Table	   5).	   All	   patients	   had	   LBBB	   with	   QRS	   duration	   155±24ms.	   Two	  patients	  were	  recruited	  with	  QRS	  duration	  less	  than	  120ms.	  These	  two	  patients	  had	  severe	  LV	  impairment	  and	  would	  have	  been	  100%	  RV	  paced	  and	  therefore	  it	  was	  felt	  they	  would	  benefit	  from	  CRT.	  Twenty-­‐five	  patients	  had	  DCM	  and	  23	  ICM.	  Forty-­‐four	  (92%)	  patients	  were	  followed	  up	  at	  6	  months.	  Of	  the	  four	  patients	  that	  were	   not	   followed	   up	   at	   six	   months	   one	   patient	   with	   DCM	   had	   died	   of	   heart	  failure,	  one	  patient	  declined	  any	  further	  intervention	  after	  the	  LV	  lead	  displaced	  twice,	  one	  patient	  had	  their	  LV	  lead	  turned	  off	  due	  to	  diaphragmatic	  pacing	  and	  one	  patient	  declined	  a	  device	  post	  recruitment.	  	   	  
Acute	  Response	  In	   twenty	   seven	   patients,	   LV-­‐dP/dtmax	   was	   measured	   at	   the	   time	   of	   implant.	  (Table	   7)	   The	   baseline	   (AAI	   or	   RV	   pacing)	   LV-­‐dP/dtmax	  was	   823±199mmHg/s,	  this	   increased	   to	   940±216mmHg/s	   with	   LVCS	   pacing	   (P<0.001).	   The	   average	  number	   of	   baseline	   readings	   was	   4.2±1.2.	   Baseline	   drift	   in	   LV-­‐dP/dtmax	   was	  58±19	  mmHg/s.	  The	  average	  percentage	   increase	   in	  LV-­‐dP/dtmax	   from	  baseline	  with	   LVCS	   pacing	  was	   16±17%.	   	   Eighteen	   (66%)	   of	   the	   patients	   had	   a	   ≥	   10%	  increase	  in	  LV-­‐dP/dtmax	  and	  were	  deemed	  acute	  responders.	  	  	  
Measures	  of	  Dyssynchrony	  Predicting	  Acute	  Haemodynamic	  Response	  A	   wider	   QRS	   duration	   strongly	   predicted	   AHR	   (P=0.008)	   with	   a	   moderate	  correlation	  between	  QRS	  width	  and	  %	  rise	  in	  LV-­‐dP/dtmax	  (r=0.73).	  For	  measures	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of	   global	   dyssynchrony	   a	   high	   volume	   derived	   SDI	   strongly	   predicted	   AHR	  (P=0.008)	   with	   a	   moderate	   correlation	   between	   high	   SDI	   and	   %	   rise	   in	   LV-­‐dP/dtmax	  (r=0.7).	  (Figure	  20)	  (Table	  8)	  For	  all	  other	  measures	  of	  dyssynchrony	  I	  found	  no	  relationship	  between	  AHR	  and	  derived	  SDI.	  (Figure	  21)	  	  Receiver-­‐operating	   characteristics	   (ROC)	   analysis	   (Table	   8)	   showed	   an	   SDI	  derived	  from	  volume	  change	  of	  ≥10.3%	  was	  sensitive	  (0.76)	  and	  specific	  (0.88)	  for	   predicting	   AHR.	   None	   of	   the	   other	   methods	   for	   deriving	   a	   SDI	   were	  comparable.	  Using	  ROC	  analysis,	  QRS	  duration	  of	   ≥158ms	  was	   found	   to	  have	   a	  sensitivity	  of	  0.71	  and	  specificity	  of	  0.89	  for	  predicting	  AHR.	  	  The	  only	  echocardiographic	  measure	  of	  dyssynchrony	  that	  was	  found	  to	  predict	  AHR	  was	   IVMD	   (P=0.03)	   and	  volume	  SDI	  derived	   from	  3D	  echo	   (P=0.02).	   	  The	  ROC	  analysis	  showed	  that	  an	  SDI	  of	  ≥7.2%	  had	  a	  sensitivity	  of	  0.92	  and	  specificity	  of	  0.63	  and	   IVMD	  of	  ≥60ms	  had	  a	   sensitivity	  of	  0.61	  and	   specificity	  of	  0.89	   for	  predicting	  AHR.	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Table	  7	   Characteristics	  of	  patients	   in	  whom	  AHR	  was	  measured	  at	   the	   time	  of	  CRT	  implant	  




Age	  (years)	   63.8±13.9	   64.4±11.7	  
Sex	  (male/female)	   43/5	   23/4	  
Aetiology	   25	  DCM	  23	  ICM	   18	  DCM	  9	  ICM	  
NYHA	  status	   2.9±0.5	   2.7±0.5	  
QOL	  score	  pre	  CRT	   50.9±24	   48±22	  
QRS	  duration	  (ms)	   154±24	   158±24	  
	   	   	  
Rhythm	   42	  SR	  6	  AF	   22	  SR	  5AF	  
6	  minute	  walk	  distance	  
(m)	  
255±112	   270±108	  
Ejection	  fraction	  (%)	   25±9	   25±9	  
End	  diastolic	  volume	  
(ml)	  
230±70	   233±64	  
End	  systolic	  volume	  
(ml)	  
175±67	   177±62	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Table	  8	   Shows	   the	  P	   valves	   for	   each	  SDI	  derived	   from	   the	  various	  methods	   to	  predict	   AHR.	   Receiver-­‐operating	   characteristic	   are	   shown	  with	   the	   area	   under	  the	  curve	  (AUC)	  and	  the	  cut-­‐off	  values	  and	  sensitivities	  and	  specificities	  for	  each	  method	  shown.	  
	   P	  value	  to	  predict	  
AHR	  
AUC	   Cut-­‐Off	   Sensitivity	   Specificity	  
QRS	  duration	  (ms)	   0.008*	   0.81	   ≥158ms	   0.71	   0.89	  
Volume	  SDI	   0.008*	   0.82	   ≥10.3%	   0.76	   0.88	  
Thickening	  SD	   0.06	   	  	  0.7	   ≥15.8%	   	  0.72	   	  0.78	  
Radial	  strain	  SDI	   0.4	   0.5	   ≥22.2%	   0.28	   0.89	  
Longitudinal	  strain	  SDI	   0.3	   0.56	   ≥12.5%	   0.83	   0.33	  
Circumferential	  strain	  
SDI	  
0.1	   0.62	   ≥6.0%	   0.72	   0.56	  
Combined	  strain	  SDI	   0.3	   0.58	   ≥4.4%	   0.94	   0.33	  *Significant	  relationship	  	  	  
	   105	  
Figure	   20	   Shows	   the	   ANOVA	   plots	   for	   QRS	   duration,	   volume	   and	   muscle	  thickening	  derived	  SDI	  to	  predict	  AHR	  and	  RR	  	  
	  	  MRI	   16	   sdi	   =	   CMR	   volume	   SDI,	   0.5sdithick	   =	   SDI	   derived	   from	   CMR	   muscle	  thickening	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Figure	  21A	  &	  B	   Shows	   the	  ANOVA	  plots	   for	  SDI	  derived	   from	  various	   types	  of	  strain	  to	  predict	  AHR	  (top	  rows)	  and	  RR	  (bottom	  rows).	  
A	  
	  
	  	  	  	  	  	  	  	  
B	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Reverse	  Remodelling	  	  Pre-­‐implant	  LVESV	  and	  LVEF	  were	  175±64ml	  and	  25.0±8.5%	  respectively.	  These	  improved	   over	   the	   follow-­‐up	   period	   to	   155±68ml	   (P<0.01)	   and	   31.8±10.2%	  respectively.	  	  QRS	   duration	   predicted	   RR	   (P<0.0001).	   Using	   ROC	   analysis	   QRS	   duration	   of	  ≥162ms	   was	   sensitive	   (0.79)	   and	   specific	   (0.92)	   for	   predicting	   RR.	   (Table	   9)	  (Figure	  20)	  	  Volume	  derived	  SDI	  strongly	  predicted	  RR	  (P<0.0001)	  (Figure	  20).	  ROC	  analysis	  showed	   that	  an	  SDI	  of	  ≥10%	  was	  highly	  sensitive	   (0.94)	  and	  specific	   (0.87)	   for	  predicting	  which	  patients	   are	   likely	   to	  RR.	   SDI	  derived	   from	  muscle	   thickening	  predicted	  RR	  (P=0.001	  for	  thickening	  of	  >	  0.5mm)	  (Figure	  20).	  SDI	  derived	  from	  thickening	   was	  much	   less	   sensitive	   and	   specific	   than	   QRS	   duration	   or	   volume	  derived	   SDI	   at	   determining	  which	  patients	  were	   likely	   to	  RR.	  None	  of	   the	   SDIs	  derived	   from	   strain	   (radial,	   longitudinal,	   circumferential	   and	   combined)	   were	  predictive	  for	  RR	  (Table	  9)	  (Figure	  21).	  	  For	   standard	   echocardiographic	   measures	   of	   dyssynchrony	   (Table	   10),	   LVPE	  (P=0.003)	   and	   IVMD	   (P=0.0008)	   predicted	   RR.	   TDI	   derived	   indices	   of	  dyssynchrony	  did	  not	  predict	  RR.	  Volume	  derived	  SDI	  from	  3D	  echocardiography	  showed	  predicted	  RR	  (P=0.02).	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Table	  9	  P	  valves	   for	  each	  SDI	  derived	   from	  the	  various	  methods	  to	  predict	  RR.	  Receiver-­‐operating	  characteristic	  are	  shown	  with	  the	  area	  under	  the	  curve	  (AUC)	  and	  the	  cut-­‐off	  values	  and	  sensitivities	  and	  specificities	  for	  each	  method	  shown.	  	  




AUC	   Cut-­‐Off	   Sensitivity	   Specificity	  
QRS	  duration	  (ms)	   <0.0001*	   0.88	   ≥162ms	   0.79	   0.92	  
Volume	  SDI	   <0.0001*	   0.92	   ≥10.0%	   0.94	   0.87	  
Thickening	  SDI	  
(>0.5mm)	  
0.001*	   0.75	   ≥15.8%	   0.65	   0.79	  
Radial	  strain	  SDI	   0.8	   0.59	   ≥22.2%	   0.95	   0.29	  
Longitudinal	  strain	  
SDI	  
0.8	   0.59	   ≥20.7%	   0.83	   0.4	  
Circumferential	  strain	  
SDI	  
0.9	   0.60	   ≥8.9%	   0.6	   0.62	  
Combined	  strain	  SDI	   0.7	   0.58	   ≥5.6%	   0.8	   0.46	  *Significant	  relationship	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Table	  10	  Sensitivity,	  Specificity	  and	  AUC	  for	  echo	  measures	  of	  dyssynchrony	  to	  predict	  RR	  	  




Sensitivity	   Specificity	  
LVPE	  (ms)	   0.003*	   0.74	   ≥160	   0.68	   0.75	  
IVMD	  (ms)	   0.0008*	   0.83	   ≥60	   0.67	   0.83	  
TDI	   Septal/lateral	   delay	  
(ms)	  
0.4	   0.56	   ≥90	   1.0	   0.17	  
SDI	  (%)	  
N=26	  
0.02*	   0.71	   ≥12.1	   0.69	   0.84	  
	  
Clinical	  Response	  Thirty	  six	  (82%)	  patients	  had	  a	  reduction	  of	  at	  least	  one	  NYHA	  class	  at	  6	  months,	  and	  38	   (86%)	  had	  a	  ≥	  10%	   improvement	   in	  quality	  of	   life	   score.	  Twenty-­‐six	  of	  the	   patients	   performed	   six-­‐minute	   walks	   pre	   and	   post	   CRT	   implantation.	  Seventeen	  of	   the	  patients	   (65%)	  had	  a	  ≥	  10%	  improvement	   in	  six-­‐minute	  walk	  distance.	  	  	  QRS	   duration	   was	   predictive	   for	   reduction	   in	   NYHA	   score	   (P=0.0005).	   LVPE	  (P=0.02),	  IVMD	  (P=0.005),	  CMR	  volume	  SDI	  (P=0.02)	  and	  muscle	  thickening	  SDI	  (0.002)	  predicted	  reduction	  in	  NYHA	  score.	  None	  of	  the	  strain	  indices	  showed	  a	  relationship	  with	   improvement	   in	  NYHA	  class.	  Only	  muscle	   thickening	  SDI	  was	  found	  to	  predict	  improvement	  in	  QOL	  score	  (P=0.01).	  No	  relationship	  was	  found	  between	   improvement	   in	   six-­‐minute	   walk	   duration	   and	   any	   measure	   of	  dyssynchrony.	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Aetiology:	  DCM	  vs	  ICM	  Differences	  between	  patients	  with	  DCM	  and	  ICM	  pre	  CRT	  are	  shown	  in	  table	  11.	  There	   was	   significantly	   greater	   RR	   in	   patients	   with	   DCM	   compared	   to	   ICM	  patients	   (decrease	   in	   ESV	   for	   DCM	   36±55ml	   vs	   1.0±51ml	   for	   ICM,	   P=0.02).	  Fourteen	  (61%)	  of	  patients	  with	  DCM	  reverse	  remodeled,	  compared	  to	  only	  six	  (29%)	  of	  the	  patients	  with	  ICM.	  	  For	  patients	  with	  DCM,	  QRS	  duration	  and	  SDI	  derived	  from	  CMR	  volume	  change	  and	   muscle	   thickening	   predicted	   RR	   (Figure	   22).	   SDI	   derived	   from	   radial	   and	  circumferential	  strain	  weakly	  predicted	  RR	  (Figure	  23).	  For	  echo	  derived	  indices	  of	  dyssynchrony,	  LVPE,	  IVMD	  and	  volume	  derived	  SDI	  with	  3D	  echocardiography	  predicted	  RR	  (Table	  12).	  	  For	  patients	  with	  ICM,	  SDI	  derived	  CMR	  volume	  change	  was	  highly	  predictive	  for	  RR.	  QRS	  duration	  (Figure	  22)	  and	  IVMD	  were	  also	  predictive	  for	  RR,	  however	  had	  weaker	  relationship	  (Table	  12).	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Pre	  CRT	   Post	  CRT	   P	  
value	  




NYHA	  Score	   2.9±0.5	   1.7±0.8	   <0.001	   2.8±0.4	   1.7±0.8	   <0.001	  








160±28	   	   	   148±19	   	   	  
Ejection	  
Fraction	  (%)	  
25±10	   34±11	   <0.001	   25±8	   29±9	   0.04	  
End	  systolic	  
volume	  (ml)	  
175±70	   139±71	   <0.002	   171±62	   173±62	   0.5	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Figure	  22	  Shows	  the	  ANOVA	  plots	  for	  QRS	  duration,	  volume	  and	  muscle	  thickening	  derived	  SDI	  in	  both	  DCM	  and	  ICM	  patients.	  
	  MRI	   16	   sdi	   =	   CMR	   volume	   SDI,	   0.5sdithick=SDI	   derived	   from	   CMR	   muscle	  thickening	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Figure	  23	  Shows	  the	  ANOVA	  plots	  for	  SDI	  derived	  from	  various	  types	  of	  strain	  for	  DCM	  and	  ICM.	  
	  MRI	   16	   sdi	   =	   CMR	   volume	   SDI,	   0.5sdithick=SDI	   derived	   from	   CMR	   muscle	  thickening	  	  
	   114	  
Table	   12	   P	   values	   for	   echocardiographic	   measures	   of	   dyssynchrony	   for	  predicting	  RR	  in	  DCM	  and	  ICM	  patients	  
	   P	  value	  for	  predicting	  ≥	  15%	  
decrease	  ESV	  for	  DCM	  pts	  
P	  value	  for	  predicting	  ≥	  15%	  
decrease	  ESV	  for	  ICM	  pts	  
QRS	  duration	   <0.0001*	   0.02*	  
LVPE	   0.03*	   0.2	  
IVMD	   0.002*	   0.02*	  
TDI,	  septal/lateral	  
delay	  
0.9	   0.3	  
3D	  echo	  16	  seg	  SDI	   0.01*	   0.1	  *Significant	  relationship	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Aetiology	  and	  Clinical	  Response	  For	   patients	   with	   ICM;	   QRS	   duration	   (P=0.03),	   SDI	   derived	   from	   muscle	  thickening	   (P=0.007),	   SDI	   derived	   from	   volume	   change	   (P=0.02)	   and	   IVMD	  (P=0.04)	   predicted	   improvement	   in	   NYHA	   score.	   For	   improvement	   in	   heart	  failure	  score	  there	  was	  no	  relationship	  found	  with	  any	  marker	  of	  dyssynchrony	  in	  ICM	  patients.	  Only	  SDI	  derived	  from	  volume	  change	  predicted	  improvement	  in	  six-­‐minute	  walk	  distance	  in	  ICM	  patients	  (P=0.02).	  	  For	  patients	  with	  DCM	  only	  QRS	  duration	   (P=0.004)	  predicted	   improvement	   in	  NYHA	   score.	   For	   improvement	   in	   heart	   failure	   score	   only	   SDI	   derived	   from	  volume	   change	   (P=0.03)	   and	   muscle	   thickening	   (P=0.003)	   predicted	  improvement	  in	  score.	  For	  improvement	  in	  six-­‐minute	  walk	  distance	  no	  measure	  of	  dyssynchrony	  showed	  a	  relationship	  in	  DCM	  patients.	  	  
Agreement	  of	  Methods	  and	  Reproducibility	  To	  assess	  agreement	  of	  methods	  and	  reproducibility,	   ten	  subjects	  (five	  patients	  and	  five	  volunteers	  with	  normal	  LV	  function)	  had	  repeat	  scans.	  Between	  the	  two	  methods	   to	   assess	   volume	   SDI	   there	   was	   a	   good	   agreement,	   with	   a	   mean	  difference	  of	  0.61%±3.39%	  (Figure	  24).	  Both	  methods	  for	  deriving	  a	  volume	  SDI	  were	   assessed	   to	   see	   agreement	   between	   two	   CMR	   scans.	   There	  was	   excellent	  agreement	  with	  mean	  difference	  for	  4D	  Tomtec	  analysis	  derived	  SDI	  0.57±1.26%	  compared	  with	  0.66±2.15%	  for	  the	  automotive	  method.	  	  In	   the	   five	   patients	   and	   five	   volunteers	   selected	   for	   intra	   and	   inter-­‐observer	  variability	   for	   volume	   SDI	   derived	   from	   Tomtec	   4D	   LV-­‐Analysis	   software	   was	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excellent.	   The	   intra-­‐observer	   average	   difference	   was	   0.04±0.3%	   and	   COV	   was	  1.8±1.2%	  and	  the	  inter-­‐observer	  average	  difference	  was	  0.55±1.4%	  and	  COV	  was	  4.2±4.6%.	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Figure	   24:	   A	   Scatter	   plot	   of	   two	   different	   methods	   to	   assess	   volume	  dyssynchrony.	  B	  Bland	  and	  Altman	  plot	   for	   the	  difference	  between	  volume	  SDI	  assessed	  with	  Tomtec	  4D	  LV-­‐Analysis	  software	  and	  via	  automotive	  framework.	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Discussion	  Using	   a	   framework	   that	   enabled	   comparable	  measures	   of	   global	   dyssynchrony	  (SDIs	   for	   volume,	   muscle	   thickening	   and	   peak	   radial,	   circumferential,	  longitudinal	   and	   combined	   strain)	   the	   ability	   of	   these	   indices	   to	   predict	   both	  acute	  response	  and	  RR	  in	  patients	  referred	  for	  CRT	  was	  assessed.	  	  The	  following	  was	  shown:	  1. A	  SDI	  of	  ≥ 10% derived	  from	  volume	  change	  is	  sensitive	  and	  specific	  and	  superior	  to	  other	  mechanical	  dyssynchrony	  measures	  at	  predicting	  acute	  response	  and	  reverse	  remodelling.	  	  2. A	   SDI	   derived	   from	   peak	   strain	   (radial,	   longitudinal,	   circumferential	   or	  combined)	   is	   poor	   at	   predicting	   which	   patients	   will	   respond	   acutely	   to	  CRT	  or	  RR.	  	  3. Muscle	   thickening	   SDI	   does	   not	   predict	   acute	   response,	   but	   is	   strongly	  predictive	  of	  RR	  although	  is	  less	  sensitive	  and	  specific	  than	  volume	  SDI.	  	  4. Other	   than	   QRS	   duration	   volume	   SDI	   is	   the	   only	   global	  measure	   that	   is	  predictive	  of	  RR	  both	  for	  DCM	  and	  ICM	  patients.	  	  
Systolic	  Dyssynchrony	  Index	  Measurements	  In	   this	   work	   radial,	   longitudinal,	   circumferential	   and	   combined	   strain	  measurements	   did	   not	   help	   predict	   which	   patients	   would	   respond	   to	   CRT.	  Although	   surprising,	   considering	   the	   focus	   of	   previous	   studies	   on	  measures	   of	  myocardial	  strain,	   this	  apparent	  separation	  of	  volume	  and	  thickening	  measures	  of	   dyssynchrony	   from	   strain	   indices	  may	   be	   explained	   by	   a	   closer	   look	   at	   the	  mechanics	  involved	  in	  myocardial	  contraction.	  Ejection	  is	  due	  to	  wall	  thickening	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and	  apical-­‐basal	  shortening.	  In	  a	  normal	  subject,	  wall	  thickening	  contributes	  25-­‐48%	   to	   stroke	   volume	   and	   is	   the	   result	   of	   a	   combination	   of	   shearing	   and	  elongation	   along	   the	   laminar	   sheets	   that	   make	   up	   the	   myocardium	   and	   has	   a	  limited	  correlation	  with	  fibre	  shortening	  that	  is	  more	  closely	  related	  to	  measures	  of	  strain.	  	  The	   use	   of	   longitudinal,	   radial	   and	   circumferential	   strain	   dyssynchrony	  measurements	   that	   are	   not	   aligned	   with	   the	   orientation	   of	   the	   helical	   cardiac	  microstructure	   is	   fraught	  with	  physiological	   limitations.	  The	  measured	  strain	   is	  then	  made	  up	  of	  a	  combination	  of	  different	  muscle	  fibre	  orientated	  segments	  and	  sheets	   and	   the	   intrinsic	   variation	   in	   the	   time	   taken	   for	   different	   regions	   of	   the	  heart	   to	  contract	  and	  reach	   their	  peak	  strain	   in	   the	  healthy	  heart	  obscures	  any	  changes	   in	   synchrony	   that	   may	   occur	   with	   heart	   failure.	   The	   timing	   of	   peak	  contraction	  in	  the	  heart	  varies	  transmurally,	  circumferentially	  and	  in	  the	  apex	  to	  base	  directions.	  This	  variation	   is	  significant	  with	  an	  83ms	  dispersion	   in	  time	  to	  peak	   strain	   across	   the	   heart	  wall	   in	   canines	   compared	  with	   a	   QRS	   duration	   of	  approximately	   60ms	   and	   the	   time	   to	   peak	   circumferential	   strain	   variations	   of	  121ms	   in	   human	   LV,	   where	   the	   QRS	   duration	   is	   approximately	   80ms.	   The	  distribution	  of	  timing	  of	  peak	  deformation	  is	  consistent	  with	  the	  distribution	  of	  electrical	   activation	   only	   amplified.	   This	   increased	   heterogeneity	   in	   the	   spatial	  variation	   in	   deformation	   is	   potentially	   facilitated	   by	  multiple	   factors	   including	  the	   non-­‐uniformity	   of	   fibre	   and	   sheet	   orientation,	   activation	   times,	   regional	  cavity	   curvature,	   contractile	   function,	   electrophysiology	   and	   passive	   material	  properties.	  Therefore	  using	  indices	  of	  strain	  to	  measure	  myocardial	  motion	  does	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not	  provide	  a	  useful	  measure	  of	  dyssynchrony	  and	  explains	  why	  these	  measures	  are	  not	  useful	  in	  predicting	  which	  patients	  are	  likely	  to	  respond	  to	  CRT.	  	  	  This	  is	  clearly	  seen	  in	  volunteers	  with	  normal	  ventricles	  (Figure	  19).	  The	  volume	  SDI	  is	  low,	  indicating	  synchrony,	  but	  SDI	  for	  peak	  strain	  (longitudinal,	  radial	  and	  circumferential)	   is	   high,	   which	   indicates	   dyssynchrony	   even	   though	   the	  volunteers	   ventricles	   are	   normal.	   Using	   cruder	   measures	   of	   myocardial	  dyssynchrony	   such	   as	   volume	   SDI	   gives	   a	   clear	   indication	   of	   how	   well	  coordinated	   the	   ventricular	   contraction	   is	   as	   it	   does	   not	   take	   into	   account	   the	  difference	  forces	  working	  with	  and	  against	  each	  other	  during	  systole.	  	  
Aetiology	  Part	  of	  the	  aim	  of	  the	  study	  was	  to	  use	  muscle	  thickening	  and	  strain	  derived	  SDI	  to	   take	   into	   account	   the	   difference	   between	   active	   and	   passive	   myocardial	  motion.	   It	   is	   known	   that	   position	   and	   extent	   of	   myocardial	   scar	   affect	   the	  likelihood	  of	  response	  to	  CRT.	  134	  Using	  a	  volume	  derived	  SDI	  does	  not	  take	  into	  account	  the	  difference	  between	  active	  and	  passive	  motion	  that	  occurs	  in	  scarred	  akinetic	  regions.	  Patients	  with	  DCM	  are	  much	  more	  likely	  to	  RR	  (61%)	  compared	  to	  ICM	  (29%).	  I	  found	  SDI	  derived	  from	  volume	  change	  was	  highly	  predictive	  for	  RR	   in	  both	  DCM	  and	   ICM	  patients.	   I	  would	  have	   expected	   an	  SDI	  derived	   from	  muscle	  thickening	  or	  strain	  derivatives	  to	  be	  more	  helpful	  in	  patients	  with	  ICM	  as	  these	  parameters	  give	  a	  better	  understanding	  of	  the	  dyssynchrony	  seen	  in	  active	  muscle	  contraction	  but	  no	  such	  relationship	  was	  found.	  The	  reasons	  for	  this	  are	  unclear.	   The	   aim	   of	   CRT	   is	   to	   synchronise	   contraction	   in	   a	   failing	   ventricle	   to	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improve	  ventricular	  efficiency.	  A	  volume	  derived	  index	  of	  dyssynchrony	  may	  be	  better	  at	  predicting	  which	  patients	  are	  likely	  to	  respond	  to	  CRT	  as	  it	  gives	  a	  far	  more	   accurate	   assessment	   of	   mechanical	   dyssynchrony	   and	   therefore	   the	  possible	   treatable	   substrate	   for	   CRT.	   Furthermore	   the	   inherent	   problems	  with	  strain	  measurements	  already	  discussed	  may	  explain	  this.	  	  
Comparing	  Imaging	  Techniques	  Volume	   SDI	   derived	   from	  3D	   echo	   showed	   a	   significant	   relationship	  with	   both	  AHR	  and	  RR,	  but	  not	  with	  any	  clinical	  measures	  of	  response.	  It	  is	  interesting	  that	  similar	  volume	  derived	  measure	  of	  dyssynchrony	  both	  predict	  AHR	  and	  RR.	  The	  relationship	  for	  3D	  echo	  derived	  SDI	  is	  not	  as	  strong	  as	  for	  CMR	  volume	  derived	  SDI.	  This	  is	  probably	  due	  to	  the	  poor	  image	  quality	  and	  therefore	  a	  less	  accurate	  assessment	  of	  dyssynchrony.	  For	  3D	  echo	  SDI	   the	   image	  quality	  was	  only	  good	  enough	  to	  accurately	  analyse	   in	  26	  (60%)	  patients.	  Only	  IVMD	  was	  comparable	  to	  volume	  SDI	  derived	  from	  CMR	  at	  predicting	  RR.	  However,	  this	  was	  much	  less	  sensitive	  (0.67	  compared	  with	  0.94).	  	  
Understanding	  Relationships	  Between	  SDI	  and	  LBBB	  The	  aim	  of	  CRT	  is	  to	  synchronise	  the	  contraction	  of	  the	  LV.	  It	  is	  implied	  that	  the	  greater	  LV	  dyssynchrony,	  the	  greater	  the	  substrate	  for	  CRT	  and	  the	  more	  likely	  a	  patient	  will	   respond.	   It	   is	   inferred	   that	   the	  broader	   the	  QRS	  duration	   the	  more	  electrical	  dyssynchrony	   there	   is	  and	  more	  mechanical	  dyssynchrony	   is	  present.	  The	   relationship	   between	   QRS	   duration	   and	   mechanical	   dyssynchrony	   is	   not	  clear.	   I	   found	   that	   the	   correlation	   between	   QRS	   duration	   and	   volume	   SDI	  was	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only	  moderate	  (r=0.6).	  Having	  a	  broad	  QRS	  does	  not	  always	  lead	  to	  mechanical	  dyssynchrony	   and	   vice	   versa.	   All	   patients	   had	   LBBB,	   with	   a	   QRS	   duration	   ≥	  120ms	  yet	   only	  45%	  RR.	  Therefore	   current	  use	  of	  QRS	  duration	  of	   ≥	  120ms	   is	  very	  poor	  at	  selecting	  which	  patients	  will	  respond	  to	  CRT.	  	  Current	  guidelines	  for	  patient	  selection	  for	  CRT	  are	  a	  QRS	  duration	  greater	  than	  120ms.	   The	   broader	   the	   QRS	   the	   more	   likely	   patients	   are	   to	   RR.	   This	   is	  underpinned	  by	  QRS	  duration	  of	  162ms	  being	  the	  best	  cut-­‐off	  for	  sensitivity	  and	  specificity	  in	  this	  study.	  Using	  a	  cut-­‐off	  of	  10%	  for	  volume	  derived	  SDI	  from	  CMR,	  21	   (47%)	   patients	   had	   an	   SDI	   ≥	   10%,	   of	   those	   18	   (86%)	   RR.	   Using	   a	   volume	  derived	  SDI	  of	  ≥	  10%	   is	  a	   far	  better	  discriminator	  at	  predicting	  which	  patients	  are	  likely	  to	  RR	  than	  QRS	  duration	  of	  ≥	  120ms.	  	  	  
Measurement	  Techniques	  Previous	   echocardiographic-­‐based	   studies135	   have	   showed	   the	   poor	  reproducibility	   of	   particularly	   strain	   based	  measures	   of	   dyssynchrony.	   I	   found	  excellent	   intra	   and	   inter-­‐observer	   agreement	   for	   volume	   derived	   SDI.	   The	  measures	  of	  agreement	  between	  two	  difference	  scans	  were	  also	  good	  for	  volume	  derived	  SDI.	  The	  framework	  that	  was	  developed	  as	  part	  of	   this	  project	  to	  allow	  assessment	  of	  muscle	  thickening	  and	  strain	  involved	  a	  complex	  procedure,	  which	  was	  long	  and	  time	  consuming	  and	  not	  practical	  in	  the	  clinical	  arena.	  Assessment	  of	  volume	  SDI	  was	  easy	   to	  perform	  providing	  valid	   results	  within	   five	  minutes.	  This	  provides	  a	  simple	  clinical	  tool	  to	  improve	  patient	  selection	  for	  CRT.	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Limitations	  For	  this	  study	  both	  RR	  and	  clinical	   indicators	  were	  used	  to	  determine	  response	  to	   CRT.	   SDI	   for	   volume	   change	   and	  muscle	   thickening	  were	   predictive	   for	   RR.	  Although	  a	  weak	  relationship	  with	  improvement	  in	  NYHA	  class	  and	  SDI	  derived	  from	  volume	  change	  and	  muscle	  thickening,	  and	  a	  weak	  relationship	  with	  muscle	  thickening	  SDI	  and	  improvement	  in	  QOL	  score	  were	  found,	  no	  other	  statistically	  significant	   relationship	   with	   functional	   measures	   were	   identified.	   It	   has	   been	  shown	  that	  RR	  is	  an	  independent	  predictor	  of	  clinical	  outcome	  at	  up	  to	  five	  years	  
136,	   but	   RR	   does	   not	   predict	   symptomatic	   response	   and	   that	   there	   is	   a	  discordance	   between	   symptomatic	   response	   and	   survival	   benefit	   of	   CRT.	   It	   is	  therefore	   important	   that	   a	   volume	  derived	   SDI	   of	   ≥	   10%	   strongly	   predicts	   RR.	  Furthermore	  this	  study	  is	  underpowered	  to	  show	  the	  true	  relationship	  between	  functional	  measures	  of	  improvement	  and	  SDI.	  	  	  When	   the	   patients	  were	   separated	   into	   aetiology,	   only	   six	   of	   the	   patients	  with	  ICM	   RR,	   all	   having	   a	   volume	   SDI	   ≥	   10%.	   A	   highly	   significant	   relationship	   for	  volume	  and	  RR	  in	  ICM	  and	  DCM	  patients	  was	  found.	  For	  muscle	  thickening	  SDI	  a	  significant	  relationship	  in	  DCM	  patients	  but	  no	  relationship	  in	  ICM	  patients	  was	  identifed	  Due	   to	   the	   small	   numbers	   of	   patients	   that	  RR	  particularly	   in	   the	   ICM	  group	   it	   is	   difficult	   to	   interpret	   these	   results	   and	   a	   larger	   study	   is	   required	   to	  answer	  this	  question.	  	  	  A	  major	  limitation	  of	  the	  echo	  data	  was	  the	  image	  quality,	  where	  particularly	  the	  3D	  echo	  image	  quality	  was	  only	  good	  enough	  for	  accurate	  analysis	  in	  26	  (60%)	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patients.	  This	  is	  one	  of	  the	  major	  limitations	  of	  echo	  assessment	  of	  dyssynchrony	  and	  a	  clear	  benefit	  of	  CMR	  due	  to	  superior	  image	  quality.	  
	  
Conclusions	  A	  volume	  derived	  systolic	  dyssynchrony	   index	  from	  cine	  CMR	  strongly	  predicts	  reverse	   remodelling	   in	   heart	   failure	   patients	   referred	   for	   cardiac	  resynchronisation	   therapy.	   Volume	   derived	   systolic	   dyssynchrony	   index	   is	  superior	  to	  echo	  measures	  of	  dyssynchrony	  and	  muscle	  thickening	  at	  predicting	  reverse	   remodelling.	   Different	   strain	   based	   measures	   of	   dyssynchrony	   do	   not	  predict	   reverse	   remodelling.	   Furthermore,	   volume	   derived	   SDI	   is	   a	   highly	  reproducible	  measurement	   that	  has	  significant	  potential	   clinical	   implications	   in	  the	  future	  for	  improving	  patient	  selection	  for	  cardiac	  resynchronisation	  therapy.	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Chapter	  4	  	  
Relationship	  Between	  Acute	  and	  Chronic	  Response	  to	  
CRT	  
	  
Introduction	  What	   follows	   is	   the	   methodology	   and	   results	   for	   the	   study	   of	   acute	  haemodynamic	   response	  and	   its	   relationship	  with	   chronic	   response	   to	  CRT.	  To	  study	  this,	  invasive	  maximum	  rate	  of	  LV	  pressure	  rise	  (LV-­‐dP/dtmax)	  was	  used	  to	  guide	  conventional	  coronary	  sinus	  LV	  lead	  placement	  in	  an	  unselected	  group	  of	  heart	   failure	  patients	  at	   the	   time	  of	  CRT	   implant.	  The	  relationship	  between	  LV-­‐dP/dtmax	  and	  reverse	  remodelling	  was	  then	  investigated.	  	  
Methods	  Patients	  with	  severe	  heart	  failure	  fulfilling	  standard	  criteria	  for	  CRT	  (NYHA	  class	  III-­‐IV	   drug	   refractory	   heart	   failure,	   LVEF	   ≤35%,	   LV	   end-­‐diastolic	   diameter	  ≥55mm	  and	  prolonged	  QRS	  >	  120ms)	  were	  recruited.	  Clinical	  characteristics	  of	  the	   patients	   are	   presented	   in	   Table	   13.	   Symptomatic	   response	   was	   assessed	  using	  a	  quality-­‐of-­‐life	  questionnaire,	  which	  was	  repeated	  six	  months	  post	  CRT.	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Table	  13	  Patient	  Characteristics	  







DCM	  vs	  ICM	  
Age	  (years)	   63.6±12.1	   62.3±12.7	   65.9±10.9	   N/S	  
Sex	  (male/female)	   29/4	   18/3	   11/1	   N/S	  
NYHA	  status	   30	  class	  III	   20	  class	  III	   10	  class	  III	   N/S	  
QOL	  score	  pre	  CRT	   52±22	   50±23	   53±21	   N/S	  
QRS	  duration	  (ms)	   160±23	   162±28	   156±13	   N/S	  
Rhythm	   27	  SR	  6	  AF	   16	  SR	  5AF	   11SR	  1AF	   N/S	  
Ejection	  fraction	   25±8%	   24±9	   26±5	   N/S	  
End	  diastolic	  volume	  (ml)	   239±69	   250±83	   229±56	   N/S	  
End	  systolic	  volume	  (ml)	   185±67	   193±77	   170±43	   N/S	  
B	  Blockers	  (%)	   86	   88	   75	   	  
ACE/ARB	  (%)	   100	   100	   100	   	  
Diuretics	  (%)	   64	   78	   45	   	  
Aldosterone	  antagonists	  (%)	   39	   41	   36	   	  N/S=Non	  significant	  	  
Echocardiographic	  Assessment	  	  Prior	  to	  CRT	  implantation	  patients	  underwent	  echocardiogram,	  acquired	  on	  a	  GE	  vivid	  7	  scanner	  (General	  Electric-­‐Vingmed,	  Milwaukee,	  Wisconsin).	  Analysis	  was	  performed	   using	   EchoPac	   version	   6.0.1	   (General	   Electric-­‐Vingmed,	   Milwaukee,	  Wisconsin).	   Ejection	   fractions	   and	   LV	   dimensions	   were	   measured	   using	   2D	  biplane	   Simpson’s	   modified	   method.	   Echocardiography	   measures	   of	  dyssynchrony	  were	  measured	  as	  described	  in	  chapter	  3.	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Implant	  and	  Acute	  Haemodynamic	  Measurements	  All	   patients	   underwent	   CRT	   implantation	   (Table	   14).	   During	   CRT	   implantation	  haemodynamic	   evaluation	   was	   performed	   using	   a	   0.014	   inch	   diameter	   high	  fidelity	   Certus	   PressureWire	   and	   PhysioMon	   software	   (Radi	   Medical	   Systems,	  Uppsala,	  Sweden)	  with	  a	  500	  Hz	  frequency	  response	  introduced	  into	  the	  LV.	  131	  (chapter	  3	  for	  more	  details	  of	  method)	  	  LV-­‐dP/dtmax	  was	  calculated	  electronically	  from	  every	  heartbeat	  for	  a	  period	  of	  at	  least	   ten	   seconds	   to	   ensure	   steady-­‐state	   conditions.	   The	   results	  were	   averaged	  for	   the	   complete	   measurement	   period.	   A	   waiting	   period	   of	   at	   least	   twenty	  seconds	   was	   respected	   after	   any	   change	   in	   pacing	   settings	   or	   lead	   position	   in	  order	  to	  achieve	  haemodynamic	  stabilization18.	  This	  method	  has	  previously	  been	  shown	  to	  reliably	  measure	  LV-­‐dP/dtmax	  38.	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Table	  14	  Implant	  details	  	  	   Implant	  
Device	   8	  St	  Jude	  Promote	  Q	  CD3221	  16	  St	  Jude	  Promote	  RF	  3213-­‐36	  5	  St	  Jude	  Pacesetter	  Atlas	  II	  HF	  v-­‐367	  4	  St	  Jude	  Frontier	  II	  5596	  	  
LV	  lead	  position	   2	  Posterior	  vein	  19	  Postero-­‐lateral	  vein	  11	  Lateral	  vein	  1	  Middle	  cardiac	  vein	  1	  Antero-­‐lateral	  vein	  	  
Types	  of	  LV	  lead	   27	  Quickflex®	  	  (St	  Jude	  Medical)	  6	  Quartet	  Model	  1458Q	  (St	  Jude	  Medical)	  
LV	  lead	  threshold	   1.4±0.7	  
RV	  lead	  threshold	   0.7±0.3	  
	   	  	  	   	  
	   129	  
Haemodynamic	  Measurement	  Protocol	  and	  Data	  Analysis	  	  An	   occlusive	   venogram	   was	   performed	   and	   the	   LV	   lead	   was	   then	   placed	   in	  branches	  of	   the	   coronary	   sinus	   that	  were	   considered	  potential	   targets	   to	   allow	  multiple	  measurements	  of	  dP/dtmax.	  In	  these	  sites	  the	  LV-­‐dP/dtmax	  was	  measured	  during	   intrinsic	   rhythm	  and	  atrial	  pacing	   (AAI	  5-­‐10	  beats	  above	   intrinsic	   atrial	  rate	   to	   ensure	   consistent	   capture)	   and	  with	   LV	   coronary	   sinus	   pacing	   (DDDLV	  (fixed	   AV	   delay	   100ms)	   or	   VVI	   (patients	   in	   atrial	   fibrillation	   (AF)	   5-­‐10	   beats	  above	  intrinsic).	  In	  patients	  with	  AF,	  baseline	  was	  considered	  as	  right	  ventricular	  (RV)	  pacing	  5-­‐10	  beats	  above	  intrinsic	  ventricular	  rate.	  132	  	  	  Results	  at	  each	  pacing	  site	  were	  expressed	  as	  a	  percentage	  of	  variation	  from	  the	  baseline	  (AAI	  pacing,	  5-­‐10	  beats	  above	   intrinsic	  rate).	  The	  best	  position	   for	   the	  LV	   lead	   location	  was	  defined	  as	   the	  site	  with	   the	   largest	  percentage	  rise	   in	  LV-­‐dP/dtmax	  from	  baseline.	  Baseline	  drift	  in	  dP/dtmax	  was	  determined	  by	  calculating	  the	  mean	  standard	  deviation	  over	  the	  course	  of	  the	  procedure.	  At	  the	  end	  of	  the	  procedure,	  pressure	  wire	  guided	  AV	  and	  VV	  optimization	  was	  performed.	  
	  
Reverse	  Remodelling	  and	  Responders	  Patients	  were	  deemed	  to	  have	  RR	   if	   there	  was	  a	  ≥	  15%	  reduction	   in	  LV	  ESV	  as	  measured	   using	   Simpson’s	   modified	   biplane	   method	   on	   2D	   echo	   images.	   48,	   49	  Evaluation	  of	  symptomatic	  response	  was	  made	  using	  NYHA	  class	  and	  quality-­‐of-­‐life	  questionnaire.	  50	  To	  assess	  sensitivity	  and	  specificity	  for	  dP/dtmax	  to	  predict	  RR	   patients	   were	   deemed	   acute	   responders	   if	   the	   percentage	   improvement	   in	  dP/dtmax	  was	  ≥	  10%	  compared	  with	  fixed	  rate	  atrial	  /	  RV	  pacing	  (baseline).	  This	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cut-­‐off	   value	   has	   been	   used	   in	   previous	   studies.	   37,	   51	   Patients	   were	   labeled	  clinical	  responders	  if	  the	  NYHA	  class	  fell	  by	  ≥	  1	  or	  if	  there	  was	  a	  ≥10%	  reduction	  in	  quality-­‐of-­‐life	  questionnaire	  score.	  	  
Statistical	  Analysis	  Statistical	   analysis	   was	   performed	   using	   JMP	   software	   (version	   8.0.2,	   Marlow,	  Buckinghamshire,	   UK).	   A	   Shapiro-­‐Wilk	   test	  was	   used	   to	   ensure	   variables	  were	  normally	   distributed.	   Continuous	   variables	   were	   expressed	   as	   mean	   ±	   SD	   and	  compared	   with	   parametric	   (One-­‐way	   ANOVA)	   and	   non-­‐parametric	   (Wilcoxon	  rank	  sum)	  tests.	  Changes	  with	   in	  variables	  were	  compared	  using	  paired	   t	   tests.	  Nominal	   variables	   are	   expressed	   as	   absolute	   count	   and	   percentages	   and	  compared	   with	   a	   Fisher’s	   exact	   test.	   Outcomes	   were	   assessed	   with	   logistic	  regression	  to	  create	  receiver-­‐operator	  characteristic	  (ROC)	  curves.	  Optimal	  cut-­‐offs	   were	   selected	   as	   the	   level	   with	   the	   highest	   (Sensitivity-­‐	   (1-­‐Specificity)).	   P	  values	  of	  <	  0.05	  were	  considered	  statistically	  significant.	  
	  
Results	  Thirty-­‐three	  patients	  were	  recruited	  (29	  males,	  age	  63.6±12.1	  years),	  with	  mean	  ejection	   fraction	   of	   25±8%.	   All	   patients	   had	   LBBB,	   QRS	   duration	   160±23ms.	  Twelve	   had	   ICM	   and	   21	   DCM	   (Table	   13).	   Assessment	   of	   LV-­‐dP/dtmax	   was	  successfully	  achieved	  in	  all	  patients.	  All	  patients	  had	  a	  BIV	  pacemaker	  inserted	  at	  the	   time	   of	   the	   pressure	   wire	   study	   (Table	   14).	   Average	   procedure	   time	   was	  138±38	  minutes	  and	  fluoroscopy	  time	  20.7±7.4minutes.	  One	  patient	  had	  a	  groin	  haematoma	   from	   the	   pressure	   wire,	   and	   one	   a	   wound	   haematoma,	   neither	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requiring	   further	   intervention.	   One	   patient	   had	   RV	   lead	   displacement	   that	  required	   repositioning	   the	   following	   day.	   One	   patient	   had	   a	   coronary	   sinus	  dissection,	  however	  a	  LV	  lead	  was	  still	  successfully	  implanted.	  One	  patient	  with	  an	   ICM	   post	   implant	   had	   excessive	   diaphragmatic	   pacing,	   which	   led	   to	   the	   LV	  lead	  being	  turned	  off	  and	  this	  patient	  being	  excluded	  from	  six-­‐month	  follow	  up.	  	  	  The	  mean	   intrinsic	  LV-­‐dP/dtmax	  was	  722±148	  mmHg/s	   compared	  with	  AAI/RV	  pacing	  10	  beats	  above	  intrinsic	  which	  was	  801±194	  mmHg/s	  (p<0.001)	  (used	  as	  baseline).	  The	  baseline	  drift	   in	  LV-­‐dP/dtmax	  over	  the	  course	  of	  the	  implants	  was	  68±17	   mmHg/s.	   There	   was	   a	   highly	   significant	   increase	   in	   LV-­‐dP/dtmax	   from	  baseline	  to	  DDDLV	  pacing	  in	  the	  optimal	  (best	  AHR)	  position	  (801±194mmHg/s	  to	  924±203mmHg/s	  P<0.001,	  18±18%	  rise)(Figure	  25)	  (Table	  15).	   In	  30	  of	   the	  patients	  at	  least	  two	  separate	  branches	  of	  the	  coronary	  sinus	  were	  paced.	  There	  was	   a	   highly	   significant	   difference	   between	   best	   and	   worst	   LV	   pacing	   site	  (924±203mmHg/s	  best	  site,	  782±160mmHg/s	  worst	  site	  P<0.001)(Figure	  25	  &	  26).	   Using	   a	   10%	   cut-­‐off	   to	   define	   acute	   response,	   23	   (70%)	   of	   patients	   were	  acute	  responders	  to	  DDDLV	  pacing.	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Table	  15	  RR	  and	  acute	  haemodynamic	  response	  depending	  on	  LV	  lead	  position	  
	   ≥	  15%	  
reduction	  in	  
ESV	  
Intrinsic	   AAI	  pacing	   DDD-­‐LV	  pacing	  








†All	  patients	  n=33	  
	  




11	  	  	  (64%)	   730±123*	   828±174	   978±222*	   19±16	  
LV	  lead	  Lateral	  vein	  
n=11	  
5	  	  	  	  	  	  (45%)	   725±164	   795±255	   894±178*	   18±23	  
LV	  lead	  Posterior	  vein	  
n=2	  
1	  	  	  	  	  	  (50%)	   745	   831	   978	   18	  
LV	  lead	  middle	  
cardiac	  vein	  n=1	  
1	  	  	  (100%)	   519	   516	   599	   15	  
LV	  lead	  anterolateral	  
vein	  n=1	  
0	  	  	  	  	  	  	  	  (0%)	   780	   948	   982	   4	  
*Significant	  difference	  from	  AAI	  pacing	  (P<0.05)	  †One	  patient	  excluded	  from	  long-­‐term	  follow	  up	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Figure	   25	   Change	   in	   LV-­‐dP/dtmax	   for	   various	   pacing	   modes	   and	   difference	  between	  best	  and	  worst	  LV-­‐dP/dtmax	  for	  DDDLV	  pacing.	  
	  	  
Figure	  26	  Best	  and	  Worst	  Sites	  for	  Each	  Individual	  pacing	  position	  
	  Percentage	   of	   change	   in	   LV-­‐dP/dtmax	   from	   AAI	   or	   RV	   baseline	   LV-­‐dP/dtmax	   for	  each	  individual	  patient	  at	  best	  (blue	  bar)	  and	  worst	  (red	  bar)	  LV	  lead	  position.	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Response	  and	  Reverse	  Remodelling	  Pre-­‐implant	   LV	   ESV	   and	   LV	   EF	   were	   185±67ml	   and	   24.8±8.0%	   respectively.	  These	   improved	   over	   the	   follow-­‐up	   period	   to	   157±69ml	   and	   32.8±9.7%.	   This	  represented	  a	  15%	  relative	  reduction	  in	  LV	  ESV	  and	  a	  41%	  relative	  improvement	  in	  LV	  EF	  (both	  p<0.001).	  Eighteen	  (56%)	  patients	  RR.	  Percentage	  rise	  in	  dP/dtmax	  with	   DDDLV	   pacing	   strongly	   predicted	   RR	   (P<0.001)	   (Figure	   27),	   as	   did	   QRS	  duration	   (P<0.001).	   Using	   echocardiographic	   measure	   of	   dyssynchrony,	   LVPE,	  IVMD	   and	   SDI	  measured	  with	   3D	   echocardiography	  were	   found	   to	   predict	   RR	  (P=0.01,	  P<0.001	  and	  P=0.01	  respectively).	  It	  should	  be	  noted	  that	  seven	  (21%)	  of	  the	  3D	  echo	  data	  sets	  were	  not	  analyzable	  due	  to	  poor	  image	  quality.	  Septal-­‐lateral	  delay	  with	  TDI	  showed	  no	  association	  with	  RR	  (P=0.8)	  (Figure	  28).	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Figure	   27	   ANOVA	   plot	   showing	   the	   percentage	   change	   in	   LV-­‐dP/dtmax	   from	  baseline	  for	  DDD-­‐LV	  pacing	  plotted	  against	  the	  presence	  or	  absence	  of	  RR.	  
	  AAI_LV=	  %rise	  in	  LV-­‐dP/dtmax	  with	  DDDLV	  pacing	  from	  baseline	  AAI	  pacing.	  
Figure	   28	   Shows	   the	   ANOVA	   plots	   for	   echocardiographic	   parameters	   of	  dyssynchrony	  to	  predict	  RR	  
	  	  
A	  LV	   pre	   ejection	   period;	   B	   Interventricular	  mechanical	   delay;	  C	   Septal	   lateral	  delay	   measured	   with	   tissue	   Doppler	   imaging;	   D	   Systolic	   dyssynchrony	   index	  measured	  with	  3D	  echocardiography.	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A	   greater	   than	   10%	   improvement	   in	   LV-­‐dP/dtmax	   from	   baseline	   with	   DDDLV	  pacing	  was	  more	   sensitive	   at	   predicting	  which	   patients	  were	   likely	   to	  RR	   than	  echocardiographic	   parameters	   (Table	   16).	   Seventeen	   (77%)	   of	   the	   22	   patients	  that	  RR	  had	  a	  ≥	  10%	  rise	   in	  LV-­‐dP/dtmax,	  with	  only	  one	  patient	  that	  had	  a	  10%	  rise	   in	   LV-­‐dP/dtmax	   not	  RR	   (sensitivity	   0.94,	   P<0.001	   compared	  with	   best	   echo	  parameter	   LVPE	   sensitivity	   0.82,	   P=0.06).	   Receiver-­‐operating	   characteristics	  (ROC)	   (Table	   17)	   11.1%	   rise	   in	   LV-­‐dP/dtmax	   from	   baseline	   had	   a	   sensitivity	   of	  0.94	  and	  specificity	  of	  0.86	  (P=0.009)	  to	  predict	  RR.	  This	  supports	  the	  use	  a	  10%	  cut-­‐off	   value	   to	   distinguish	   between	   responders	   and	   non-­‐responders.	   A	   QRS	  duration	   cut	   off	   of	   146ms	   was	   found	   to	   be	   good	   predictor	   of	   RR.	   With	   ROC	  analysis	   the	   only	   echocardiographic	   parameter	   of	   dyssynchrony	   that	   had	  comparable	   sensitivity	   and	   specificity	   was	   IVMD	   with	   a	   cut	   off	   of	   29ms	  (sensitivity	  0.94,	  specificity	  0.79,	  P=0.003).	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Table	  16	  Sensitivity	  and	  Specificity	  for	  10%	  rise	  in	  LV-­‐dP/dtmax	  for	  LV	  pacing	  as	  well	  as	  standard	  echocardiographic	  measures	  of	  dyssynchrony	  predicting	  RR	  
	  
	  
	   	  
Assessment	  method	   Cutoff	  
Met?	  
Total	   n	   %	   Sensitivity	   Specificity	   P	  
%	  rise	  LV	  dP/dtmax	  ≥	  
10%	  
N=32	  
Yes	   22	   17	   77	   0.94	   0.64	   <0.001	  No	   10	   1	   10	  
LVPE	  ≥	  140ms	  
N=31	  
Yes	   21	   14	   67	   0.82	   0.5	   0.06	  No	   10	   3	   30	  
IVMD	  ≥	  40ms	  
N=31	  
Yes	   15	   13	   86	   0.76	   0.86	   <0.001	  No	   16	   4	   25	  
TDI	  Septal	  lateral	  ≥	  
80ms	  
N=32	  
Yes	   8	   4	   50	   0.22	   0.71	   0.7	  No	   24	   14	   56	  
SDI	  ≥	  10.3%	  
N=26	  
Yes	   16	   12	   75	   0.8	   0.64	   0.02	  
No	   10	   3	   30	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Table	  17	  Sensitivity,	  Specificity	  and	  Area	  under	  the	  curve	  for	  RR	  
Assessment	  method	   AUC	   Cut-­‐
off	  
Sensitivity	   Specificity	  
QRSD	  (ms)	  
N=32	  
0.84	   146	   1	   0.64	  
%	  rise	  LV	  dP/dtmax	  
N=32	  
0.89	   11.1	   0.94	   0.86	  
LVPE	  (ms)	  
N=31	  
0.75	   160	   0.65	   0.79	  
IVMD	  (ms)	  
N=31	  
0.91	   29	   0.94	   0.79	  
TDI	  Septal	  lateral	  
(ms)	  
N=32	  
0.5	   90	   0.88	   0.29	  
SDI	  (%)	  
N=26	  
0.8	   11.9	   0.73	   0.82	  
Table	   uses	   receiver-­‐operating	   characteristics	   curve	   analysis	   to	   investigate	  whether	   changing	   the	   cut-­‐off	   values	   used	   in	   table	   16	   could	   give	   a	   better	  prediction	  of	  improvement	  in	  ESV	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Aetiology	  and	  Reverse	  Remodelling	  Differences	  between	  patients	  with	  DCM	  and	  ICM	  pre	  CRT	  are	  shown	  in	  table	  18.	  Reverse	   remodeling	   occurred	   in	   13	   (61%)	   patients	   with	   DCM	   and	   five	   (45%)	  with	   ICM	   (Table	   18).	   There	   was	   a	   trend	   towards	   patients	   with	   DCM	   having	   a	  greater	   percentage	   reduction	   in	   ESV	   (19±21%	   vs	   8±28%)	   compared	   to	   ICM	  patients	  although	  this	  was	  non-­‐significant.	  AHR	  predicted	  RR	  for	  both	  DCM	  and	  ICM	   patients	   (P=0.01	   and	   P=0.006	   respectively)	   (Figure	   29).	   Similar	   QRS	  duration	   predicted	   RR,	   for	   both	   DCM	   and	   ICM	   patients	   (P=0.01	   and	   P=0.04	  respectively).	   For	   patients	   with	   DCM,	   SDI,	   (P=0.004)	   and	   IVMD	   predicted	   RR	  (P=0.006).	  For	  patients	  with	  ICM	  the	  only	  echocardiographic	  parameter	  that	  was	  useful	  for	  predicting	  RR	  was	  IVMD	  (P=0.006).	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Figure	  29	  Shows	  the	  percentage	  rise	  in	  LV-­‐dP/dtmax	  from	  baseline	  with	  DDDLV	  pacing	  in	  patients	  with	  DCM	  (A)	  and	  ICM	  (B).	  	  
	  AAI_LV=	  %rise	  in	  LV-­‐dP/dtmax	  with	  DDDLV	  pacing	  from	  baseline	  AAI	  pacing.	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Table	  18	  Differences	  in	  AHR	  and	  RR	  between	  DCM	  and	  ICM	  





AAI	  pacing	   DDLV	  pacing	  








16±24	   18	  	  	  (56%)	   798±197	   910±188*	   16±17	  
DCM	  
N=21	  
19±21	   13	  	  	  (61%)	   766±205	   887±185*	   19±18	  
ICM	  
N=11	  
8±28	   5	  	  	  	  	  	  (45%)	   857±173	   953±193*	   12±14	  
*Significant	  difference	  between	  AAI	  pacing	  (P<0.05)	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Lead	  Position	  With	   respect	   to	   LV	   lead	   position	   in	   18	   (54%)	   patients	   the	   largest	   rise	   in	   LV-­‐dP/dtmax	  was	  in	  a	  posterolateral	  vein	  (one	  patient	  had	  LV	  lead	  turned	  off	  due	  to	  diaphragmatic	  pacing	  and	  was	  therefore	  excluded	  from	  long-­‐term	  follow	  up).	  Of	  these	  11	  (64%)	  reverse	  remodelled.	  In	  11	  (33%)	  patients	  the	  largest	  rise	  in	  LV-­‐dP/dtmax	  was	   in	   a	   lateral	   vein,	   and	   five	   (45%)	  of	   these	  RR.	   In	   two	  patients	   the	  largest	  rise	   in	  LV-­‐dP/dtmax	  was	   in	  a	  posterior	  vein	  with	  of	   these	  patients	  RR.	   In	  one	  patient	  the	  largest	  rise	  in	  LV-­‐dP/dtmax	  was	  in	  the	  middle	  cardiac	  vein,	  and	  the	  patient	  RR.	  In	  one	  the	  best	  position	  was	  the	  anterolateral	  vein,	  but	  the	  subject	  did	  not	  RR	  (Table	  15,	  Figure	  30	  and	  31).	  	  
Clinical	  Response	  Twenty-­‐nine	  (91%)	  patients	  improved	  by	  at	  least	  one	  NYHA	  class	  and	  30	  (94%)	  patients	  had	  a	  ≥	  10%	  reduction	  in	  quality-­‐of-­‐life	  score.	  There	  was	  a	  statistically	  significant	   relationship	   between	   percentage	   rise	   in	   LV-­‐dP/dtmax	   and	  improvement	  in	  NYHA	  score	  and	  10%	  reduction	  in	  quality-­‐of-­‐life	  score	  (P=0.02	  for	  both).	  No	  relationship	  between	  QRS	  duration	  or	  echocardiographic	  measures	  of	  dyssynchrony	  and	  measures	  of	  clinical	  improvement	  were	  found.	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Figure	  30	   Comparison	   of	   LV-­‐dP/dtmax	   for	   intrinsic,	   AAI,	   DDDLV	  pacing	   for	   the	  different	  final	  LV	  lead	  positions.	  
	  	  PosLat=Posterolateral	   vein,	   Lat=Lateral	   vein,	   Pos=Posterior	   vein,	   Mid=Middle	  cardiac	  vein,	  AntLat=Anterolateral	  vein.	  	  
Figure	  31	  A	  shows	  the	  percentage	  of	  LV	  leads	  positioned	  in	  the	  branches	  of	  the	  coronary	  sinus.	  B	  shows	  the	  percentage	  of	  patients	  that	  remodelled.	  
	  The	  middle	  cardiac	  vein	  is	  not	  represented	  on	  this	  diagram	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Discussion	  Using	   invasive	   acute	   haemodynamic	   response	   at	   the	   time	   of	   CRT	   implant	   this	  study	  shows:	  	  1)	  There	  is	  a	  strong	  relationship	  between	  the	  magnitudes	  of	  rise	  in	  LV-­‐dP/dtmax	  from	  baseline	  for	  DDDLV	  pacing	  and	  RR.	  	  2)	  For	  DDDLV	  pacing	  giving	  a	  ≥	  10%	  increase	  in	  LV-­‐dP/dtmax	  from	  baseline	  is	  a	  highly	   sensitive	   and	   specific	   predictor	   of	   RR	   which	   was	   under-­‐pinned	   by	   the	  receiver	  operator	  characteristics	  giving	  a	  cut	  off	  of	  11.1%.	  	  3)	   The	   percentage	   rise	   in	   LV-­‐dP/dtmax	   for	   LV	   pacing	   is	   better	   at	   predicting	  RR	  than	  QRS	  duration	  greater	  or	  equal	  to	  120ms	  and	  is	  at	  least	  as	  good	  as	  the	  best	  echocardiographic	  parameters	  of	  dyssynchrony	  (IVMD).	  	  4)	  LV-­‐dP/dtmax	  varies	  significantly	  depending	  on	  site	  of	  LV	  lead	  positioning	  and	  maybe	  useful	  for	  guidance.	  	  
Aetiology	  and	  Reverse	  Remodelling	  More	  of	  the	  patients	  with	  DCM	  than	  with	  ICM	  reverse	  remodelled	  (61%	  vs	  45%).	  There	  was	  a	  trend	  towards	  increased	  RR	  in	  DCM	  patients	  although	  this	  was	  not	  statistically	   significant.	   However	   the	   acute	   response	   appeared	   to	   be	   similarly	  predictive	   of	   RR	   in	   both	   groups.	   The	   fact	   that	   fewer	   ICM	   patients	   RR	   can	   be	  explained	   by	   the	   presence	   of	   myocardial	   scar,	   which	   may	   give	   rise	   to	   a	   more	  varied	   response	   to	   CRT.	   Nevertheless,	   the	   rise	   in	   LV-­‐dP/dtmax	   may	   reflect	  contractile	  reserve	  and	  therefore	  provides	  an	  indicator	  of	  how	  a	  patient	  is	  likely	  to	  respond	  137	  independent	  of	  aetiology.	  There	  was	  a	  good	  relationship	  between	  QRS	   duration	   and	   RR	   for	   both	   DCM	   and	   ICM	   patients.	   For	   echocardiographic	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parameters	   of	   dyssynchrony	   only	   IVMD	   delay	   was	   found	   to	   be	   predictive	   of	  response	   in	   ICM	  patients.	   This	   underpins	   that	   LV-­‐dP/dtmax	  may	   be	   particularly	  usefully	  in	  determining	  which	  ICM	  patients	  are	  likely	  to	  respond,	  as	  conventional	  methods	  are	  less	  helpful.	  	  	  
LV	  Pacing	  Site	  Although	  in	  the	  majority	  of	  patients	  the	  greatest	  percentage	  rise	  in	  LV-­‐dP/dtmax	  was	   in	  a	  posterolateral	  or	   lateral	   lead	  position	  (88%),	   there	  were	   four	  patients	  (12%)	   where	   the	   optimum	   position	   based	   on	   the	   rise	   in	   LV-­‐dP/dtmax	   was	   in	  either	  a	  posterior,	  middle	  or	  anterolateral	  vein.	  Of	  these	  four	  patients,	  50%	  RR.	  Only	   one	   of	   these	   four	   patients	   had	   an	   ICM.	   This	   patient	   had	   extensive	  transmural	   inferior	   lateral	  scar,	  a	   lead	  was	  placed	   in	   the	  anterolateral	  vein	  and	  they	   showed	   a	   less	   than	   10%	   increase	   in	   LV-­‐dP/dtmax	   and	   did	   not	   RR.	   It	   is	  unlikely	   this	   patient	  would	   have	  RR	  due	   to	   position	   and	   extent	   of	   scar.	   Recent	  published	   data	   have	   demonstrated	   that	   pacing	   the	   site	   of	   latest	   mechanical	  activation	  was	  associated	  with	  a	  better	  long-­‐term	  prognosis	  and	  RR	  at	  six	  months	  
14.	  A	  further	  study	  34	  using	  an	  individually	  based	  approach	  showed	  that	  there	  was	  marked	   individual	   variation	   between	   patients	   and	   LV-­‐dP/dtmax	   measured	   at	  different	   LV	   pacing	   sites	   and	   concluded	   that	   an	   individual	   based	   approach	   to	  pacing	  is	  possibly	  superior	  to	  empirical	  placement	  of	  the	  lead	  in	  a	  posterolateral	  or	   lateral	  vein.	   In	   this	   study	  epicardial	  pacing	  via	   the	  coronary	  sinus	  was	  used,	  which	   limits	   the	   potential	   targets	   (three	   patients	   had	   only	   one	   suitable	   vein).	  However	   I	   found,	   using	   a	   targeted	   approach	   with	   LV-­‐dP/dtmax,	   that	   empirical	  implantation	   of	   the	   LV	   lead	   in	   a	   posterolateral	   or	   lateral	   vein	   does	   not	   always	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produce	  the	  best	  AHR.	  It	  is	  interesting	  that	  in	  some	  positions	  LV	  lead	  placement	  was	   no	   better	   than	   AAI	   or	   RV	   pacing	   (Figure	   25	   &	   26).	   This	   emphasises	   the	  importance	  of	  optimising	  the	  final	  site	  for	  the	  LV	  lead.	  	  
Role	  of	  LV-­‐dP/dtmax	  Patients	  were	  recruited	  on	  the	  basis	  of	  QRS	  duration	  ≥120ms.	  On	  this	  basis,	  only	  18	  (56%)	  patients	  RR.	  For	  LV-­‐dP/dtmax	  17	  (94%)	  of	  the	  18	  patients	  that	  RR	  had	  a	  ≥10%	  rise	  in	  LV-­‐dP/dtmax	  and	  only	  one	  patient	  with	  a	  ≥	  10%	  rise	  in	  LV-­‐dP/dtmax	  did	  not	  RR	   (figure	  32).	  The	   receiver	  operator	   analysis	   showed	  a	  QRS	   cut	  off	   of	  146ms	  was	  a	  far	  more	  sensitive	  predictor	  of	  RR	  than	  120ms.	  Of	  10	  patients	  with	  a	  QRS	  between	  120-­‐149ms	  only	  one	  RR,	  this	  patient	  did	  have	  a	  ≥	  10%	  rise	  in	  LV-­‐dP/dtmax.	  Although	  the	  numbers	  are	  small	  it	  is	  possible	  that	  LV-­‐dP/dtmax	  could	  be	  particularly	   useful	   in	   determining	   responders	   in	   this	   group	   as	   it	  would	   appear	  that	   if	   the	  QRS	   is	   <	   150ms	   and	   there	   is	   a	   <	   10%	   rise	   in	   dP/dtmax	   RR	   it	   is	   very	  unlikely	  to	  occur.	  	  	  IVMD	  was	  nearly	  equivalent	  in	  its	  predictive	  value	  for	  RR	  as	  LV	  dP/dtmax.	  When	  groups	  were	  separated	  into	  DCM	  and	  ICM,	  only	  IVMD	  was	  found	  to	  be	  predictive	  of	   RR	   for	   both	   aetiologies.	   No	   relationship	   for	   septal	   lateral	   delay	   and	  RR	  was	  seen.	  3D	  Echo-­‐derived	  SDI	  was	  predictive	  of	  RR	  overall	  and	  in	  DCM	  patients,	  but	  did	   not	   give	   superior	   discrimination	   compared	   to	  QRS	  duration	   alone	   and	  was	  not	   helpful	   in	   ICM	   patients.	   Furthermore	   seven	   (22%)	   data	   sets	   were	   not	  analyzable	  due	  to	  poor	  image	  quality.	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Figure	  32	  Breakdown	  of	  patients	  that	  RR	  that	  had	  ≥	  10%	  rise	  in	  LV-­‐dP/dtmax.	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Assessment	  of	  LV-­‐dP/dtmax	   is	  highly	   invasive	  (requires	  arterial	  access)	  whereas	  conventional	  2D	  echocardiographic	  assessment	  of	  dyssynchrony	  is	  not.	  However	  dp/dtmax	  measurement	  is	  a	  more	  practical	  method	  to	  assess	  response	  during	  the	  procedure,	  whereas	  echocardiography	  would	  be	  more	  difficult.	  The	  real	  benefit	  of	   using	   both	   echocardiography	   and	   dP/dtmax	   is	   complimentary	   -­‐	  echocardiography	  should	  be	  used	  to	  predict	  pre-­‐procedure	  who	  would	  respond,	  while	  dP/dtmax	  should	  be	  used	  intra-­‐procedure	  to	  identify	  best	  site	  for	  response.	  	  	  
Clinical	  Implications	  With	  respect	   to	  symptomatic	  response,	  29	  (91%)	  patients	   improved	  by	  at	   least	  one	  NYHA	  class	  and	  30	  (94%)	  patients	  had	  a	  ≥	  10%	  reduction	   in	  quality	  of	   life	  questionnaire	   score.	   There	   was	   a	   statistically	   significant	   relationship	   between	  percentage	  rise	  in	  LV-­‐dP/dtmax	  and	  improvement	  in	  quality	  of	  life	  questionnaire	  and	   NYHA	   score.	   For	   QRS	   duration	   and	   echocardiographic	   parameters	   no	  relationship	  was	  found.	  It	  has	  been	  shown	  that	  up	  to	  28%	  of	  patients	  experience	  clinical	  response	  without	  significant	  LV	  RR.	  46	  It	  could	  be	  inferred	  that	  using	  LV-­‐dP/dtmax	   to	   guide	   LV	   lead	   placement	   leads	   to	   a	   high	   clinical	   responder	   rate.	  However,	  there	  are	  few	  clinical	  non-­‐responders	  and	  a	  larger	  study	  is	  required	  to	  understand	  the	  relationship	  between	  rise	  in	  LV-­‐dP/dtmax	  and	  clinical	  response.	  	  
Study	  Limitations	  Due	   to	   the	   small	   number	   of	   ICM	   patients	   it	   is	   difficult	   to	   fully	   understand	   the	  relationship	  between	  rise	   in	  LV-­‐dP/dtmax	  and	  RR.	  I	  have	  been	  able	  to	  show	  that	  LV-­‐dP/dtmax	   is	   helpful	   at	   predicting	   RR	   in	   all	   patients	   undergoing	   CRT	   and	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although	  I	  have	  shown	  that	  rise	  in	  LV-­‐dP/dtmax	  seems	  to	  be	  helpful	  in	  predicting	  response	   in	   DCM	   and	   ICM	   patients	   greater	   numbers	   are	   required	   to	   fully	  understand	   this	   relationship.	   The	   high	   clinical	   responder	   rate	   means	   that	   this	  study	   is	   underpowered	   to	   determine	   if	   LV-­‐dP/dtmax	   can	  predict	  which	  patients	  are	  likely	  to	  improve	  symptomatically.	  	  	  To	  keep	  the	  pacing	  protocol	  simple	  DDDLV	  pacing	  was	  used	  to	  determine	  the	  LV	  lead	  position	  rather	  than	  BIV	  pacing.	  It	  could	  be	  argued	  that	  determining	  the	  LV	  lead	   position	   with	   DDDBIV	   pacing	   would	   be	   superior	   as	   this	   would	   be	   more	  comparable	   to	   a	   normal	   resynchronisation	   pacing	   strategy,	   but	   using	   DDDLV	  pacing	   was	   the	   only	   option	   to	   ensure	   steady	   rate	   for	   accurate	   haemodynamic	  measurements	   throughout	   the	  study.	  Also,	  previous	  studies	  have	  demonstrated	  the	  non-­‐inferiority	  of	  DDDLV	  pacing	  compared	  to	  DDDBIV	  pacing	  35,	  37,	  138.	  We	  are	  aware	  that	  further	  studies	  are	  required	  with	  the	  LV	  lead	  position	  optimised	  with	  BIV	   pacing	   to	   see	   if	   there	   are	   differences	   in	   final	   lead	   placement	   and	   if	   this	  changes	   the	   long	   term	   outcome	   although	   a	   protocol	   optimising	   every	   lead	  position	   with	   BIV	   pacing	   would	   run	   the	   risk	   of	   having	   unfeasible	   procedure	  times.	  	  The	   absence	   of	   a	   control	   group	   is	   a	  major	   limitation.	   Our	   results	   do,	   however,	  highlight	   the	  potential	   of	   LV-­‐dP/dtmax	   to	   guide	  LV	   lead	  placement	   and	   improve	  response	  rates.	  This	  study	  emphasises	  the	  need	  for	  a	  randomised	  control	  study	  of	  a	  guided	  versus	  conventional	  approach	  to	  CRT.	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Conclusions	  I	  have	  shown	  that	  rise	  in	  LV-­‐dP/dtmax	  from	  baseline	  AAI	  or	  RV	  pacing	  to	  guide	  LV	  lead	  position	  is	  helpful	  in	  predicting	  which	  patients	  are	  likely	  to	  reverse	  remodel	  following	  CRT.	  Using	  a	  10%	  rise	  in	  LV-­‐dP/dtmax	  is	  superior	  to	  QRS	  duration	  and	  at	   least	   as	   good	   as	   the	   best	   echocardiographic	   parameters	   at	   selecting	   which	  patients	  are	  likely	  to	  reverse	  remodel	  both	  for	  DCM	  and	  ICM	  patients.	  This	  work	  supports	  the	  use	  of	  LV-­‐dP/dtmax	   to	  aid	   in	   lead	  placement	  and	  this	  may	  improve	  the	   responder	   rates	   in	   CRT	   with	   respect	   to	   determining	   which	   patients	   will	  reverse	  remodel.	  	  It	  is	  logical	  that	  rise	  in	  LV-­‐dP/dtmax	  during	  LV	  pacing	  at	  the	  time	  of	  CRT	  implant	  should	   help	   predict	   which	   patients	   are	   likely	   to	   reverse	   remodel.	   The	   energy	  which	  is	  wasted	  as	  a	  result	  of	  LV	  dyssynchrony,	  may	  be	  “harnessed”	  by	  LV	  pacing	  in	  order	  to	  improve	  cardiac	  function.	  Measuring	  the	  LV-­‐dP/dtmax	  rise	  at	  implant	  potentially	  is	  a	  marker	  of	  how	  much	  the	  cardiac	  function	  can	  be	  improved	  during	  CRT	  and	  therefore	  the	  likelihood	  of	  long	  term	  reverse	  remodeling.	  	  Clearly	  this	  is	  a	  small	  study	  and	  a	  prospective	  randomised	  controlled	  study	  will	  be	  needed	  to	  confirm	   a	   favourable	   effect	   of	   LV-­‐dP/dtmax	   guided	   therapy	   on	   prognosis	   and	  functional	  status	  after	  CRT	  in	  the	  future.	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Chapter	  5	  	  
Relationship	  Between	  Myocardial	  Electrical	  Activation	  
and	  Motion	  in	  Helping	  to	  Understand	  Response	  to	  CRT	  
	  
Introduction	  What	  follows	  is	  a	  brief	  discussion	  about	  LV	  dyssynchrony	  and	  the	  methodology,	  results	   and	   discussion	   for	   work	   investigating	   the	   relationship	   between	  myocardial	  motion	  and	  electrical	  activation	  of	  the	  LV.	  	  A	   recent	   study	   59	   hypothesised	   that	   response	   to	   CRT	   is	   governed	   by	   multiple	  independent	   mechanisms.	   One	   of	   these	   was	   true	   LV	   intra-­‐ventricular	  dyssynchrony,	   characterised	  by	  an	  early	   septal	   contraction	  and	   inward	  motion,	  stretching	   the	   lateral	  wall,	   immediately	   followed	   by	   a	   septal	   lengthening	  while	  the	   lateral	  wall	   starts	   to	   contract.	   This	   fast	   inward	   and	   outward	  motion	   of	   the	  septum	  is	  within	  the	  isovolumic	  contraction	  time	  (between	  the	  onset	  of	  the	  QRS	  complex	  and	  aortic-­‐valve	  opening	  (AVO))	  and	  is	  referred	  to	  as	  a	  septal	  flash	  (SF).	  Elimination	   of	   the	   SF	   results	   in	   significant	   RR	   and	   good	   response	   to	   CRT.	   59	  Groups	   have	   reported	   this	   abnormal	   septal	   motion	   as	   a	   pathophysiological	  mechanism	   underlying	   heart	   failure	   in	   patients	   with	   LBBB.	   139-­‐142	   In	   these	  studies,	   septal	   abnormalities	   are	   associated	  with	   abnormal	   stretching	   of	   (non-­‐ischemic)	   tissues,	   where	   LBBB	   induced	   anterior	   and	   inferior	   wall	   stretching	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extending	   towards	   the	   lateral	   wall.	   139	   Similar	   findings	   were	   reported	   in	   the	  presence	  of	  ventricular	  pacing.	  143	  	  The	  presence	  of	  a	  SF	  is	  visualised	  on	  echocardiography	  in	  all	  views	  showing	  the	  septum	  (short	  axis	  (SAX),	  parasternal	  long	  axis	  (PLAX)	  and	  apical	  four	  chamber	  (4CH)	  views)	  and	  can	  be	  appreciated	  using	  either	   (slowed	  down)	  grey	  scale	  or	  (anatomical)	  M-­‐mode	  (Figure	  33).	  	  	  
Figure	  33	  1A	  Grey	  scale	  M-­‐mode	   image	  of	  a	  patient	  with	  a	   large	  SF.	  Septum	  is	  seen	  to	  have	  early	  and	  fast	  thickening	  and	  thinning.	  1B	  Patient	  with	  no	  SF.	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Non-­‐contact	   mapping	   (NCM)	   has	   been	   used	   in	   several	   human	   studies	   to	  characterize	   the	   LV	   endocardial	   activation	   pattern	   144	   in	   patients	   with	   heart	  failure	   and	   intra-­‐ventricular	   conduction	   delay.	   These	   studies	   showed	   the	  presence	  of	  functional	  lines	  of	  block	  in	  patients	  with	  LBBB,	  often	  with	  the	  pattern	  of	  activation	   taking	  a	   “U-­‐shape”	  around	   the	  area	  of	  slow	  conduction.	   53,	   145	  This	  “U-­‐shaped”	  activation	  wave	  front	  was	  the	  result	  of	  the	  presence	  of	  a	  line	  of	  block	  that	   was	   located	   anteriorly	   (about	   50%	   of	   cases),	   laterally	   or	   inferiorly.	   53	  Previous	  work	  in	  our	  institution	  demonstrated	  that	  NCM	  can	  identify	  regions	  of	  slow	   conduction	   and	   that	   LV	   pacing	   outside	   these	   areas	   leads	   to	   significant	  hemodynamic	  improvement.	  56	  	  	  Mechanical	  deformation	  changes	  the	  electrical	  properties	  of	  myocardial	   tissues,	  
146	   with	   stretching	   of	   myocytes	   decreasing	   their	   conductivity.	   147	   Computer	  models	  have	  shown	  that	  electro-­‐mechanical	  interaction	  may	  play	  a	  role	  in	  LBBB.	  
148	  These	  concepts	  have	  yet	  to	  be	  translated	  into	  the	  clinical	  arena.	  Given	  that	  in	  a	  subset	  of	  CRT	  candidates	   the	  SF	   is	  present	  during	   the	  LV	  activation	  period	  and	  that	  there	  is	  evidence	  for	  electro-­‐mechanical	  interaction	  at	  the	  myocyte	  level,	  it	  is	  hypothesised	   that	   evidence	   of	   direct	   electro-­‐mechanical	   interaction	   might	   be	  present	  in	  CRT	  candidates	  showing	  a	  SF.	  Conversely	  this	  would	  not	  be	  the	  case	  in	  the	   absence	   of	   a	   SF.	   Furthermore	   it	   would	   be	   anticipated	   that	   the	   effects	   of	  electro-­‐mechanical	  interaction	  would	  change	  with	  LV	  pacing.	  	  	  In	  this	  study	  I	  characterised	  the	  electrical	  activation	  and	  mechanical	  action	  of	  the	  LV	   during	   the	   activation	   period	   by	   directly	   comparing	   NCM	   and	  echocardiography	  imaging	  in	  patients	  prior	  to	  CRT.	  	  




Study	  Population	  Patients	  with	  severe	  heart	  failure	  fulfilling	  standard	  criteria	  for	  CRT	  (NYHA	  class	  III-­‐IV	   drug	   refractory	   heart	   failure,	   LVEF	   ≤35%,	   LV	   end-­‐diastolic	   diameter	  ≥55mm)	  and	  with	  LBBB	  on	  ECG	  (QRS	  duration	  of	  >	  120ms	  with	  QS	  or	  RS	  complex	  in	  lead	  V1	  and	  a	  monophonic	  R	  wave	  in	  leads	  V1	  and	  V6).	  	  	  
Echocardiographic	  Acquisition	  Prior	   to	   NCM,	   standard	   echocardiograms	   with	   tissue	   Doppler	   imaging	   (TDI),	  were	   acquired	   on	   a	   GE	   vivid	   7	   scanner	   (General	   Electric-­‐Vingmed,	  Milwaukee,	  Wisconsin).	   Analysis	   was	   performed	   using	   EchoPac	   version	   6.0.1	   (General	  Electric-­‐Vingmed).	  	  	  Ejection	   fraction	  and	  LV	  dimensions	  were	  measured	  using	  2D	  modified	  biplane	  Simpson’s	   method.	   Transmitral	   flow	   velocities	   were	   obtained	   from	   the	   apical-­‐4CH	   view	   with	   pulsed-­‐wave	   Doppler	   positioned	   at	   the	   tip	   of	   the	   leaflets.	   End	  diastole	  (onset	  of	  isovolumic	  contraction)	  and	  end	  systole	  (aortic	  valve	  closure)	  were	  determined	  using	  transmitral	  and	  aortic	  Doppler	  profiles.	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Assessment	  of	  Dyssynchrony	  and	  Septal	  Flash	  Echocardiography	  assessment	  of	  dyssynchrony	  has	  been	  described	  in	  chapter	  3.	  	  To	  determine	  the	  presence	  and	  extent	  of	  the	  SF,	  two	  independent	  clinical	  experts,	  who	   were	   blinded	   to	   the	   electrophysiology	   studies,	   reviewed	   all	  echocardiographic	  images.	  The	  existence	  of	  a	  SF	  was	  defined	  as	  the	  presence	  of	  early	  inward	  and	  outward	  motion	  within	  the	  isovolumic	  contraction	  period	  seen	  both	  visually	  from	  the	  grey	  scale	  SAX	  and	  4CH	  views	  as	  well	  as	  on	  M-­‐mode	  in	  the	  PSLAX,	   SAX	   and	   4CH.	   Bull’s	   eye	   plots	   of	   the	   LV	  were	   generated,	   indicating	   the	  presence	   and	   spatial	   extent	   (segments	   involved)	   of	   the	   SF.	   Patients	   were	  categorised	  according	  to	  the	  appearance	  and	  extent	  of	  the	  SF:	  a	  large	  SF	  if	  there	  was	   marked	   fast	   early	   septal	   inward/outward	   motion	   with	   a	   prominent	  displacement	   involving	   ≥	   50%	   of	   the	   septal	   segments	   in	   an	   American	   heart	  association	  (AHA)	  model;	  a	  small	  SF	  if	  there	  was	  early	  inward/outward	  motion,	  but	  with	  a	  very	  limited	  displacement;	  or	  no	  SF	  present.	  	  
	  
CMR	  Imaging	  CMR	   delayed	   gadolinium	   enhancement	   imaging	   was	   performed	   to	   assess	  myocardial	  scar.	  CMR	  was	  performed	  on	  a	  Philips	  Achieva	  1.5T	  scanner	  (Philips,	  Healthcare,	  Best,	  The	  Netherlands).	  DE-­‐MR	  was	  performed	  15-­‐20mins	  following	  the	  administration	  of	  0.1-­‐0.2mmol/kg	  gadopentetate	  dimeglumine	  (Magnevist®,	  Bayer	   Healthcare,	   Dublin,	   Ireland)	   using	   conventional	   inversion	   recovery	  techniques.	  149	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Non-­‐contact	  Mapping	  Procedure	  	  Patients	  underwent	  NCM	  11±8.6	  days	  prior	  to	  CRT	  implant	  in	  our	  interventional	  X-­‐ray/MRI	   catheter	   laboratory	   (Philips	   Medical	   Systems,	   Best,	   Netherlands).	  Bilateral	   femoral	   venous	   access	   was	   used	   to	   place	   5F	   Supreme	   JSN	   401443	  quadripolar	  electrode	  catheters	   (St.	   Jude	  Medical,	  Minnetonka,	  MN,	  USA)	   to	   the	  high	  right	  atrium	  and	  right	  ventricular	  apex	  to	  perform	  atrial	  and	  RV	  ventricular	  sensing	  and	  pacing,	  a	  5F	  Supreme	  CRD-­‐2	  401860	  quadripolar	  electrode	  catheter	  (St.	   Jude	  Medical,	  Minnetonka,	  MN,	  USA)	  was	  positioned	  at	   the	  His	  bundle.	  The	  coronary	   sinus	   was	   intubated	   using	   a	   pre-­‐shaped	   8F	   Fast-­‐Cath	   SL3	   406842	  guiding	   sheath	   (St.	   Jude	   Medical,	   Minnetonka,	   MN,	   USA)	   and	   a	   multipolar	  Pathfinder	   16	   electrode	   catheter	   01-­‐16-­‐1003	   (Cardima	   Inc.,	   Fremont,	   CA,	  USA)	  was	  passed	  to	  a	  postero-­‐lateral	  or	  lateral	  branch	  of	  the	  coronary	  sinus	  to	  perform	  epicardial	  LV	  pacing	  to	  replicate	  standard	  CRT.	  	  A	  NCM	  Ensite	  Array	  EC1000	  (St.	  Jude	  Medical,	  St	  Paul,	  MN,	  USA)	  was	  passed	  via	   the	   femoral	  artery	  retrogradely	  across	  the	  aortic	  valve	  to	  the	  LV	  cavity.	  Via	  the	  other	  femoral	  artery,	  a	  decapolar	  steerable	  6F	  Livewire	  401915	  electrode	  catheter	  (St.	   Jude	  Medical,	  Minnetonka,	  MN,	  USA)	  was	  passed	   to	   the	  LV	   cavity	   along	  with	   a	  high	   fidelity	  pressure	  wire	  (Radi	  Medical	  Systems,	  Uppsala,	  Sweden)	  with	  a	  5-­‐Fr	  multipurpose	  catheter.	  The	  chamber	  geometry	  was	  reconstructed	  using	  a	   locator	  signal	   from	  the	  decapolar	  catheter.	  150	  	  The	   following	   pacing	   protocol	   was	   performed;	   (100	   beats	   per	   minute	   with	  consistent	  capture,	  AV	  delay	  100ms,	  VV	  simultaneous):	  AAI	  (atrium	  sensed	  and	  paced),	   DDDRV	   (atrium	   and	   ventricle	   sensed	   and	   paced	   from	   RV),	   DDDLV	  (atrium	   and	   ventricle	   sensed	   and	   paced	   from	   coronary	   sinus)	   and	   DDDBIV	  
	   157	  
(conventional	  CRT).	  AAI	  pacing	  at	  100	  beats	  per	  minute	  was	  used	  as	  baseline	  for	  assessment	   of	   LV-­‐dP/dtmax	   measurements	   and	   was	   performed	   prior	   to	   each	  change	  in	  pacing	  mode.	  34	  Ensite	  data,	  pacing	  parameters	  and	  percentage	  rise	  in	  LV-­‐dP/dtmax	   for	   each	  pacing	  mode	  were	   recorded	  once	   steady	   state	  pacing	  had	  been	   achieved	   for	   at	   least	   one	   minute.	   Capture	   without	   fusion	   was	   confirmed	  using	  VVI	  pacing	  and	  examining	   the	  paced	  QRS	  morphology.	  Endocardial	  maps	  were	   obtained	   in	   sinus	   rhythm	  and	   in	   each	   pacing	   configuration.	   Electrograms	  were	  acquired	  at	  1200Hz,	  giving	  a	  temporal	  resolution	  of	  0.83ms.	  High	  pass	  filter	  was	   set	   at	   8Hz.	   Virtual	   unipolar	   electrograms	   recorded	   from	   the	   endocardial	  surface	  were	   analysed	   to	  measure	   the	  duration	  of	   LV	   activation.	   Peak	  negative	  dV/dt	  is	  a	  universally	  accepted	  indicator	  of	  the	  onset	  of	  activation	  in	  a	  region	  of	  myocardium.	  Thus	  the	  onset	  of	  activation	  was	  taken	  as	  the	  time	  to	  the	  first	  peak	  negative	   8	   Hz	   high-­‐passed	   unipolar	   virtual	   electrogram	   anywhere	   in	   the	  chamber.	   The	   end	   of	   LV	   activation	   was	   defined	   as	   the	   time	   of	   the	   latest	   peak	  negative	   8	  Hz	   unipolar	   electrogram	  on	   the	   virtual	   endocardial	   surface.	   151	  QRS	  duration	   was	   obtained	   from	   the	   surface	   12	   lead	   ECG.	   Lines	   of	   block	   were	  interpreted	   from	  both	   the	  patterns	  of	   activation	  observed	   in	   isopotential	  maps	  and	  the	  associated	  morphological	  features	  of	  electrograms	  (Figure	  34).	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Figure	  34	  Patient	  with	  a	  large	  SF	  
	  Unipolar	   isochronal	   map	   with	   NCM	   electrograms	   showing	   fragmented	   signals	  (development	   of	   split	   potentials)	   indicating	   a	   reduction	   of	   conduction	   and	  inability	  to	  cross	  throughout	  the	  inferior	  region.	  The	  NCM	  mapping	  electrograms	  show	  the	  criteria	  used	  by	  Auricchio	  et	  al	  to	  define	  block,	  with	  the	  emergence	  of	  R-­‐wave,	   smallest	   and	   earliest	   at	   the	   superior	   part	   of	   the	   block	   (where	   area	   of	  block	  begins)	  with	  largest	  negative	  peak.	  Bold	  white	  arrows	  on	  the	  electrogram	  indicate	   how	   the	   electrical	   activation	   spreads	   superiorly	   in	   a	   U-­‐shape	   pattern	  leading	  to	  the	  development	  of	  split	  potentials.	  	  	  Bull’s	  eye	  activation	  maps	  were	  generated	  from	  the	  NCM	  data	  sets	  by	  computing	  the	   long	   axis	   from	   the	   manual	   identification	   of	   the	   ventricular	   apex	   and	   the	  centre	   of	   the	   mitral	   valve	   in	   at	   least	   two	   views.	   I	   estimated	   the	   short	   axis	   by	  identifying	  the	  ventricular	  septum,	  and	  lateral	  wall	  and	  drawing	  a	  perpendicular	  line	  through	  the	  long	  axis.	  From	  this	  information,	  temporal	  bull’s	  eye	  plots	  were	  constructed	  representing	  the	  percentage	  of	  activated	  tissue	  (black	  in	  the	  figures)	  through	   time.	   In	   parallel,	   bull’s	   eye	   plots	   were	   generated	   of	   the	   presence	   and	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location	   of	  mechanical	   septal	  motion	   visually	   identified	  with	   echocardiography	  as	  well	  as	  the	  position	  and	  extent	  of	  scar	  determined	  by	  DE-­‐MR	  imaging.	  These	  visualisation	   tools	   allowed	   a	   multimodal	   analysis	   and	   integration	   to	   directly	  compare	   different	   factors	   involved	   in	   the	   studied	   pathophysiology,	   mainly	  mechanical	   septal	   motion,	   presence	   and	   location	   of	   scar	   and	   presence	   and	  location	   of	   lines	   of	   conduction	   blocks.	   Lines	   of	   conduction	   block	   are	   areas	   of	  tissue	  where	  propagation	  of	  the	  activation	  wave	  front	  is	  halted	  for	  several	  tens	  of	  milliseconds.	   This	   is	   visualised	   as	   a	   stagnation	   of	   the	   black-­‐white	   transition	  during	   several	   frames	   in	   the	   series	   of	   bull’s	   eyes	   plots	   (Figure	   35).	   Acute	  haemodynamic	   responders	  were	   considered	  as	   an	   increase	   in	  LV-­‐dP/dtmax	   of	  ≥	  10%	  from	  baseline	  AAI	  pacing.	  37	  Patients	  were	  followed	  up	  six	  months	  after	  CRT	  with	  a	  repeat	  echocardiogram.	  	  
	  
Statistical	  Analysis	  Statistical	  analysis	  was	  performed	  using	  SPSS	  software	  package	  (IBM,	  Chicago,	  IL,	  USA).	   Continuous	   variables	   were	   expressed	   as	   mean	   values	   ±	   SD.	   Where	  appropriate	  continuous	  variable	  were	  assessed	  with	  a	  Student’s	  t	  test	  and	  1-­‐way	  ANOVA.	  P	  values	  of	  <	  0.05	  were	  considered	  statistically	  significant.	  	  	  	  
Results	  	  Thirteen	   patients	   were	   recruited	   (aged	   63±10	   years,	   ten	   males	   and	   three	  females).	   At	   baseline	   all	   were	   in	   NYHA	   class	   3,	   with	   LBBB	   (QRS	   duration	   of	  158±24ms).	  Eight	  patients	  had	  DCM	  and	   five	   ICM.	  Ejection	   fraction	  22.8±5.8%,	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inter	  ventricular	  delay	  47.8±23.6ms,	   septal-­‐lateral	  delay	   from	  TDI	  79.2±40.3ms	  and	  SD	  of	  12	  segments	  TDI	  50.2±13.5ms	  (Table	  19).	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Table	  19	  Comparison	  of	  patients	  with	  varying	  size	  of	  SF	  
	   All	  patients	   Large	  SF	   Small	  SF	   Absent	  SF	  
Number	   13	   5	   4	   4	  
Age	   63±10	   66±7	   57±13	   67±12	  
Sex	   10	  M:3	  F	   4	  M:1F	   4	  M	   2	  M:2F	  
Etiology	  of	  HF	   8	  DCM	  5	  ICM	   4	  DCM	  1	  ICM	   1	  DCM	  3	  ICM	   3	  DCM	  1	  ICM	  
QRS	  duration	  (ms)	   158±24	   172±25*	   156±18	   143±21	  
Ejection	  fraction	  (%)	   23±6	   22±7	   23±4	   24±8	  
EDV	  (ml)	   255±67	   270±66	   248±89	   245±62	  
ESV	  (ml)	   198±59	   211±65	   196±83	   185±30	  
IVMD	  (ms)	   48±24	   69±14*	   41±17	   22±29	  
Septal/lateral	  delay	  TDI	  (ms)	   79±40	   56±53	  
	  
83±22	   105±21	  
TDI	  12	  segment	  SD	  (ms)	   50±14	   51±16	   47±14	   52±13	  
TIVT	  (ms)	   186±128	   304±72*	   222±57	   125±72	  
IVCT	  (ms)	   68±63	   133±29	   59±55	   38±49	  
IVRT	  (ms)	   118±88	   171±68*	   163±81	   89±41	  *Significant	   difference	   between	   patients	   with	   a	   large	   SF	   and	   small/absent	   SF	  (P<0.05)	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Baseline	  Analysis	  Five	  patients	  had	  a	  large	  SF,	  four	  small	  SF	  and	  four	  no	  SF	  (Table	  19).	  Figures	  35	  and	  36	  shows	  the	  comparison	  of	  the	  NCM	  and	  echo	  bull’s	  eye	  plots	  from	  a	  typical	  patient	  with	   or	  without	   a	   SF.	  While	   the	   activation	   spreads	   homogenously	   over	  the	   endocardial	   surface	   when	   no	   SF	   is	   present,	   there	   are	   definite	   areas	   of	  conduction	  block	  surrounding	  the	  region	  of	  the	  large	  SF	  (Fig	  35).	  A	  very	  specific	  pattern	   of	   conduction	   slowing	   is	   present	   in	   the	   large	   SF	   cases.	   After	   the	   initial	  activation	  of	  a	  small	  septal	  region,	  there	  is	  a	  delay	  of	  further	  activation	  during	  2-­‐3	  frames	   on	   the	   ensite	   activation	   map	   corresponding	   to	   20-­‐40	   ms.	   Next,	   the	  activation	  continues	  either	  anteriorly	  or	  inferiorly	  (Fig	  35)	  and	  the	  opposite	  area	  (inferior	  or	   anterior	   (Fig	  35)	   respectively)	   remains	  blocked	  until	   it	   is	   activated	  retrogradely.	  The	  persistence	  of	  one	  part	  of	  the	  initial	  conduction	  block	  results	  in	  an	   overall	   U-­‐shaped	   activation	   with	   a	   persistent	   line	   of	   block	   in	   either	   the	  anterior	   or	   inferior	   region.	   In	   patients	   with	   a	   small	   or	   no	   SF	   there	   was	   no	  conduction	  block	  (Figure	  36)	  except	  in	  one	  of	  the	  patients	  with	  a	  small	  SF	  and	  an	  ICM	   where	   there	   was	   an	   area	   of	   block	   associated	   with	   anterior-­‐lateral	   scar.	  Figures	  37	  to	  39	  show	  activation	  maps	  for	  all	  patients.	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Figure	  35	  Patient	  with	  a	  large	  SF	  
	  
A	   Fused	   activation	   and	   echo	   bull’s	   eye	   plots.	   Black	   area	   indicates	   activation	  pattern,	   red	   segments	   area	   with	   SF.	   There	   is	   initial	   depolarisation	   of	   the	  ventricular	  septum,	  followed	  by	  slowed	  conduction	  (20	  to	  40ms)	  both	  anteriorly	  and	  inferiorly.	  Areas	  of	  block	  indicated	  with	  white	  arrows.	  There	  is	  breakout	  of	  activation	   inferiorly	   although	   slowed	   depicted	   by	   the	   dashed	   arrows.	   Block	  remains	   anteriorly.	   Activation	   continues	   inferiorly	   untill	   the	   anterior	   wall	   is	  retrogradely	  activated.	  B	  Unipolar	   isochronal	  map.	  Top	  row	  anterior:	  Bottom	  
row	   posterior.	   There	   is	   a	   line	   of	   anterior	   block	   with	   activation	   spreading	  inferiorly.	  C	   LV	  NCM	  unipolar	   activation	  map.	   The	   activation	   breaks	   out	   in	   the	  ventricular	   septum,	   instead	   of	   spreading	   uniformly	   there	   is	   an	   anterior	   line	   of	  block	   show	   by	  white	   arrows.	   The	   activation	   spreads	   inferiorly,	   leading	   to	   a	   U-­‐shaped	  activation	  pattern.	  Ant=Anterior,	  Sep=Septum,	  Inf=Inferior,	  Lat=Lateral.	  	  	  
	   164	  
	  
Figure	  36	  Patient	  with	  no	  SF	  
	  
A	   Fused	   activation	   and	   echo	   bull’s	   eye	   plots.	   There	   is	   uniform	   activation	   both	  anterior	   and	   inferiorly	   with	   no	   block.	   B	   Unipolar	   isochronal	   map.	   Top	   row	  
anterior:	  Bottom	  row	  posterior.	  Uniform	  activation	  with	  no	  block.	  C	   LV	  NCM	  unipolar	  activation	  map.	  The	  activation	  breaks	  out	  in	  the	  ventricular	  septum,	  and	  spreads	  uniformly	  with	  no	  areas	  of	  block.	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Figure	  37	  Activation	  maps	  for	  all	  patients	  with	  a	  large	  SF	  
	  In	  all	  patients,	  early	  breakthrough	  is	  seen	  in	  the	  septum	  there	  is	  then	  slowing	  and	  even	  halting	  of	  activation	  at	  the	  borders	  of	  the	  SF	  (3	  patients	  inferior	  block,	  A,	  B	  &	  C,	  2	  patients	  anterior	  block,	  D	  &	  E).	  This	  is	  followed	  by	  a	  period	  of	  no	  further	  activation	   (lasting	   about	   half	   of	   the	   total	   activation	   time).	   Next,	   a	   further	  breakthrough	  of	   the	  activation	   is	  observed,	   either	   from	   the	  anterior	  or	   inferior	  side	  of	  the	  SF	  propagating	  homogeneously	  over	  the	  rest	  of	  the	  LV.	  Row	  B	  shows	  a	  patient	  with	  an	  ICM	  with	  the	  area	  of	  scar	  shown	  by	  the	  green	  gridded	  area.	  The	  other	  rows	  are	  all	  patients	  with	  DCM.	  Ant=Anterior,	  Inf=Inferior,	  Lat=Lateral.	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Figure	  38	  Activation	  maps	  for	  all	  the	  patients	  with	  a	  small	  SF	  
	  There	   is	   no	   area	   of	   block	   seen	   accept	   in	   B	   where	   there	   is	   an	   area	   of	   block	  associated	  with	  scar	  seen	  by	   the	  green	  grid.	  Rows	  B,	  C	  and	  D	  are	  patients	  with	  ICM	  with	  the	  scar	  depicted	  with	  the	  gridded	  area.	  Row	  A	  is	  a	  patient	  with	  a	  DCM.	  	  
Figure	  39	  Activation	  maps	  for	  all	  the	  patients	  with	  no	  SF	  
	  Row	  D,	   patient	  with	   an	   ICM	  with	   extensive	  myocardial	   scar	   as	  depicted	  by	   the	  green	  gridded	  area.	  Other	  rows	  show	  patients	  with	  DCM.	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Influence	  of	  BIV	  and	  RV	  Pacing	  	  Patients	  with	   a	   large	   SF	   the	   conduction	   block	  was	   seen	   to	   disappear	  with	   BIV	  pacing,	  but	  remained	  with	  RV	  pacing	  (Figure	  40).	  
	  
Figure	  40	  Activation	  maps	  of	  patient	  with	  a	  large	  SF	  
	  Row	  A,	   baseline	  with	   area	   of	   block	   and	   late	   anterior	   breakthrough.	  Row	  B,	   RV	  pacing	  showing	  the	  area	  of	  anterior	  block	  remains.	  Row	  C,	  BIV	  pacing.	  Functional	  conduction	  block	  has	  disappeared.	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Acute	  Haemodynamic	  Response	  	  Overall	   there	  was	   a	   significant	   increase	   in	   acute	   response	   to	   both	   DDDLV	   and	  DDDDBIV	   pacing	   (baseline	   AAI	   pacing	   LV-­‐dp/dtmax	   782±214mmHg/s,	   DDDLV	  pacing	   916±219mmHg/s	   (p<0.05)	   and	   DDDBIV	   pacing	   998±254mmHg/s	  (p<0.05)).	   Comparing	   percentage	   rise	   in	   LV	   dP/dtmax	   from	   baseline	   for	   both	  DDDDLV	  and	  DDDBIV	  pacing	  patients	  with	  a	  large	  SF	  had	  a	  larger	  response	  than	  patients	   with	   a	   small	   or	   no	   SF	   (Table	   20).	   Using	   a	   cut	   off	   of	   10%	   rise	   in	   LV	  dP/dtmax	   from	   baseline	   all	   patients	   with	   a	   large	   SF	   were	   acute	   haemodynamic	  responders	  for	  DDDLV	  and	  DDDBIV	  pacing.	  One	  patient	  with	  a	  small	  SF	  did	  not	  respond	   to	   DDDLV	   pacing	   and	   two	   did	   not	   respond	   to	   DDDBIV	   pacing.	   No	  patients	  without	   a	   SF	   responded	   to	   LV	  pacing	   and	   one	   did	   not	   respond	   to	  BIV	  pacing.	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782±214	  	   915±219*	   20±18	   998±254*	   31±24	  
Large	  SF	   828±240	  	   1038±229*	   28±14	   1141±256*	   42±28	  
Small	  SF	   713±216	  	   876±182*	   25±14	   835±141	   21±22	  
No	  SF	   880±112	  	   856±179	   -­‐4±9	   1063±152	   22±24	  
Combined	  
small	  &	  no	  
SF	  
797±179	  	   866±161	   11±19	   949±181*	   22±21	  
*Significant	  difference	  from	  AAI	  pacing	  (p<0.05)	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Clinical	  Response	  and	  Reverse	  Remodelling	  (Table	  24)	  At	  six	  months	  one	  patient	  with	  no	  SF	  had	  died.	  All	  except	  one	  patient	  (small	  SF)	  improved	  by	  at	  least	  one	  NYHA	  class	  (responder	  rate	  92%,	  (P<0.05)).	  The	  SF	  was	  no	   longer	   present	   after	   CRT.	  With	   respect	   to	   RR	   (decrease	   in	   ESV	   ≥	   15%)	   the	  overall	   responder	   rate	   was	   64%	   (average	   decrease	   in	   ESV	   19.8±21.4%,	  (P<0.05)).	   All	   patients	   with	   a	   large	   SF	   RR	   (decrease	   in	   ESV	   37.1±21.2%),	   two	  patients	  RR	  with	  a	   small	   SF	   (decrease	   in	  ESV	  11.5±7.4%)	  and	  none	  with	  no	  SF	  (decrease	   in	  ESV	  1.9±13.7%).	   (Table	  21)	  Comparing	   large	  SF	   to	   small	  or	  no	  SF	  there	  was	  a	  greater	  improvement	  in	  EF,	  larger	  reduction	  in	  ESV	  and	  NYHA	  score.	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Table	  21	  NYHA	  class	  and	  echocardiographic	  parameters	  pre	  and	  post	  CRT	  	  
















3±0	   1.6±0.8*	   3±0	   1.0±0.7	   3±0	   2.3±0.5	   3±0	   1.7±0.6	  
EF	  (%)	   23±6	   32±11*	   22±7	   37±13	   23±4	   31±5	   24±8	   23±7	  
EDV	  (ml)	   256±67	   228±71*	   270±66	   211±83	   248±89	   245±83	   245±62	   231±16	  
ESV	  (ml)	   198±59	   158±56*	   211±65	   137±61	   196±83	   171±69	   185±30	   175±7	  
TIVT(ms)	   186±128	   147±107	   304±72	   173±61	   222±57	   144±98	   127±72	   139±120	  
IVCT(ms)	   68±63	   48±47	   171±68	   33±19	   59±55	   53±37	   38±49	   64±62	  
IVRT(ms)	   118±88	   99±74	   133±29	   140±65	   163±81	   91±63	   89±41	   74±69	  *Significant	  difference	  from	  pre	  CRT	  measurements	  †One	  patient	  died	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Discussion	  Comparing	   mechanical	   events	   with	   intra-­‐cardiac	   electrical	   activation,	   I	   have	  demonstrated	   that	   in	   the	   presence	   of	   a	   large	   SF,	   there	   is	   a	   spatially	   related	  functional	   conduction	   block	   resulting	   in	   a	  U-­‐shaped	   activation.	  With	   LV	   or	  BIV	  pacing	   there	   is	   restoration	   of	   a	   more	   normal	   pattern	   of	   electrical	   activation	  without	   areas	  of	   slow	  conduction,	  which	  was	  associated	  with	  disappearance	  of	  the	   SF.	   Patients	   without	   a	   prominent	   SF	   did	   not	   show	   an	   abnormal	   electrical	  activation	   pattern.	   These	   results	   suggest	   for	   the	   first	   time,	   in	   a	   clinical	   setting,	  that	   there	   is	   a	   direct	   electro-­‐mechanical	   interaction	   at	   the	   macroscopic	   level	  during	  the	  activation	  period	  of	  the	  LV	  in	  a	  subset	  of	  patients	  with	  LBBB.	  	  Figure	   41	   summarises	   this	   hypothesis	   with	   regard	   to	   the	   electrical	   activation,	  mechanical	  events,	  and	  their	  interaction,	  in	  patients	  with	  LBBB	  and	  a	  SF.	  Shortly	  after	   the	   onset	   of	   the	   activation	   (breaking	   trough	   at	   the	   mid/basal	   septum,	  coming	   from	   the	   right	   side)	   (Fig	   41	   A),	   the	   fast	   and	   large	   contraction	   of	   the	  septum	   during	   the	   initial	   phase	   of	   the	   SF	   (Fig	   41	   B)	   leads	   to	   mechanical	  stretching	  of	  the	  surrounding	  tissues,	  thus	  changing	  its	  conductivity	  and	  slowing	  down	   or	   halting	   further	   activation.	   When	   activation	   slowly	   surpasses	   the	  stretched	   region	   (around	   half	   of	   the	   total	   activation	   time,	  while	   only	   a	   limited	  area	   of	   the	   LV	   is	   activated	   at	   this	   point),	   either	   anterior	   or	   inferior	   of	   the	   SF	  region	   (Fig	   41	   C/D),	   it	   rapidly	   conducts	   further	   over	   the	   LV	   endocardium,	  activating	   the	   rest	  of	   the	  ventricle	  and	   initiating	  mechanical	   activity	   in	   the	   free	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walls,	  which	  start	  to	  contract	  and	  exhibit	  force	  on	  the	  contracted	  septum,	  which	  in	   its	   turn	   is	   stretched,	   resulting	   in	   the	  outward/lengthening	  portion	  of	   the	  SF.	  (Fig	  41	  E/F).	  	  	  As	   a	   result,	   total	   activation	   time	   is	   long	   (QRS	  width	   in	   large	   SF	   patients	   is	   the	  longest),	   the	   isovolumic	   contraction	   period	   is	   long,	   since	   during	   the	   SF	   period,	  septal	   contraction	   is	   used	   for	   stretching	   surrounding	   tissue	   and	   the	   first	  mechanical	   activity	   of	   the	   free	   walls	   for	   stretching	   the	   septum.	   During	   this	  period,	  all	  mechanical	  energy	  is	  used	  for	  stretching	  tissue	  instead	  of	  building	  up	  pressure	   (very	   low	   LV	   dP/dtmax	   in	   SF	   patients	   while	   the	   tissue	   does	   show	  substantial	  mechanical	  activity)	  and	  aortic	  valve	  opening	  is	  very	  late.	  	  While	   RV	   pacing	   does	   not	   change	   the	   activation	   pattern	   within	   the	   LV	  (breakthrough	   of	   activation	   and	   the	   pattern	   of	   propagation,	   including	   the	  presence	   of	   the	   SF,	   remain	   the	   same),	   both	   LV	   and	   BIV	   pacing	   induce	   an	  additional	   activation	   wave	   front	   initiation	   within	   the	   LV	   and	   preventing	   the	  septum	  from	  stretching	  the	  surrounding	  region	  and	  changing	  its	  conductivity.	  As	  a	   result,	   the	  whole	   ventricle	   is	   activated	   faster,	   there	   is	   no	   longer	   detrimental	  mechanical	   interaction	  between	  the	  opposing	  free	  wall	  and	  the	  IVT	  is	  markedly	  reduced.	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Figure	  41	  Electrical	  activation	  and	  associated	  mechanical	  events	  in	  patients	  with	  LBBB	  and	  a	  Septal	  Flash	  
	  A=anterior	   wall,	   AVO=Aortic	   valve	   opening,	   I=Inferior	   wall,	   L=lateral	   wall,	  MVC=mitral	  valve	  closure,	  RV=Right	  ventricle,	  S=Septum.	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The	  area	  of	  the	  induced	  functional	  conduction	  block	  corresponds	  very	  closely	  to	  the	   borders	   of	   the	   area	   observed	   to	   be	   involved	   in	   the	   SF.	   The	   consequent	  progression	   of	   activation,	  which	   seems	   in	   about	   half	   of	   the	   patients	   anteriorly	  and	   in	   the	   other	   half	   inferiorly,	   results	   in	   the	   previously	   described	   U	   shaped	  activation	  pattern.	  	  	  
LBBB:	  Measures	  of	  Dyssynchrony	  and	  the	  Septal	  Flash	  All	  patients	  had	  LBBB,	  however	   the	  presence	  of	   large	  SF	  was	  only	   seen	   in	   five.	  LBBB	  is	  a	  complex	  electrical	  disease	  resulting	   from	  conduction	  delay	   located	  at	  several	  anatomical	  levels	  of	  the	  activation	  sequence.	  53	  The	  group	  with	  a	  large	  SF	  seemed	   to	   have	   a	   predisposition	   to	   a	   longer	   QRS	   duration	   (large	   SF,	  172.4±25.0ms,	   small	   SF,	   155.5±18.0ms,	   no	   SF,	   142.8±21.0ms),	   however	   it	   is	  known	   that	   surface	  ECG	  recordings	  are	  unable	   to	   characterize	   the	   location	  and	  extent	  of	  specific	  ventricular	  delays.	  54	  	  	  Looking	  at	  inter-­‐ventricular	  dyssynchrony,	  patients	  with	  a	  large	  SF	  have	  a	  larger	  delay	  (large	  SF,	  69±13.9ms,	  small	  SF,	  40.5±17.2ms,	  no	  SF,	  21.8±29.1ms).	  This	  fits	  the	   hypothesis	   that	   the	   presence	   of	   the	   SF	   results	   in	   a	  much	   longer	   TIVT	   and	  IVCT	   in	   the	   LV,	   which	   is	   confirmed	   by	   our	   findings,	   while	   the	   RV	   is	   activated	  almost	   normally.	   Previously	   reported	   parameters	   to	   describe	   intra-­‐ventricular	  dyssynchrony,	   the	   septal/lateral	  delay	  show	   the	  opposite.	  Patients	  with	  a	   large	  SF	  appear	  less	  dyssynchronous.	  This	  is	  possibly	  due	  to	  the	  measurement	  method.	  Firstly,	  the	  peak	  velocity	  in	  patients	  with	  a	  SF	  is	  often	  outside	  the	  ejection	  period	  (AVO/AVC)	  and	  therefore	  excluded	  from	  the	  measurements.	  Secondly,	  since	  the	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SF	  induces	  stretching/unstretching	  of	  the	  different	  segments	  of	  the	  LV,	  this	  is	  not	  necessarily	   reflected	   in	   the	  velocity	  of	   the	  basal	   segments.	  When	  a	  12-­‐segment	  standard	  deviation	   is	  used	   there	  does	  not	  appear	   to	  be	  any	  difference	  between	  the	  groups,	  again	  emphasizing	   that	  measurement	  based	  on	  velocities	  might	  not	  be	   the	   appropriate	  way	   to	   assess	   the	   intra	   ventricular	   dyssynchrony.	   A	   recent	  multicenter	  trial,	  showed	  that	  velocity	  based	  parameters	  was	  no	  better	  than	  the	  QRS	  duration	  in	  predicting	  response	  to	  CRT.	  103	  	  	  
Clinical	  Implications	  for	  CRT	  In	   previous	   studies	   59	   the	   correction	   of	   the	   SF	   by	   CRT	   has	   been	   shown	   to	   be	  associated	  with	  significant	  RR.	  This	  study	  has	  shown	  in	  patients	  with	  a	  large	  SF	  that	   CRT	   improves	   the	   mechanical	   inefficiency	   resulting	   from	   the	  stretching/unstretching	   of	   tissue	   as	   well	   as	   inducing	   more	   homogeneous	   and	  faster	  activation.	  By	  showing	  that	  a	  LV	  lead	  corrects	  the	  conduction	  abnormality	  leading	   to	   a	   more	   normal	   electro-­‐mechanical	   interaction	   this	   may	   explain	   the	  high	  response	  rates.	  	  	  
Study	  Limitations	  Although	  this	  study	  shows	  a	  spatio-­‐temporal	  relation	  between	  the	  presence	  and	  extent	  of	  the	  SF	  and	  the	  changes	  in	  conduction	  pattern	  of	  the	  myocardium,	  I	  can	  only	   hypothesise	   with	   respect	   to	   their	   causal	   relationship.	   Given	   that	   there	   is	  much	   evidence	   from	   basic	   science	   on	   the	   existence	   of	   electro-­‐mechanical	  interaction,	  that	  is	  consistent	  with	  this	  hypothesis,	  and	  the	  observation	  from	  the	  changes	  induced	  by	  LV	  and	  BIV	  pacing,	  it	  is	  a	  possible	  explanation	  of	  the	  findings.	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  Given	  the	  invasive	  and	  complex	  nature	  of	  these	  clinical	  measurements,	  the	  study	  has	  a	  small	  number	  of	  patients	  with	  only	  five	  having	  a	  large	  SF.	  There	  are	  definite	  trends	  that	  patients	  with	  a	  large	  SF	  have	  a	  greater	  acute	  response	  to	  LV	  and	  BIV	  pacing	  and	  the	  presence	  of	  a	  large	  SF	  leads	  to	  greater	  reverse	  remodelling	  at	  six	  months.	   However,	   due	   to	   these	   small	   numbers	   it	   is	   not	   possible	   to	   determine	  whether	  these	  differences	  are	  significant.	  	  	  The	   design	   of	   the	   bull's	   eye	   plots	   was	   crude.	   For	   further	   assessment	   a	   better	  method	  of	  quantifying	  the	  SF	  is	  required,	   including	  a	  truly	  quantitative	  analysis	  of	   the	   extent	   and	   location	   of	   the	   deformation	   association	   with	   the	   SF.	   To	  understand	   fully	   the	   relationship	  between	   the	  SF	  and	  LV	  activation	  pattern	  we	  would	  need	  a	  larger	  study.	  	  
	  
Conclusions	  In	   left	   bundle	   branch	   block	   with	   a	   septal	   flash	   there	   is	   a	   strong	   interaction	  between	  electrical	  activation	  and	  mechanical	  deformation.	  Early	  deformation	  of	  the	   septum,	   stretching	   adjacent	   tissue	   may	   induce	   functional	   changes	   in	  conductivity.	  This	  information	  may	  be	  valuable	  in	  understanding	  and	  predicting	  response	  to	  cardiac	  resynchronisation	  therapy.	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Chapter	  6	  
A	  Method	  for	  Imaging	  Coronary	  Veins	  and	  Myocardial	  
Scar	  during	  a	  Single	  CMR	  Acquisition	  
	  
Introduction	  What	  follows	  is	  a	  brief	  summary	  of	  previous	  studies	  and	  techniques	  to	  visualize	  coronary	  veins	   as	  well	   as	   the	  methods,	   results	   and	  discussion	   for	   a	  novel	  CMR	  protocol	  to	  examine	  both	  coronary	  veins	  and	  scar	  in	  a	  single	  examination.	  	  The	   most	   common	   method	   by	   which	   the	   LV	   lead	   is	   implanted	   in	   CRT	   is	  transvenously	  through	  the	  CS	  using	  a	  posterior	   lateral,	  or	   lateral	  coronary	  vein.	  Failure	   to	   implant	   a	   LV	   lead	   is	   up	   to	   12%	   in	   large	   clinical	   trials.	   23	   There	   is	  marked	   individual	   variation	   in	   coronary	   venous	   anatomy,	   which	   can	   make	   it	  difficult	  to	  find	  a	  suitable	  position	  for	  the	  LV	  lead.	  106	  One	  reason	  for	  leads	  having	  unacceptable	  pacing	  parameters	   is	   implantation	   in	  areas	  of	  myocardial	  scar.	   151	  Therefore,	   knowledge	   of	   the	   coronary	   venous	   anatomy	   as	   well	   as	   location	   of	  myocardial	   scar	  provides	  extremely	  useful	   information	   for	  procedure	  planning.	  
152,	  153	  	  At	  present	  the	  coronary	  venous	  anatomy	  is	  usually	  imaged	  at	  the	  time	  of	  implant	  with	  invasive	  coronary	  venography.	  An	  occlusive	  balloon	  catheter	  is	  inserted	  into	  the	  CS	  followed	  by	  iodine-­‐based	  contrast	  injection	  under	  X-­‐ray	  fluoroscopy.	  The	  limitation	  of	  this	  method	  is	  that	  venous	  anatomy	  is	  determined	  only	  at	  the	  time	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of	   the	   implant	   and	   it	   does	   not	   provide	   any	   information	   on	   scar	   or	   viable	  myocardium.	  Non-­‐invasive	  methods	  for	  assessment	  of	  coronary	  venous	  anatomy	  are	  developing	  both	  with	  computer	  tomography	  (CT)	  154	  and	  CMR	  imaging.	  107-­‐109,	  
155	  	  Multislice	  CT	  has	  been	  used	  to	  visualize	  coronary	  veins	   in	  three	  dimensions	  154,	  
156,	   but	   involves	   ionizing	   radiation	  and	  nephrotoxic	   contrast	   agents.	  CMR	  has	  a	  number	  of	  advantages	  over	  CT	  as	   it	  provides	   information	  about	  LV	  scar	   157,	   158,	  dyssynchrony	   124	   and	   function	   159.	   CMR	   has	   previously	   been	   used	   to	   assess	  coronary	   veins	   using	   an	   intravascular	   contrast	   agents	   107,	   108	   or	   without	   a	  contrast	   agent	   by	   employing	   an	   MTC-­‐prepulse	   109.	   Although	   the	   use	   of	   an	  intravascular	   contrast	   agent	   has	   been	   shown	   to	   give	   excellent	   CV	   anatomy,	   108	  very	   limited	   information	   with	   respect	   to	   myocardial	   scar	   can	   be	   obtained.	   A	  recent	  retrospective	  study	  110	  evaluated	  CMR	  angiograms	  of	  31	  patients	   for	   the	  ability	   to	   visualize	   coronary	   venous	   anatomy	   using	   conventional	   extravascular	  contrast	  agent.	  The	  average	  ejection	  fraction	  in	  the	  patient	  group	  was	  over	  50%.	  The	  clinical	  relevance	  of	   this	  study	   is	   therefore	   limited	  as	  heart	   failure	  patients	  requiring	   CRT	   have	   ejection	   fractions	   of	   less	   than	   35%	   and	   often	   have	   fast	  irregular	   heart	   rhythms	   and	   irregular	   breathing	   patterns	   leading	   to	   technical	  challenges	  with	  respect	  to	  MR	  image	  acquisition.	  	  	  Recently,	   the	   slow	   infusion	   of	   the	   extravascular	   contrast	   agent	   dimeglumine-­‐gadobenate	   ((Gd-­‐BOPTA),	  Bracco	   Imaging	  SpA,	  Milan,	   Italy)	  has	  been	  proposed	  for	   whole-­‐heart	   coronary	   artery	   MRA	   160	   exploiting	   the	   high	   relaxivity	  (r1=9.7(mmol/L)-­‐1	  s-­‐1	  at	  1.5	  Tesla)	  and	  the	  weak	  interaction	  of	  the	  contrast	  agent	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(CA)	  with	  serum	  albumin.	  In	  particular,	  whole	  heart	  CMR	  was	  combined	  with	  an	  inversion	   recovery	   (IR)	  preparation	   to	   improve	   contrast	  between	   the	   coronary	  arteries	  and	  myocardium.	  Studies	  have	  shown	  that	  Gd-­‐BOPTA	  can	  be	  used	  for	  the	  assessment	   of	   myocardial	   scar	   and	   viability	   161,	   162,	   which	   were	   found	   to	   be	  comparable	   to	   other	   gadolinium	   based	   contrast	   agents	   163.	   This	   agent	   has	   not	  previously	   been	   used	   for	   the	   combined	   assessment	   of	   coronary	   vein	   and	  myocardial	  scar.	  	  In	   this	   study	   I	   investigated	   a	   CMR-­‐examination	   in	   patients	   with	   heart	   failure	  using	  a	  slow	  infusion	  protocol	  of	  a	  high	  relaxivity	  CA	  Gd-­‐BOPTA	  to	  evaluate	  the	  coronary	   venous	   anatomy,	   myocardial	   scar	   and	   left	   ventricular	   function.	   In	  patients	  with	  myocardial	  scar	  the	  relationship	  between	  myocardial	  scar	  and	  the	  coronary	  veins	  was	  assessed.	  The	  potential	  of	  CMR	  to	  aid	  implant	  planning	  was	  also	  assessed	  by	  comparing	  the	  imaging	  data	  from	  the	  occlusive	  venogram	  taken	  at	  the	  time	  of	  CRT	  implantation	  with	  the	  CMR	  venous	  anatomy.	  	  
Methods	  
Study	  Population	  Fourteen	   heart	   failure	   patients	   (ejection	   fraction	   from	   transthoracic	  echocardiography	   27±7.0%)	   having	   a	   CMR	   as	   part	   of	   assessment	   for	   CRT	  implants,	  along	  with	  two	  patients	  with	  normal	  LV	  function	  were	  recruited.	  Seven	  patients	  had	  ICM	  and	  seven	  DCM	  (Table	  22).	  Subjects	  with	  contraindications	  to	  MRI	   or	   history	   of	   anaphylaxis	   to	   contrast	   agent	   or	  GFR	  of	   <	  30ml/min/1.73m2	  were	  excluded.	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Table	  22	  Demographics	  of	  heart	  failure	  patients	  	   Heart	  Failure	  Patients	  
Sex	  
	  
12	  men	  2	  women	  
Age	   59.3±14.5yrs	  
Aetiology	   7	  Non-­‐ischaemic	  cardiomyopathy	  7	  Ischaemic	  cardiomyopathy	  
Weight	  (Kg)	   86.0±12.5kg	  
Average	  NYHA	  class	   2.9±0.4	  





10	  in	  sinus	  rhythm	  3	  in	  sinus	  rhythm	  with	  ventricular	  ectopics	  1	  in	  atrial	  fibrillation	  
Ejection	  fraction	  
(trans	  thoracic	  ultrasound)	  
27±7%	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Data	  Acquisition	  The	  patients	  were	  scanned	  using	  1.5T	  MR-­‐scanner	  (Achieva,	  Philips	  Healthcare,	  Best,	  Netherlands)	  with	  a	  32-­‐element	  cardiac	  coil	  (12	  patients)	  and	  a	  5-­‐element	  cardiac	   coil	   (4	   large	   patients	   due	   to	   claustrophobia).	   Cardiac	   gating	   was	  performed	  with	  vector	  electrocardiography	  (VECG).	  After	  localization	  and	  a	  coil	  sensitivity	   reference	   scan	   an	   interactive	   real-­‐time	   scan	   was	   performed	   to	  determine	  the	  geometry	  of	  the	  SA,	  4CH,	  3CH	  and	  2CH.	  A	  multiple	  slice	  (M2D)	  cine	  steady	  state	  free	  precession	  (cine-­‐SSFP)	  scan	  was	  performed	  in	  SA	  orientation	  to	  assess	   the	   ventricular	   function	   (FA=60°,	   TR/TE=2.9/1.5ms,	   resolution	  2.2x2.2x10mm,	   30	   heart	   phases).	   The	   4CH,	   3CH	   and	   2CH	   views	   were	   used	   to	  assess	   LV	   function	   for	   regional	  wall	  motion	   abnormalities.	   Furthermore,	   visual	  assessment	  of	  the	  3CH	  (FA=60°,	  TR/TE=3.0/1.5ms,	  resolution	  2.5x2.5x10mm,	  60	  heart	   phases)	   view	   was	   used	   to	   determine	   timing	   of	   the	   end	   systole.	   For	   the	  contrast	   enhanced	   coronary	   vein	   scan,	   Gd-­‐BOPTA	   (dose	   of	   0.1	   mmol/kg)	   was	  slowly	  infused	  at	  a	  rate	  of	  0.3ml/sec	  with	  subsequent	  saline	  flushing	  as	  proposed	  by	  Bi	  et	  al	  160	  for	  coronary	  arteries.	  In	  order	  to	  determine	  the	  optimal	  start	  point	  of	   the	   whole	   heart	   coronary	   vein	   MR-­‐scan,	   a	   dynamic	   ECG-­‐triggered	   2D-­‐scan	  with	   inversion	   recovery	   (IR)	   preparation	   (TI=300ms)	   was	   used.	   For	   coronary	  vein	   visualization,	   an	  ECG-­‐triggered	   respiratory	  navigated	  3D	   IR-­‐SSFP	  MR-­‐scan	  was	  applied	  to	  acquire	  the	  whole-­‐heart	  during	  a	  short	  interval	  (60-­‐80ms)	  in	  end	  systole	   using	   a	   centric	   profile	   order	   and	   the	   following	   parameters:	   FA=50°,	  TI=300ms,	   TR/TE=4.25/1.44ms,	   SENSE=3-­‐4	   (with	   SENSE	   =2	   AP	   direction	   and	  SENSE=1.5-­‐2	   in	   RL-­‐direction),	   resolution	   1.5	   x	   1.5	   x	   2mm	   (average	   number	   of	  slices	  180±15).	  The	  overall	  scan	  time	  for	   the	  protocol	  was	  3.5	  min	  (assuming	  a	  100%	   respiratory	   gating	   efficacy).	   After	   the	   coronary	   vein	   scan	   a	   delayed	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contrast-­‐enhanced	   multi-­‐slice	   IR	   gradient	   echo	   sequence	   (FA=25°,	   TR/TE=	  5.8/2.0ms)	   was	   performed	   at	   end	   systole	   to	   depict	   areas	   of	   scar.	   A	   preceding	  Look-­‐Locker	   sequence	   was	   used	   to	   determine	   the	   optimal	   inversion	   time	   TI	  (320±22ms)	  to	  null	  the	  signal	  of	  the	  myocardium.	  
Data	  Analysis	  LV	   volumes	   were	   derived	   from	   the	   M2D-­‐cine	   SSFP	   data	   by	   manually	   drawing	  endocardial	  borders	  (Philips,	  Viewforum).	  Papillary	  muscles	  were	  excluded	  and	  EDV	   and	   ESV	  were	   calculated	   for	   the	   LV,	   from	  which	   the	   ejection	   fraction	   and	  cardiac	  output	  (CO)	  were	  derived.	  The	  arrival	  of	  contrast	  agent	  bolus	  in	  LV	  was	  determined	   from	   dynamic	   ECG-­‐triggered	   IR-­‐scan.	   A	   linear	   regression	   analysis	  was	  performed	  between	   the	   times	   taken	   for	   contrast	   to	   reach	  maximum	  signal	  intensity	  for	  the	  different	  cardiac	  output	  (Figure	  42).	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Figure	  42	  
A	  Time	  difference	  for	  contrast	  to	  reach	  maximal	  signal	  intensity	  within	  the	  LV	  in	  a	  patient	  with	  normal	  and	  impaired	  LV	  function.	  B	  Correlation	  between	  cardiac	  output	   and	   time	   for	   contrast	   to	   reach	   maximum	   signal	   intensity	   in	   the	   left	  ventricle.	  The	  two-­‐circled	  points	  indicate	  the	  patients	  with	  normal	  LV	  function.	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Volume	   rendering	   of	   the	   whole-­‐heart	   coronary	   vein	   scan	   (3D	   IR-­‐SSFP)	   was	  performed	  (Philips,	  Viewforum)	  to	  identify	  the	  CS	  and	  its	  tributaries.	  The	  ostium	  of	   the	   CS	  was	   defined	   as	   the	   site	  where	   the	   CS	  makes	   an	   angle	  with	   the	   right	  atrium.	  The	  origin	  of	   the	  Great	  cardiac	  vein	  (GCV)	  was	  considered	   immediately	  after	  the	  bifurcation	  of	  the	  Posterior	  vein	  of	  the	  left	  ventricle	  (PVLV)	  when	  visible	  or	   after	   the	   Posterior	   inter-­‐ventricular	   vein	   subjects.	   	   Cardiac	   veins	   were	  classified	  according	  to	  Ortale	  et	  al	  and	  adopted	  terminology	  of	  Jongbloed	  et	  al.	  154,	  
164	  	  In	   all	   the	   patients	   with	   late	   enhancement	   two	   clinical	   experts	   reviewed	   the	  position	   and	   transmurality	   of	   the	   scar.	   To	   determine	   the	   relationship	   between	  scar	  and	  veins	  I	  co-­‐registered	  the	  3D	  whole	  heart	   images	  with	  the	  scar	   imaging	  using	  Osirix	  software.	  165	  For	  this,	  I	  superimposed	  a	  cast	  of	  the	  LV	  volume	  from	  the	  3D	  whole	  heart	  image	  with	  the	  veins	  on	  the	  scar	  image.	  To	  further	  visualize	  the	   coronary	   venous	   anatomy	   and	   position	   in	   relation	   to	   myocardial	   scar	   I	  manually	  segmented	   the	  3D	  whole	  heart	   images	  with	   ITK-­‐SNAP	  software	   166	   to	  form	   high	   fidelity	   models.	   The	   scar	   was	   manually	   segmented	   using	   Osirix	  software	  and	   then	  registered	   to	   the	  3D	  segmentation	  of	   the	   left	  ventricle	  using	  geometry	   information	   stored	   in	   the	   DICOM	   header.	   Once	   registered,	   scar	  segmentation	   images	   were	   projected	   onto	   the	   LV	   segmentation	   to	   provide	   3D	  visualization	  of	  the	  scar	  geometry.	  Using	  all	  this	  information	  the	  number	  of	  veins	  that	  were	  related	  to	  areas	  of	  scar	  was	  determined.	  	  	  In	  patients	  that	  went	  on	  to	  have	  a	  CRT	  implant	  at	  our	  institute	  (n=11)	  I	  compared	  the	   occlusive	   venogram	   with	   the	   CMR	   imaging	   to	   determine	   the	   correlation	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between	  the	  two	  imaging	  techniques	  and	  to	  determine	  if	   the	  vein	  used	  for	  final	  LV	  lead	  position	  was	  seen	  on	  the	  CMR	  imaging.	  	  
Quantitative	  Analysis	  Multiplanar	  reformatting	  was	  used	  to	  determine	  the	  size	  of	  the	  ostium	  of	  the	  CS	  in	   anterioposterior	   and	   superioinferior	   direction	   and	   to	   measure	   the	   starting	  diameter	  of	  each	  tributary.	  The	  distance	  between	  the	  ventricular	  tributaries	  was	  measured	  from	  the	  volume	  rendered	  reconstructions	  (Figure	  43).	  	  
Figure	  43	  
	  
A	   and	   B	   Whole	   heart	   3D	   reconstruction	   with	   the	   coronary	   sinus	   (CS)	   and	  tributaries.	  Also	  seen	  are	  two	  saphenous	  vein	  graphs	  (SVG).	  C	  An	  example	  of	  the	  distance	  between	  the	  origin	  of	  the	  CS	  and	  the	  Left	  marginal	  vein	  (LMV)	  and	  also	  the	   angle	   the	   LMV	   makes	   with	   the	   Great	   cardiac	   vein	   (GCV).	   D	   shows	   the	  measurement	  of	   the	  diameter	  of	   the	  CS	   in	  various	  plans.	   LV,	   Left	   ventricle;	   LA,	  Left	  atrium;	  AIV,	  Anterior	  inter-­‐ventricular	  vein.	  	  The	  signal	  to	  noise	  ratio	  was	  measured	  by	  drawing	  a	  region	  of	  interest	  (ROI)	  in	  the	  CS	  to	  measure	  mean	  signal	  intensity	  and	  two	  areas	  in	  the	  background	  define	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background	   noise.	   Since	   a	   SENSE	   acquisition	   was	   used	   the	   image	   noise	   is	  spatially	  varying	  and	  usually	  highly	  suppressed	  outside	  the	  body.	  Therefore,	  two	  ROI	  inside	  the	  lung	  were	  used	  to	  define	  background	  noise.	  	  Image	   quality	   of	   3D	   coronary	   vein	   images	   was	   graded	   using	   an	   image	   quality	  score	  of	  0	   to	  4.	  0=CS/GCV	  not	  visible,	  1=CS/GCV	  visible	  with	  markedly	  blurred	  borders	  or	   edges,	  2=CS/GCV	  visible	  with	  moderately	  blurred	  borders	  or	   edges,	  3=CS/GCV	  visible	  with	  mildly	  blurred	  borders	  or	   edges,	  4=CS/GCV	  visible	  with	  sharply	   defined	   borders	   or	   edges.	   167	   For	   inter	   observer	   variability	   two	  experienced	  independent	  observers	  analyzed	  the	  data	  sets.	  	  
Results	  The	   ejection	   fraction	   calculated	   from	  M2D-­‐cine	   SSFP	   for	   heart	   failure	   patients	  was	   27±10%,	   End	   diastolic	   volume	   was	   308±140ml	   and	   cardiac	   output	   was	  4.6±0.9	   l/min.	  Twelve	  of	   the	  patients	  went	  on	   to	  have	  a	  CRT	   implant,	   in	  one	  of	  those	   the	   implant	  was	  performed	  at	   another	   institute	   and	   in	   another	  patient	   it	  was	   not	   possible	   to	   implant	   a	   LV	   lead	   due	   to	   inability	   to	   find	   a	   stable	   lead	  position.	  Of	   the	   two	   that	   did	  not	   go	  on	   to	  have	   implants,	   one	  patient,	   although	  referred	   with	   an	   ejection	   fraction	   of	   35%	   from	   their	   transthoracic	  echocardiogram,	   was	   found	   at	   MRI	   assessment	   to	   have	   an	   ejection	   fraction	   of	  55%,	  and	  one	  was	  too	  unwell	  to	  have	  an	  implant.	  	  	  The	   time	   taken	   for	   the	   contrast	   agent	   to	   reach	   the	   LV	  was	   71.1±27.2	   seconds	  (Figure	  42A).	  In	  one	  patient	  with	  severe	  LV	  impairment	  the	  bolus	  track	  sequence	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was	  completed	  before	  the	  contrast	  reached	  the	  left	  ventricle	  (maximum	  duration	  of	   bolus	   track	   sequence	   120	   seconds).	   The	   time	   taken	   for	   contrast	   to	   reach	  maximum	   signal	   intensity	   and	   cardiac	   output	   were	   correlated	   with	   r=0.82	  (Figure	  42B).	  	  The	  scan-­‐time	  for	   the	  ECG-­‐triggered	  respiratory	  navigated	  3D	  IR-­‐SSFP	  MR-­‐scan	  varied	  within	  all	  16	  patients	  due	  to	  different	  respiratory	  gating	  efficiencies.	  In	  13	  patients	  the	  scan	  time	  was	  12.8±3.2min	  (gating	  efficiency	  29±7%)	  whereas	  there	  was	   a	   very	   low	   gating	   efficiency	   (12-­‐15%)	   in	   3	   patients	   resulting	   in	   long	   scan	  times	  of	  up	  to	  30	  min.	  	  
Anatomical	  Observations	  The	   CS	   and	   GCV	   were	   visualized	   (Table	   23)	   in	   all	   subjects	   with	   example	  reformatted	   images	   and	   segmentations	   given	   in	   figures	   44	   and	   45.	   A	   PIV	   and	  LMV	  was	  seen	  in	  12	  patients	  (75%),	  PVLV	  in	  8	  patients	  (50%)	  and	  an	  AIV	  in	  11	  patients	  (69%).	  The	  mean	  ostial	  diameter	  of	  the	  CS	  and	  coronary	  vein	  branches	  as	  well	  as	  the	  mean	  distance	  from	  the	  ostium	  of	  the	  CS	  to	  the	  various	  tributaries	  is	  shown	  is	  table	  24.	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Table	  23	  Anatomical	  observations	  and	  the	  correlation	  with	  vein	  anatomy	  during	  occlusive	  venography	  	  
Vessel	  seen	   Number	  of	  
vessel	  seen	  by	  
CMR	  for	  all	  
patients	  	  	  
(n=16)	  
Number	  of	  











%	  of	  vessels	  seen	  
by	  CMR	  compared	  
to	  venogram	  
Coronary	  sinus	   16	   100%	   11	   11	   100%	  
Great	  cardiac	  
vein	  
16	   100%	   11	   11	   100%	  
Posterior	  Inter-­‐
ventricular	  vein	  
12	   75%	   8	   8	   100%	  
Posterior	  vein	  of	  
the	  LV	  
8	   50%	   7	   7	   100%	  
Left	  marginal	  
vein	  
12	   75%	   8	   8	   100%	  
Anterior	  inter-­‐
ventricular	  vein	  
11	   69%	   9	   7	   78%	  
Additional	  
lateral	  veins	  
4	   25%	   2	   2	   100%	  
Additional	  
posterior	  veins	  
1	   6%	   0	   0	   N/A	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Table	  24	  Ostial	  diameters	  of	  the	  identified	  vein	  and	  the	  distance	  from	  the	  ostium	  of	  the	  coronary	  sinus	  to	  the	  identified	  vein	  and	  measurable	  vessel	  length.	  	  
CS	  
Tributary	  











the	  CS	  or	  GCV	  
Average	  
distance	  from	  
the	  ostium	  of	  






CS	   12.5±4.1	   13.9±5.7	   N/A	   143.8±50.0†	   N/A	  
PIV	   5.0±0.8	   4.7±1.2	   74.7°±27.6°	   12.0±4.3	   35.8±13.6	  
PVLV	   5.4±1.5	   5.4±1.0	   108.3°±30.7°	   32.6±16.4	   42.0±34.3	  
LMV	   4.8±1.0*	   4.7±1.2*	   99.1°±32.0°	   68.8	  ±19.4	   33.3±23.5	  
AIV	   3.2±1.0*	   3.1±0.8*	   119.6°±28.7°	   146.5±27.6	   23.9±16.1	  *Unable	  to	  accurately	  measure	  in	  2	  patients	  †Total	   length	   of	   vessel	   measurable	   (length	   from	   Coronary	   sinus	   to	   end	   of	  Anterior	  intra-­‐ventricular	  vein)	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Figure	  44	  	  
	  
A	  and	  B	  MPR	  images	  of	  the	  CS	  and	  GCV	  with	  the	  PVLV.	  C	  MPR	  image	  showing	  the	  extent	  of	   the	   coronary	  vein	   from	   the	  CS	   to	   the	  AIV.	  D	   3D	   reconstruction	  of	   the	  coronary	  venous	  system	  with	  the	  various	  branches.	  E	  Late	  enhancement	  images	  showing	  inferior	  scar.	  
Figure	  45	  
	  
A,	   B	   and	   C	   MPR	   images	   of	   the	   CS	   and	   the	   GCV.	   D	   3D	   reconstruction	   of	   the	  coronary	   venous	   system.	   E	   and	   F	   Late	   enhancement	   images	   with	   extensive	  anterior	  apical	  scar.	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Scar	  Imaging	  Seven	  patients	  with	  ICM	  had	  late	  enhancement	  (Figure	  44	  and	  45)	  and	  one	  of	  the	  non-­‐ischemic	  patients	  had	   late	  enhancement	  attributed	   to	  an	  embolic	  event.	  Of	  the	   patients	   with	   scar	   one	   had	   anterior	   scar,	   two	   anterior/lateral	   scar,	   one	  anterior/septal	   scar,	   one	   lateral	   scar	   and	   three	   inferior	   scar.	   For	   six	   of	   the	  patients	  with	  scar	  we	  were	  able	  to	  attribute	  at	  least	  one	  coronary	  vein	  to	  an	  area	  of	  scar	  (Figure	  46	  and	  47)	  (Table	  25).	  	  
Figure	  46	  Shows	  a	  patient	  with	  a	  dilated	  cardiomyopathy	  and	  anterior	  scar	  
	  
A	  Occlusive	  venogram	  performed	  at	  time	  of	  CRT	  implant.	  B	  Volume	  rendered	  3D	  reconstruction	  of	  the	  heart	  and	  coronary	  veins	  showing	  the	  correlation	  with	  the	  occlusive	  venogram.	  C	  Mid	  ventricular	  short	  axis	  late	  gadolinium	  enhanced	  image	  showing	  sub	  endocardial	  anterior	  scar	  of	  50	  to	  75%	  transmurality.	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Table	   25	  Position,	   transmurality	   of	   scar	   and	   number	   of	   veins	   associated	  with	  scar	  




1	   ICM	   Inferior,	  basal/mid	   75-­‐100%	   2*	  
2	   ICM	   Inferior	  basal/mid	  	   50-­‐100%	   1	  
4	   ICM	   Anterior/septal/lateral	  	   Basal/mid	  25-­‐50%	  Apex	  100%	   1	  
5	   ICM	   Anterior/lateral	  Mid/apical	   100%	   0	  
7	   ICM	   Anterior/septum	  Mid/apical	  Apex	  
100%	  	  100%	  
0	  
9	   ICM	   Anterior/septum	  Lateral	  Apex	  
75-­‐100%	  75-­‐100%	  100%	  
1	  
10	   DCM	   Anterior	   75-­‐100%	   1	  
15	   ICM	   Inferior	   25-­‐50%	   1	  *Images	  for	  this	  patient	  seen	  in	  figure	  47	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Figure	  47	  
	  
A	  3D	  reconstruction	  of	  the	  heart	  with	  the	  coronary	  venous	  system.	  B	  2	  chamber	  multislice	   delayed	   contrast-­‐enhanced	   MR-­‐scan	   showing	   inferior	   late	  enhancement	  C	   Segmented	   LV	   registered	   to	   the	   scar	   imaging	   in	   the	   short	   axis	  view.	  The	  scar	  has	  been	  manually	  segmented	  and	  is	   imposed	  on	  the	  segmented	  LV	  shown	  as	  red	  in	  the	  image.	  D	  Segmented	  whole	  heart	  with	  the	  coronary	  veins	  and	  scar	  all	  superimposed.	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Comparison	  of	  CMR	  Venous	  Anatomy	  and	  Venography	  at	  Implantation	  In	  all	  11	  patients	  that	  had	  implants	  at	  our	  institute	  there	  was	  100%	  correlation	  between	  the	  CS,	  GCV,	  PIV,	  PVLV,	  LMV	  and	  additional	   lateral	  veins	  seen	  on	  CMR	  compared	  with	  the	  occlusive	  venography	  (Figure	  46).	  In	  two	  of	  the	  patients	  the	  AIV	  was	  not	  seen	  with	  CMR	  imaging,	  but	  was	  visible	  at	  venography.	  In	  all	  of	  the	  patients	  the	  vein	  used	  for	  final	  LV	  lead	  placement	  was	  visualized	  (Table	  23).	  	  	  
Image	  Quality	  	  The	   average	   score	   for	   the	   CS	   was	   3.0	   and	   GCV	   2.6	   with	   a	   good	   agreement	  between	   two	  observers.	  With	   respect	   to	   the	   vessels	   seen	   the	   observers	   agreed	  for	   in	   all	   cases	   for	   the	  CS,	  GCV	  and	  PIV.	  Observer	  1	   identified	   an	  AIV	  vein	   that	  observer	   2	   did	   not	   and	   also	   two	   additional	   lateral	   veins.	   The	   average	   signal	   to	  noise	  ratio	  for	  all	  patients	  was	  19.5.	  
Discussion	  This	  is	  the	  first	  study	  to	  demonstrate	  that	  CMR	  can	  be	  used	  to	  accurately	  assess	  function,	   coronary	   venous	   anatomy	   and	  myocardial	   scar	   in	   a	   group	  of	   patients	  with	   heart	   failure	   and	   dilated	   ventricles	   awaiting	   CRT	   in	   a	   single	   MR	  examination.	   I	  have	  shown	  that	   this	  CMR	  protocol	  can	  be	  used	   to	  delineate	   the	  coronary	  venous	  anatomy	  and	  correlates	  well	   to	  the	  occlusive	  venography.	  Due	  to	   the	  resolution	  of	   the	  3D	  whole	  heart	   image	  (1.5	  x	  1.5	  x	  2mm)	  the	  venogram	  gives	   more	   detailed	   information	   about	   small	   vessels	   and	   the	   distal	   parts	   of	  coronary	   vein	   branches,	   however	   the	   CMR	   imaging	   provides	   an	   accurate	   non	  invasive	   assessment	   of	   the	   CS	   and	  main	   tributaries.	  When	   comparing	   the	   CMR	  venous	  anatomy	  to	  the	  venogram	  in	  only	  two	  patients	  I	  was	  unable	  to	  see	  main	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vessels,	  which	  were	  visible	  on	  the	  venogram.	  In	  both	  patients	  the	  vessel	  was	  the	  AIV,	  which,	   is	  not	  normally	  a	  target	   for	  LV	  lead	  placement	   in	  CRT.	  Furthermore	  using	  MPR	  and	  volume	  rendered	  images	  allowed	  measurement	  of	  the	  CS	  ostium	  diameter	  and	  the	  distance	  potential	  target	  vessels	  are	  from	  the	  CS	  ostium	  as	  well	  as	   the	  angle	  of	   take	  off	   from	  the	  GCV.	  This	   information	  can	  be	  valuable	   in	  CRT-­‐procedure	   planning.	  When	   an	   occlusive	   venogram	   is	   performed	   the	   balloon	   is	  blown	  up	  some	  distance	  from	  the	  CS	  ostium	  and	  then	  contrast	  is	  injection.	  Veins	  between	  the	  CS	  ostium	  and	  the	  balloon	  are	  often	  poorly	  filled	  by	  contrast	  and	  it	  is	  possible	   to	   miss	   potential	   target	   vessels.	   The	   ability	   to	   show	   potential	   targets	  vessels	  are	  present	  and	  their	  size	  and	  distance	  from	  the	  CS	  prior	  to	  the	  procedure	  means	  that	  these	  vessels	  are	  less	  likely	  to	  be	  missed	  by	  a	  sub-­‐optimal	  venogram.	  	  	  In	   all	   patients	   that	   underwent	   CRT	   the	   target	   vessels	   for	   LV	   placement	   were	  visualized	  by	  CMR	  as	  were	  all	   the	  veins	   for	   final	   lead	  position.	  Furthermore	  by	  overlaying	  segmented	  coronary	  vein	  anatomy	  and	  scar	   I	  was	  able	   to	  determine	  which	   veins	   were	   in	   areas	   of	   scar	   and	   transmurality	   of	   the	   scar.	   Using	   this	  technique	   has	   the	   potential	   to	   guide	   implanters	   prior	   to	   the	   procedure	   on	   the	  coronary	   venous	   anatomy	   and	   the	   potential	   of	   which	   veins	  may	   be	   related	   to	  scar.	  	  	  Previous	   studies	   have	   used	   volunteers	   or	   patients	   principally	   with	   normal	   LV	  size	   and	   function.	   107,	   108,	   110,	   155	   This	   study	   demonstrates	   that	   it	   is	   feasible	   to	  provide	  clinically	  relevant	  information	  in	  patients	  with	  heart	  failure.	  This	  cohort	  of	   patient	   is	   technically	  more	   challenging	   to	   scan,	   as	   there	   are	   often	   problems	  with	  arrhythmias.	  One	  patient	  was	   in	   atrial	   fibrillation	  and	  a	   further	   three	  had	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multiple	   ventricular	   ectopics.	   Interestingly	   the	   patient	   with	   atrial	   fibrillation	  although	   having	   a	   long	   scan	   time	   had	   good	   image	   quality	   graded	   as	   3	   by	   both	  observers	  for	  the	  CS	  and	  the	  GCV.	  Patients	  also	  have	  difficulty	  lying	  flat	  for	  long	  periods	  due	  to	  the	  nature	  of	  heart	  failure	  symptoms.	  This	  often	  leads	  to	  irregular	  breathing	   patterns	   and	   therefore	   difficulty	   with	   the	   navigator	   efficiency	  prolonging	  scan	  times.	  All	  of	  the	  patients	  with	  heart	  failure	  had	  intra-­‐ventricular	  conduction	  delay	  with	  significant	  ventricular	  dyssynchrony.	  The	  3D	  whole	  heart	  scan	  was	   triggered	  during	  end	  systole	  because	  although	   the	  diastolic	  quiescent	  period	  is	  longer	  the	  area	  of	  the	  CS	  is	  larger	  during	  the	  systolic	  quiescent	  period	  making	  imaging	  easier.	  109	  A	  narrow	  acquisition	  window	  of	  60	  to	  90ms.	  Although	  this	  increased	  the	  scan	  duration	  it	  is	  was	  important	  to	  ensure	  image	  quality.	  The	  scan	  times	  were	  long	  due	  to	  both	  irregular	  heart	  rates	  and	  breathing	  patterns	  as	  well	  as	  short	  acquisition	  windows.	  The	  scan	  would	  benefit	  from	  new	  innovations	  that	  improve	  the	  respiratory	  gating	  efficiency.	  	  Due	  to	  poor	  cardiac	  output	  of	  heart	  failure	  patients	  there	  is	  marked	  variation	  in	  the	   time	   for	   contrast	  agent	   to	  disseminate	  within	   the	  blood	  pool	  and	  reach	   the	  coronary	  veins	  compared	  to	  subjects	  with	  normal	  LV	  function.	  Using	  a	  dynamic	  ECG-­‐triggered	  IR-­‐scan	  to	  measure	  bolus	  arrival	  in	  the	  LV	  I	  was	  able	  to	  optimize	  the	  timing	  of	  the	  3D	  IR-­‐SSFP	  scan	  (Figure	  42A).	  In	  one	  of	  the	  patients	  with	  a	  DCM	  the	   bolus	   track	   sequence	  had	   finished	  prior	   to	   contrast	   entering	   the	   LV	   cavity.	  This	  emphasizes	  the	  importance	  of	  the	  correctly	  timing	  the	  start	  of	  the	  3D	  whole	  heart	  scan	  with	  centric	  profile	  order	  when	  using	  a	  slow	  infusion	  protocol.	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Scar	   imaging	  was	   done	   at	   the	   same	   timing	   as	   the	   3D	   IR	   recovery	  whole	   heart	  acquisition	   (end	   systole).	   This	   allowed	   direct	   comparison	   between	   the	   scar	  imaging,	   segmented	   left	   ventricle	   and	   coronary	   veins.	   However,	   in	   both	   scans	  two	   different	   respiratory	   motion	   compensation	   strategies	   were	   applied,	   i.e.	   a	  respiratory	  navigator	  and	  breath	  hold.	  Two	  points	  in	  the	  papillary	  muscles	  were	  used	   as	   anatomical	   landmarks	   to	   briefly	   investigate	   the	  misalignment	   between	  the	   coronary	  vein	  and	   the	   late	  enhancement	   scan.	  There	  was	  a	   relatively	   small	  displacements	   of	   3±3.5mm	   in	   14	   patients	   and	   larger	   displacements	   of	   up	   to	  20mm	   in	   two	   patients.	   In	   future,	   the	   registration	   between	   both	   scans	   can	   be	  improved	  by	  using	  the	  same	  respiratory	  navigator.	  	  	  
Study	  Limitations	  I	  looked	  at	  a	  small	  number	  of	  heart	  failure	  patients	  (n=14)	  and	  now	  need	  to	  get	  greater	   numbers	   in	   particular	   with	   ICM	   to	   allow	   further	   assessment	   of	   the	  relationship	  of	  the	  coronary	  veins	  to	  the	  myocardial	  scar.	  	  I	   did	   not	   compare	   our	   technique	   to	   other	   non-­‐invasive	   imaging	  modalities	   nor	  extra	  vascular	  contrast	  agents.	  However,	  the	  results	  with	  respect	  to	  vessels	  seen	  and	  measurements	  of	   length	  and	  diameter	  are	   comparable	   to	  previous	   studies,	  which	  involved	  volunteers	  or	  patients	  with	  normal	  LV	  function.	  	  	  I	  used	  a	  slow	  infusion	  to	  increase	  the	  circulating	  time	  for	  the	  contrast	  agent	  and	  improve	  imaging	  of	  the	  venous	  anatomy.	  Due	  to	  the	  time	  taken	  to	  acquire	  the	  3D	  whole	  heart	  scan	  it	  may	  be	  more	  appropriate	  for	  a	  bolus	  to	  be	  given	  and	  further	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work	   needs	   to	   be	   done	   to	   optimize	   the	   methods	   for	   contrast	   infusion.	  Furthermore,	   a	   constant	   inversion	   time	   for	   the	   coronary	   vein	   scan	   was	   used,	  since	  a	  determination	  of	  TI	  using	  a	  Look-­‐Locker	  scan	  before	  would	  delay	  the	  start	  3D	  IR-­‐SSFP	  MR-­‐scan	  with	  centric	  profile	  order.	  The	  use	  of	  a	  constant	  TI	  and	  the	  different	  heart	  rate	  of	  the	  patients	  resulted	  in	  different	  image	  contrast	  among	  the	  patients.	  	  	  As	  11	  of	   the	  patients	  went	  onto	  have	  devices	   I	  was	  able	   to	   show	   that	   the	  CMR	  imaging	   compared	   favourably	   to	   the	   venogram	   anatomy.	   Ideally	   I	   would	   have	  liked	  to	  compare	  the	  measurements	  made	  at	  CMR	  with	  the	  venogram	  anatomy.	  However	   for	   a	   quantitative	   assessment	   of	   the	   size	   and	   length	   of	   the	   different	  territories	  numerous	  X	  ray	  views	  would	  be	  necessary	  which	  would	  increase	  the	  procedure	  time	  and	  radiation	  dose	  to	  the	  patient.	  
Conclusions	  	  This	   study	  demonstrates	   that	  CMR	  can	  delineate	   the	  coronary	  venous	  anatomy	  and	  its	  relationship	  to	  myocardial	  scar	  in	  this	  patient	  population.	  This	  has	  been	  helpful	   for	   procedure	   planning	   and	   during	   device	   implantation	   using	   the	  segmented	   volumes	   together	   with	   overlaying	   software	   168.	   Although	   these	  techniques	  are	  in	  their	   infancy	  there	  is	  the	  potential	  to	  guide	  lead	  placement	  to	  avoid	  areas	  of	  scar	  and	  to	  reduce	  procedure	  time	  and	  exposure	  to	  contrast	  agents	  as	  well	  as	  radiation.	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Chapter	  7	  	  
Image	  Guidance	  to	  Aid	  CRT	  Implantation	  
	  
Introduction	  What	   follows	   is	   a	   brief	   summary	  of	   image	   registration	   tools	   and	   study	  of	   their	  uses	  to	  aid	  in	  CRT	  implantations.	  	  Developments	  in	  improved	  imaging	  of	  the	  coronary	  venous	  system	  with	  both	  CT	  
154,	   169,	   170	   and	   CMR	   107-­‐109,	   171	   have	   allowed	   clinically	   useful	   knowledge	   of	   the	  coronary	  venous	  anatomy	  to	  be	  gained	  prior	  to	  lead	  implantation.	  Segmentation	  tools	   166	   and	   advanced	   image	   registration	   software	   developed	   172	   enable	  coronary	  vein	  anatomy	   from	   three	  dimensional	  whole	  heart	  acquisitions	  either	  from	  CT	  or	  CMR	  to	  be	  used	  intra-­‐procedurally	  by	  using	  an	  overlay	  on	  the	  X-­‐ray	  fluoroscopy.	   The	   overlaid	   segmentations	   are	   registered	   in	   3D	   space	  with	  X-­‐ray	  views	   in	   various	   image	   planes	   with	   the	   movement	   of	   the	   C	   arm	   to	   guide	   the	  implantation	  of	  the	  LV	  lead.	  	  	  I	   studied	   the	   feasibility	   of	   using	   advanced	   imaging	   techniques	   registered	   and	  fused	   in	   real	   time	   with	   fluoroscopy	   to	   guide	   LV	   lead	   implantation	   in	   patients	  undergoing	  CRT.	  These	  techniques	  were	  used	  to	  guide	  LV	  lead	  implantation	  in	  a	  group	  of	  patients	  of	  whom	  the	  majority	  had	  undergone	  at	  least	  one	  unsuccessful	  attempt	  at	  LV	  lead	  implantation.	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Methods	  Twelve	  patients	  with	  severe	  heart	  failure	  that	  fulfilled	  standard	  criteria	  for	  CRT	  were	   recruited.	   Patient	   demographics	   are	   shown	   in	   table	   26.	   Eight	   patients	  (66%)	  had	  previous	  failed	  CRT	  implants	  due	  to	  an	  inability	  to	  successfully	  site	  a	  LV	  lead	  and	  four	  were	  primary	  implants.	  Eleven	  patients	  were	  male	  and	  all	  were	  in	   NYHA	   III	   class	   heart	   failure,	   five	   had	   ICM	   and	   six	   DCM	   and	   one	   had	   a	   viral	  cardiomyopathy.	  In	  those	  with	  previous	  failed	  implants	  six	  had	  a	  single	  previous	  attempt	   and	   two	   had	   two	   previous	   attempts	   to	   implant	   a	   LV	   lead	   at	   other	  institutions	  by	  experienced	  implanters.	  In	  five	  patients	  (63%)	  failure	  to	  implant	  initially	  a	  LV	  lead	  was	  due	  to	  inability	  to	  cannulate	  the	  CS;	  one	  patient	  had	  a	  CS	  dissection	  leading	  to	  the	  initial	  procedure	  being	  abandoned,	  in	  one	  the	  previous	  implanter	   had	   failed	   to	   find	   a	   position	  with	   acceptable	   pacing	   parameters	   and	  one	  patient	  had	  a	  left-­‐	  sided	  SVC	  with	  a	  massively	  dilated	  CS	  in	  which	  it	  was	  not	  possible	  to	  identify	  a	  target	  coronary	  vein	  to	  implant	  an	  LV	  lead.	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Table	  26	  Patient	  demographics	  
	   Patients	  
Age	  (years)	   59.0±16.8	  
Sex	   11	  male	  1	  female	  
Ejection	  fraction	   28±4%	  
NYHA	  status	   3±0	  
Aetiology	  of	  heart	  failure	   5	  ICM	  6	  DCM	  1	  Viral	  myocarditis	  
Reason	  for	  initial	  failed	  procedure	  
(8	  patients)	  
5	  unable	  to	  cannulate	  CS	  1	  CS	  dissection	  leading	  to	  1st	  attempt	  being	  abandoned	  1	  Unable	  to	  find	  lead	  position	  with	  acceptable	  pacing	  parameters	  1	  left	  sided	  SVC	  with	  inability	  to	  visualize	  Coronary	  vein	  or	  implant	  LV	  lead	  
Imaging	  methods	   6	  cardiac	  CT	  6	  cardiac	  MRI	  
	  
	  
	   203	  
Advanced	  Imaging	  Protocol	  Six	  of	   the	  patients	   (50%)	  underwent	  CMR	  to	  guide	   their	   implant.	  The	  other	  six	  patients	   already	   had	   right-­‐sided	   pacing	   leads	   in	   situ	   from	   previous	   failed	   CRT	  attempts	  and	  therefore	  were	  excluded	  from	  having	  a	  CMR.	  In	  this	  group	  cardiac	  CT	  imaging	  was	  performed.	  Standard	  exclusion	  criteria	  for	  contrast	  CMR	  and	  CT	  were	   used	   including	   contrast	   allergy,	   uncontrolled	   arrhythmia,	   and	   renal	  dysfunction	  with	  a	  creatine	  serum	  level	  of	  >1.5mg/ml.	  	  
MRI	  Examination	  For	   six	  patients	  both	   respiratory	  and	  cardiac-­‐gated	  CMR	   images	  were	  acquired	  prior	  to	  the	  initial	  implant	  on	  a	  Philips	  Achieva	  1.5T	  MR	  system	  (Phillips	  Medical	  Systems,	  Best,	  Netherlands)	  with	  the	  method	  described	  in	  chapter	  6.	  	  	  
CT	  Examination	  For	   the	   six	   patients	   who	   underwent	   cardiac	   CT	   examination	   images	   of	   the	  coronary	   veins	   were	   acquired	   using	   cardiac-­‐gated	   CT	   images	   with	   a	   Philips	  Brilliance	  40.	  A	  retrospectively-­‐	  gated	  coronary	  CT	  protocol	  was	  adopted	  using	  approximately	  60	  ml	  of	  iodinated	  contrast	  agent.	  Craniocaudal	  coverage	  was	  set	  to	   include	   the	   whole	   heart	   with	   typical	   reconstructed	   voxel	   resolution	   being	  0.4x0.4x0.4mm3	   and	   the	   number	   of	   slices	   being	   approximately	   400.	   The	  reconstructed	  phase	  at	  75%	  of	  the	  R-­‐R	  interval	  was	  used	  for	  segmentation.	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Implantation	  
Image	  Segmentation	  	  For	  the	  CT	  images,	  the	  75%	  cardiac	  cycle	  data	  were	  used	  for	  generation	  of	  a	  3D	  anatomical	  model.	  The	  segmentation	  of	   the	  data	  was	  carried	  out	  using	  the	  fully	  automatic	  Philips	  EP	  Planner	  software	  that	  produced	  3D	  models	  of	  all	  the	  cardiac	  chambers	  and	  great	  vessels,	  including	  the	  first	  part	  of	  the	  CS,	  within	  30	  seconds.	  This	  was	  augmented	  by	  manual	  segmentation	  of	  the	  main	  branches	  of	  the	  CS	  to	  yield	  a	  highly	  detailed	  anatomical	  model.	  For	  the	  CMR	  images,	  the	  systolic,	  end-­‐expiration	   3D	   image	   data	   were	   segmented	   semi-­‐automatically	   using	   the	   ITK-­‐SNAP	  software.	  Four	  of	  the	  patients	  that	  had	  CMR	  had	  ICM.	  The	  late	  gadolinium	  enhanced	   images	   were	   segmented	   manually	   for	   scar	   information.	   Using	   the	  geometry	   information	   stored	   in	   the	   DICOM	   header	   scar	   segmentations	   were	  registered	  to	  the	  high	  fidelity	  3D	  models.	  In	  the	  patients	  that	  had	  CT	  imaging	  the	  right-­‐sided	  pacing	  leads	  were	  segmented	  to	  aid	  image	  registration.	  Furthermore,	  for	  both	  CT	  and	  CMR	  data,	   the	   tracheal	  bifurcation	  was	  manually	  segmented	  to	  aid	  in	  the	  image	  registration	  process.	  	  
Image	  Registration	  and	  Fusion	  CRT	  Implants	  were	  undertaken	  in	  a	  cardiac	  catheter	  laboratory	  using	  a	  Philips®	  Allura	   Xper	   FD10	   cardiovascular	   X-­‐ray	   system,	  with	   EP	   Cockpit	   layout	   (Philips	  Medical	   Systems,	   Best,	   Netherlands).	   A	   single	   experienced	   CRT	   implanter	  undertook	   all	   procedures	   after	   review	  of	   the	   imaging	   data.	   During	   the	   implant	  procedure,	  the	  overlay	  of	  the	  anatomical	  model	  on	  to	  the	  live	  X-­‐ray	  fluoroscopy	  was	   achieved	   using	   a	   prototype	   software	   172	   using	   a	   Philips	   development	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environment	   (PII,	   Philips	   Healthcare,	   Best,	   The	   Netherlands)	   (table	   27	   for	  implant	  details).	  	  The	   registration	   procedure	  was	   different	   depending	   on	   the	   type	   of	   anatomical	  data	  being	  used,	   i.e.	  CT	  or	  CMR.	  For	  both	   types	  of	  data,	   the	  patient’s	  heart	  was	  first	   isocentred	   in	   the	   X-­‐ray	   field	   of	   view	   by	   using	   the	   PA	   and	   lateral	   X-­‐ray	  projections.	  For	  patients	  with	  CT	  data,	  the	  right-­‐sided	  implant	  electrodes	  acted	  as	  fiducials.	  These	  electrodes	  were	   imaged	  using	  PA,	  LAO	  30°,	   and	  RAO	  30°	  X-­‐ray	  projections.	   The	   segmented	   anatomical	  model	  was	   then	  manually	   aligned	  with	  segmented	   electrodes	   that	   were	   visible	   in	   the	   X-­‐ray	   images	   (figure	   48).	   For	  patients	   with	   CMR	   data,	   a	   standard	   quadripolar	   electrode	   catheter,	   St	   Jude	  Medical	  Supreme	  (St	  Jude,	  Minnetonka,	  MN,	  USA)	  was	  looped	  in	  the	  right	  atrium	  and	  imaged	  using	  PA,	  LAO	  30°,	  and	  RAO	  30°	  projections	  and	  then	  removed.	  The	  overlay	   software	   was	   then	   used	   by	   the	   clinical	   expert	   to	   align	   the	   segmented	  anatomical	  model	  to	  the	  right	  atrial	  catheter.	  For	  both	  types	  of	  imaging	  data,	  the	  registration	  was	  further	  aided	  by	  aligning	  the	  segmented	  tracheal	  bifurcation	  to	  the	  X-­‐ray	  shadow	  of	  this	  structure	  in	  the	  PA	  view.	  Subsequent	  to	  this	  registration	  procedure,	  which	  took	  typically	  less	  than	  5	  minutes,	  there	  was	  complete	  freedom	  of	  motion	  of	  the	  X-­‐ray	  table	  and	  C-­‐arm	  since	  the	  registration	  was	  automatically	  maintained	  by	  the	  internal	  tracking	  of	  these	  devices	  by	  the	  overlay	  software.	  This	  meant	   that	   when	   the	   fluoroscopic	   projection	   was	   changed	   the	   overlay	  automatically	  moved	  in	  the	  same	  projection.	  	  
	   206	  
Table	  27	  Implant	  information	  
	   Patients	  
Access	  site	   9	  left	  subclavian	  vein	  1	  right	  subclavian	  vein	  1	  cephalic	  vein	  1	  axillary	  vein	  
Guide	  catheter	  used	  to	  cannulate	  
CS	  
10	  6Fr	  AL2	  (St	  Jude	  Medical,	  Sylmar,	  California,	  USA)	  2	  6Fr	  AL1	  (St	  Jude	  Medical,	  Sylmar,	  California,	  USA)	  
Guide	  wire	  used	   11	  Whisper	  View	  TM	  EDS	  CS-­‐J	  4639	  (Guidant	  Corp.	  St.Paul,	  MN,	  USA)	  1	  HI	  TORQUE	  IRON	  MANTM	  6725	  (Guidant	  Corp.	  St.Paul,	  MN,	  USA)	  	  
Lead	  used	   6	  Quickflex	  XLTM	  1158T	  86cm	  (St	  Jude	  Medical,	  Sylmar,	  California,	  USA)	  4	  Quartet	  TM	  1458Q	  86cm	  (St	  Jude	  Medical,	  Sylmar,	  California,	  USA)	  1	  Attain	  Ability	  TM	  4196	  88cm	  (Medtronic	  Inc.	  Minneapolis,	  MN,	  USA)	  1	  unable	  to	  find	  lead	  position	  with	  acceptable	  pacing	  parameters	  
Final	  lead	  position	   6	  lateral	  vein	  5	  posterior	  lateral	  vein	  1	  no	  lead	  implanted	  
Pacemaker/ICD	  model	   3	  ATLAS	  II	  HF	  V-­‐367(St.	  Jude	  Medical,	  Sylmar,	  CA,	  USA)	  3	  PROMOTETM	  RF	  3213-­‐36(St.	  Jude	  Medical,	  Sylmar,	  CA,	  USA)	  4	  PROMOTETM	  Q	  CD3221-­‐36	  (St.	  Jude	  Medical,	  Sylmar,	  CA,	  USA)	  1	  Biventricular	  pacemaker	  INSYNC®	  III	  8042	  (Medtronic	  Inc.	  Minneapolis,	  MN,	  USA)	  	  
R	  wave	  (mV)	   12.8±6.7	  
Threshold	  (V)	   1.5±1.3	  
Screening	  time	  (min)	   28.4±22.0	  TM=trademark	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A	  Shows	  an	  occlusive	  venogram.	  B	  shows	  the	  overlay	  of	  3D	  coronary	  sinus	  (CS)	  segmentation	   from	  CMR	   imaging	  with	  a	   centre	   line	   for	  both	   the	  venogram	  and	  the	  overlaid	   coronary	  veins.	  This	   is	  used	   to	  determine	   the	   registration	  error.	  C	  Shows	   how	   the	   overlaid	   coronary	   veins	   appear	   to	   the	   operator	   during	   an	  implant.	  This	  image	  was	  taken	  during	  the	  occlusive	  venogram	  to	  show	  the	  close	  correspondence	  with	  anatomy.	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After	   venous	   access	   was	   achieved	   CS	   cannulation	   was	   performed	   in	   all	   cases	  using	  a	  St	  Jude	  OC/135	  Guide	  catheter	  with	  a	  St	  Jude	  6Fr	  AL2	  or	  St	  Jude	  6Fr	  AL1	  (Sylmar,	   California,	   USA)	   telescoped	  within	   it	   and	   a	   Radifocus®	  Guide	  Wire	  M	  Standard	   Type	   RF*GA35153M	   (Terumo	   Europe	   NV,	   Leuven,	   Belgium).	   The	  implanter	  used	  the	  overlaid	  images	  of	  the	  coronary	  sinus	  in	  the	  LAO	  projection	  to	  guide	   introduction	   of	   the	   guide	   catheter	   into	   the	   CS	   ostium.	   Once	   the	   CS	   was	  accessed	   an	   occlusion	   venogram	   was	   performed	   with	   a	   6Fr	   occlusion	   balloon	  catheter	   (Arrow	   International	   Inc,	   Reading,	   PA,	   USA)	   in	   PA	   and	   LAO	   views	   to	  allow	  comparison	  of	  this	  with	  the	  overlaid	  images	  of	  the	  coronary	  sinus	  and	  its	  branches	  (figure	  48	  and	  49).	  This	  was	  performed	  in	  all	  cases	  except	  the	  patient	  with	   a	   left	   sided	   SVC	   when	   occlusion	   venography	   was	   not	   feasible	   due	   to	   the	  massively	  dilated	  coronary	  sinus	  (figure	  50).	  Using	  the	  overlaid	  venous	  anatomy	  as	  a	   roadmap	   the	  LV	   lead	  was	   implanted	   in	  either	  a	   lateral	  or	  posterior	   lateral	  vein	  to	  achieve	  acceptable	  pacing	  parameters.	  	  	  In	   the	   four	  patients	   that	  had	   the	  overlay	  of	   the	  3D	  model	  with	  myocardial	   scar	  pacing	  was	  performed	  within	  areas	  of	  scar	  to	  determine	  any	  difference	  in	  pacing	  parameters	  between	  scarred	  and	  abnormal	  myocardium	  (figure	  51).	  In	  six	  of	  the	  patients	   that	   had	   previous	   failed	   LV	   lead	   implants	   pre-­‐existing	   RA	   and	  ventricular	   leads	  were	  already	  present.	   In	   the	  other	  cases	   the	   right-­‐sided	   leads	  were	  then	  inserted.	  The	  generator	  was	  implanted	  sub-­‐pectorally	  in	  eight	  patients	  and	  subcutaneously	  in	  four.	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Figure	  50	  Images	  from	  a	  patient	  with	  a	  left	  sided	  SVC	  draining	  directly	  into	  the	  coronary	  sinus	  
	  It	  can	  also	  be	  clearly	  seen	   from	  the	   images	   that	   this	  patient	  has	  had	  mitral	  and	  aortic	   valve	   replacements.	   Images	   A	   to	   D	   show	   the	   3D	   model	   of	   the	   cardiac	  chambers	   and	   a	  massively	   dilated	   CS	   and	   tributaries.	   Images	  E	   to	  H	   show	   the	  segmented	  model	   registered	   to	   the	   fluoroscopy	  during	   the	   left	  ventricular	   (LV)	  lead	  implant.	  In	  E	  and	  F	  the	  RV	  lead	  can	  be	  seen	  passing	  down	  the	  left	  sided	  SVC	  and	   through	   the	   CS	   to	   the	   RV.	   The	   RV	   lead	   is	   segmented	   to	   aid	   registration.	  Images	  G	  and	  H	  show	  the	  PVLV	  with	  selective	  venography	  guided	  by	  the	  overlay	  being	   used	   to	   implant	   the	   LV	   lead.	   Image	   G	   venogram	   of	   the	   PVLV	   that	  corresponds	  closely	  with	  the	  overlaid	  model.	  H	  the	  LV	  lead	  is	  seen	  implanted	  in	  the	  PVLV.	  TB=Tracheal	  bifurcation.	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Figure	  51	  Shows	  CMR	  3D	  whole	  heart	  images	  registered	  as	  an	  overlay	  to	  the	  real	  time	  fluoroscopy	  
	  This	   patient	   had	   myocardial	   scar	   that	   has	   been	   registered	   to	   the	   LV	   and	   is	  depicted	  as	  red	  on	  the	  overlay.	  A	  to	  C	  AP	  projections	  taken	  during	  the	  occlusive	  venogram	  and	  shows	  how	  accurate	  the	  registration	  is	  and	  how	  well	  the	  3D	  model	  correlates	  to	  the	  venogram	  venous	  anatomy.	  D	  to	  F	  LAO	  projections	  showing	  the	  overlay	  used	  for	  implantation	  of	  the	  LV	  lead.	  The	  LMV	  is	  being	  used	  and	  it	  can	  be	  seen	  that	  this	  is	  clearly	  outside	  an	  area	  of	  scar.	  In	  figure	  E	  and	  F	  the	  arrow	  shows	  the	  position	  of	  the	  LV	  lead.	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Registration	  Error	  and	  Statistics	  To	  evaluate	  the	  accuracy	  of	  registration	  between	  the	  3D	  anatomical	  models	  and	  the	   live	  X-­‐ray	   fluoroscopy,	   I	   calculated	   the	  distance	   errors	  between	   the	   central	  point	   of	   the	  main	   branch	   of	   CS	   in	   the	   3D	   anatomical	  models	   and	   the	   occlusive	  venogram	  in	  2D	  X-­‐ray	  images	  (figure	  49).	  A	  centre	  line	  of	  main	  branch	  of	  CS	  was	  determined	   from	   the	   venogram	   as	   well	   as	   a	   centre	   line	   for	   the	   overlay	   in	   a	  fluoroscopic	   overlay.	   The	   error	  was	   defined	   as	   the	   root	  mean	   square	   distance	  error	   between	   10	   points	   on	   the	   centre	   line	   of	   CS	   overlay	   geometry	   and	   10	  nearest	   points	   on	   the	   centre	   line	   of	   CS	   venogram.	   Statistical	   analysis	   was	  performed	  using	  SPSS	  software	  package	  (Chicago,	  IL,	  USA).	  Mean	  values	  ±	  SD	  was	  calculated	   for	   screening	   times,	   echocardiographic	   measures	   and	   pacing	  parameters.	   A	   Student’s	   t	   test	   was	   used	   to	   determine	   significant	   remodelling	  determined	   via	   echo	   parameters.	   P	   valves	   less	   than	   0.05	   were	   considered	  statistically	  significant.	  	  
	  
Results	  The	  summary	  of	  demographics	  and	  clinical	  characteristics	  are	  presented	  in	  Table	  26.	   For	   all	   patients	   high	   fidelity	   segmentations	   of	   all	   cardiac	   chambers,	   great	  vessels	  and	  coronary	  venous	  anatomy	  as	  well	  as	  achieving	  accurate	  registration	  between	  the	  3D	  anatomical	  models	  and	  the	  live	  X-­‐ray	  fluoroscopy	  was	  achieved.	  This	  was	  confirmed	  by	  balloon	  occlusion	  angiography	  of	  the	  coronary	  veins	  from	  two	  or	  more	  X-­‐ray	  views.	  	  The	  mean	  distance	  between	  the	  centre	  lines	  of	  the	  CS	  on	  the	  overlay	  and	  the	  venogram	  was	  1.3±0.68mm.	  In	  the	  patient	  that	  had	  a	  left	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sided	   SVC	   I	  was	   unable	   to	   do	   an	   occlusive	   venogram	   and	   therefore	   it	  was	   not	  possible	  to	  measure	  the	  registration	  error.	  	  In	  all	  patients	  the	  CS	  was	  cannulated	  successfully.	  Eleven	  of	  the	  twelve	  patients	  (seven	   of	   the	   eight	   previous	   failed	   implants,	   88%)	   a	   LV	   lead	   was	   successfully	  implanted	   in	   a	   posterior	   lateral	   or	   lateral	   coronary	   vein	   with	   good	   pacing	  parameters	  and	  no	  diaphragm	  stimulation.	  In	  one	  patient	  (with	  previous	  failure	  due	  to	  inability	  to	  cannulate	  the	  CS	  ostium),	  successful	  cannulation	  of	  the	  CS	  was	  achieved	  without	  difficulty	  and	   the	  operator	  was	  able	   to	  navigate	   freely	  within	  the	   coronary	   veins.	   However,	   due	   to	   extensive	   myocardial	   scarring	   he	   was	  unable	   to	   find	   a	   lead	   position	   with	   acceptable	   pacing	   parameters	   and	   the	  procedure	  was	  abandoned.	  LV	  lead	  parameters	  for	  the	  group	  are	  shown	  in	  table	  27.	   Average	   screening	   time	   for	   all	   patients	  was	   28.4±22.0	  minutes.	   In	   the	   four	  patients	   having	   primary	   implants	   the	   screening	   time	   was	   17.8±7.9	   minutes	  (operators	  average	  screening	  time	  without	  overlay	  16.4±10.4	  minutes),	  and	  total	  procedure	  time	  136±58	  minutes.	  The	  average	  R	  wave	  at	  implant	  was	  12.8±6.7mV	  and	  LV	   lead	   threshold	  was	  1.5±1.3V	  measured	  at	  pulse	  duration	  of	  0.5msec.	  At	  three-­‐month	   follow-­‐up	   all	   implanted	   leads	  were	   functioning	   satisfactorily	  with	  all	   patients	   receiving	   CRT.	   LV	   pacing	   thresholds	   were	   slightly	   lower	   than	   at	  implant,	  1.3±0.7V.	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Table	  28	  Shows	  the	  recorded	  pacing	  thresholds	  and	  R	  wave	  for	  pacing	  in	  and	  out	  of	  areas	  of	  myocardial	  scar	  as	  depicted	  on	  the	  overlay	  
	   Scar	   Non	  scar	  
	   Pos	  1	   Pos	  2	   Pos	  3	   Mean	   Pos	  1	   Pos	  2	   Mean	  


























0.8	   7.7	   0.6	   8.1	   0.5	   17.9	   0.63	   11.2	   0.8	   8.7	   0.8	   13.3	   0.8	   11	  
Case	  
2	  
6	   10.9	   1.9	   14.6	   n/a	   n/a	   6.6	   12.8	   0.9	   12.7	   0.8	   13.4	   0.85	   13.5	  
Case	  
3	  
5.6	   8.6	   4	   10	   2	   3.3	   3.9	   7.3	   0.5	   26	   0.5	   22	   0.5	   24	  
Case	  
4	  
7.5	   2	   7.5	   2	   0.5	   9.5	   5.1	   4.6	   0.8	   4.2	   0.6	   4.2	   0.7	   4.2	  
T=Threshold	  (V)	  and	  R=	  R	  wave	  (mV)	  	  All	   patients	   (except	   failed	   implant)	   symptomatically	   improved	   by	   at	   least	   one	  NYHA	   class	   (2±0.4	   from	  3±0).	  Mean	   left	   ventricular	   ejection	   fraction	   improved	  from	   28±4%	   to	   37.9±7%	   (P=0.003)	   and	   ESV	   decreased	   from	   150±57mls	   to	  129±68mls	  (P=0.15).	  	  In	   the	   four	   patients	  with	   overlaid	  myocardial	   scar,	   the	   average	   R	  wave	  within	  scar	  was	  9.0±3.7mV	  compared	  to	  pacing	  outside	  scar	  where	  the	  average	  R	  wave	  was	  13.2±8.2mV.	  The	   threshold	  within	  scar	  was	  4.0±2.5V,	  compared	   to	  outside	  scar	   where	   the	   threshold	   was	   0.7±0.15V.	   The	   breakdown	   of	   the	   pacing	  thresholds	  and	  R	  waves	  for	  all	  patients	  with	  overlaid	  scar	  is	  shown	  in	  table	  28.	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Discussion	  In	   this	   series	   I	   have	   demonstrated	   the	   feasibility	   of	   using	   an	   advanced	   image	  overlay	   system	   using	   CT	   or	   CMR	   images	   to	   guide	   CRT	   implantation.	   This	  technique	   allows	   real	   time	   visualisation	   of	   the	   CS	   and	   branches	   overlaid	   onto	  fluoroscopy	   to	   guide	   the	   implanter.	   Furthermore	   I	   have	   demonstrated	   its	  potential	   to	   facilitate	   CRT	   implantation	   in	   a	   group	   of	   patients	   who	   have	  previously	  had	  failed	  LV	  lead	  implants.	  	  	  Such	  an	  approach	  to	  overlay	  anatomical	  data	  of	  the	  CS	  was	  recently	  described	  by	  Auricchio	  et	  al.	  In	  this	  study	  the	  authors	  demonstrated	  the	  feasibility	  of	  manually	  integrating	  an	  overlay	  system	  between	  3D	  CT	  anatomical	  reconstruction	  and	  2D	  fluoroscopy	  of	   the	  CS	  and	  branches.	  Furthermore	   this	   study	  demonstrated	   that	  the	   registration	   accuracy	   was	   extremely	   high.	   These	   authors	   did	   not	   use	   the	  overlay	  system	  to	  guide	  the	  CRT	  implant.	  Previous	  work	  by	  the	  same	  authors	  had	  shown	  the	  feasibility	  to	  use	  multislice	  CT	  to	  delineate	  coronary	  venous	  anatomy	  in	  patients	  which	  LV	  lead	  replacement	  is	  required.	  173	  Previous	  work	  with	  overlay	  technology	   has	   demonstrated	   that	   fusion	   of	   CT	   and	   fluoroscopy	   may	   support	  electrophysiologists	  in	  more	  accurate	  delivery	  of	  therapy	  during	  atrial	  fibrillation	  ablation.	  174	  However,	  to	  my	  knowledge	  these	  techniques	  have	  not	  been	  used	  to	  guide	  CRT	  implants.	  	  	  In	   this	   series	   not	   only	   was	   it	   possible	   to	   guide	   CRT	   implantation	   but	   it	   also	  facilitated	  successful	  LV	  lead	  implants	  in	  a	  group	  of	  patients	  who	  had	  previously	  failed	  procedures	  predominantly	  due	  to	  technical	  difficulty	  in	  cannulating	  the	  CS	  ostium.	   It	  was	  of	  particular	  help	   in	  a	  patient	  with	  a	  persistent	   left	   sided	  SVC	   in	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which	   balloon	   CS	   angiography	  was	   impossible	   due	   to	  massive	   CS	   dilatation.	   In	  this	  case	  the	  overlay	  technique	  offered	  a	  potentially	  unique	  method	  of	  displaying	  the	  branches	  of	  the	  CS	  to	  guide	  LV	  lead	  implantation.	  	  This	   technique	   has	   wider	   clinical	   implications	   as	   it	   is	   not	   just	   restricted	   to	  patients	   that	   have	   had	   failed	   implants	   but	   may	   be	   of	   benefit	   in	   all	   patients	  undergoing	  CRT.	  Cannulation	  of	  the	  CS	  ostium	  is	  often	  difficult	  and	  a	  key	  step	  in	  the	   CRT	   implants.	   175	   From	   this	   patient	   group	   five	   initially	   had	   failed	   implants	  due	  to	  inability	  to	  cannulate	  the	  CS	  and	  one	  had	  a	  dissection	  of	  the	  CS.	  In	  all	  our	  patients	  the	  CS	  was	  cannulated	  within	  two	  minutes	  of	  central	  access.	  It	  should	  be	  noted,	  that	  in	  these	  cases	  the	  procedures	  were	  all	  undertaken	  by	  an	  experienced	  operator	   and	   it	   is	  may	   be	   that	   the	   implants	  were	   successful	   due	   to	   this	   rather	  than	   to	   the	  overlay.	  However,	   using	   the	  overlay	  has	  particular	  benefits	   for	   less	  experienced	  operators	  as	  registration	  of	  the	  CS	  ostium	  and	  branches	  would	  aid	  in	  cannulation	  of	  the	  CS	  in	  patients	  that	  often	  have	  distorted	  anatomy.	  LV	  dilatation	  and	   enlargement	   of	   both	   right	   and	   left	   atria	   lead	   to	   distortion	   of	   the	   normal	  anatomical	   landmarks	   for	   the	   CS.	   176	   Using	   an	   overlay	   has	   the	   potential	   to	  facilitate	  CS	  intubation	  by	  using	  the	  registered	  image	  as	  a	  guide	  to	  the	  site	  of	  the	  CS	   ostium.	   Such	   techniques	   therefore	   may	   offer	   the	   potential	   to	   reduce	  procedure	   time,	   contrast	   dose,	   X	   ray	   exposure	   and	   complication	   rates	  particularly	  with	  inexperienced	  operators.	  Furthermore	  registration	  of	  scar	  may	  help	   to	   avoid	   pacing	   in	   areas	   of	   non-­‐viable	  myocardium.	  As	  well	   as	   overlaying	  scar	   and	   CVs	   there	   is	   potential	   to	   overlay	   dyssynchrony	  maps	  which	  may	   also	  help	   implanters	   in	   placing	   the	   LV	   lead	   in	   a	   position	   of	   latest	   activation	   and	  theoretically	  could	  lead	  to	  improved	  response	  rates	  (figure	  52).	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Figure	  52	  Shows	  a	  16	  segment	  regional	  volume	  map	  superimposed	  on	  the	  LV	  volume.	  This	  allows	  the	  implanter	  to	  target	  areas	  of	  latest	  volume	  change	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The	  average	  screening	  times	  for	  all	  implants	  is	  high	  predominantly	  due	  to	  three	  patients.	   In	   the	   patient	   with	   persistent	   CS	   left	   sided	   SVC,	   the	   procedure	   was	  technically	   very	   challenging	   (screening	   time	   30	  minutes).	   Another	   two	   patient	  had	   two	   previous	   failed	   attempts	   at	   CRT	   with	   inability	   to	   cannulate	   the	   CS	  ostium.	  In	  these	  cases	  we	  were	  able	  to	  cannulate	  the	  CS.	  However	  the	  procedure	  were	  prolonged	  with	  multiple	  pacing	  sites	  within	  the	  coronary	  veins	  used	  before	  one	   of	   the	   procedures	   was	   abandoned.	   This	   highlights	   that	   these	   cases	   are	  extremely	   complicated	   and	   the	   use	   of	   the	   overlay	   helps	   to	   facilitate	   potential	  successful	  implantation.	  	  	  In	  the	  four	  patients	  having	  primary	  implants	  the	  screening	  times	  are	  equivalent	  to	   standard	   techniques	   (17.8±7.9	  minutes	  with	  overlay	   compared	   to	  16.4±10.4	  minutes	   without	   overlay).	   It	   is	   important	   to	   note	   that	   these	   numbers	   are	   not	  strictly	   comparable	   as	   three	   of	   these	   patients	   had	   myocardial	   scar	   and	   the	  operator	  paced	  in	  various	  sites	  to	  determine	  different	  pacing	  parameters	  which	  led	  to	  longer	  than	  expected	  screening	  times.	  Furthermore	  one	  of	  the	  patients	  had	  very	   extensive	   scar	   meaning	   it	   was	   very	   difficult	   to	   find	   a	   lead	   position	   with	  acceptable	  pacing	  parameters.	  It	  is	  likely	  that	  if	  the	  best	  LV	  lead	  position	  rather	  was	   used	   rather	   than	   pacing	   in	   different	   areas	   to	   determine	   the	   relationship	  between	  scar	  and	  non-­‐scar	  that	  using	  these	  image	  registration	  techniques	  would	  reduce	  screening	  and	  procedure	  times.	  	  In	  this	  series	  two	  imaging	  modalities,	  CT	  and	  CMR	  were	  used.	  With	  advances	  in	  CMR	  imaging	  of	   the	  coronary	  veins	  previously	  described	  in	  chapter	  six	   imaging	  sequence	   provide	   comparable	   information	   to	   CT.	   In	   patients	   with	   no	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contraindications	   to	  CMR	  this	  modality	   for	  assessing	  coronary	  venous	  anatomy	  have	  a	  number	  of	  benefits	  over	  CT.	  	  Although	  images	  of	  the	  coronary	  veins	  can	  be	  acquired	  quickly	  by	  CT,	   iodine-­‐	  based	  nephrotoxic	  contrast	  agents	  are	  required	  in	  a	  cohort	  of	  patients	  that	  often	  have	  poor	  renal	   function	  and	  that	  will	  require	  further	   nephrotoxic	   contrast	   agents	   for	   their	   implant.	   A	   further	   advantage	   of	  using	  CMR	   imaging	  over	  CT	   is	   it	  allows	  scar	   to	  be	  segmented	  and	  registered	   to	  the	  overlay.	  In	  the	  four	  patients	  with	  overlaid	  scar	  I	  was	  able	  to	  show	  a	  difference	  in	   pacing	   parameters	   between	   overlaid	   normal	   and	   scarred	  myocardium.	   It	   is	  known	   that	   implantation	   of	   the	   LV	   lead	  within	   scar	   leads	   to	   reduced	   response	  rates.	   Overlaying	   scar	   has	   the	   potential	   to	   aid	   the	   implanter	   and	  may	   improve	  response	  rates	  to	  CRT.	  	  	  
Study	  Limitations	  The	  major	   limitation	   is	   the	   small	  number	  of	  patients	   enrolled.	  Although	   the	  CS	  was	  cannulated	  successfully	  in	  all	  patients	  and	  implanted	  a	  LV	  lead	  in	  11	  (92%)	  out	   the	  12	  patients	   it	   is	  difficult	   to	  determine	  whether	   the	  patients	  would	  have	  been	  implanted	  successfully	  without	  the	  overlay.	  It	  must	  also	  be	  highlighted	  that	  in	   some	   CRT	   implants	   they	   are	   not	   successful	   not	   because	   of	   inability	   to	  cannulate	   the	   CS	   but	   due	   to	   anatomical	   conditions	   such	   as	   the	   presence	   of	   a	  valve.	  Although	   the	  pre	  procedural	   imaging	   is	  able	   to	   forewarn	   the	  operator	  of	  likely	   difficulties,	   technical	   skills	   and	   use	   of	   different	   catheters	   such	   as	   a	  diagnostic	   EP	   catheter	   may	   lead	   to	   successful	   implant	   and	   in	   these	   cases	   an	  overlay	  may	  not	   help.	   The	   small	   case	   series	   is	   a	   proof	   of	   concept	   but	   clearly	   a	  larger	   prospective	   study	   to	   determine	   if	   these	   techniques	   improve	   implant	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success,	  shorten	  procedure	  time,	  reduce	  fluoroscopy	  dose	  and	  response	  rates	  is	  required.	  	  	  With	  respect	  to	  image	  registration,	  further	  work	  needs	  to	  be	  done	  on	  improving	  segmentation	   of	   myocardial	   scar.	   The	   scar	   was	   manually	   segmented	   and	   then	  superimposed	  on	  an	  endocardial	  shell	  of	  the	  LV.	  There	  are	  two	  issues	  that	  need	  to	   be	   resolved.	   As	   an	   endocardial	   shell	   was	   used	   and	   the	   veins	   run	   along	   the	  epicardial	   surface	   it	   sometimes	   appears	   that	   the	   veins	   are	   separate	   from	   the	  myocardial	   surface.	   Furthermore	  myocardial	   scar	  was	   shown	   as	   being	   present	  (figure	  51)	  the	  transmurality	  of	  the	  scar	  was	  not	  depicted.	  This	   is	  an	  important	  issue	  as	  areas	  of	  partial	  thickness	  scar	  may	  still	  be	  viable	  and	  provide	  a	  good	  area	  for	  pacing.	  This	   is	  supported	  by	  one	  of	  the	  patients	  that	  we	  overlaid	  scar	  (table	  28,	  case	  1).	   In	   this	  patient	   the	  pacing	  parameters	  within	  and	  outside	  scar	  were	  similar.	   This	   patient	   had	   50	   to	   75%	   endocardial	   anterior	   scar	   and	   therefore	  potential	   viable	   myocardium.	   This	   could	   explain	   why	   there	   was	   no	   difference	  between	  pacing	  parameters	  between	  depicted	  areas	  of	  scar	  and	  non-­‐scar.	  Future	  work	   developing	   methods	   of	   segmenting	   CMR	   images	   and	   registering	   the	  transmurality	  of	  scar	  are	  important	  to	  improve	  the	  potential	  of	  these	  techniques	  and	  further	  aid	  our	  understanding	  of	  the	  effects	  of	  scar	  transmurality	  on	  pacing	  parameters.	   In	   the	   future	   to	   better	   understand	   the	   relationship	   between	  transmurality	  of	  scar	  and	  pacing	  parameters	  I	  intend	  to	  look	  at	  the	  electrograms	  when	  we	  are	  pacing	  in	  and	  out	  of	  overlaid	  scar.	  Using	  the	  recorded	  low	  voltage	  and/or	   late	   potentials	   I	   would	   hope	   to	   better	   understand	   the	   relationship	  between	  transmurality	  of	  myocardial	  scar	  with	  the	  timing	  of	  pacing	  artifact	  and	  QRS.	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Conclusions	  This	   case	   series	   shows	   that	   advanced	   imaging	   and	   registration	   techniques	   can	  aid	  CRT	  procedures.	  There	   is	  much	  scope	   to	  use	   these	   techniques	   in	   the	   future	  not	  only	  to	  aid	  implants	  in	  patients	  with	  previous	  failed	  LV	  lead	  insertion	  but	  also	  to	  plan	  and	  help	  implanters	  prior	  to	  the	  initial	  procedure.	  	   	  




Discussion	  and	  Personal	  Opinion	  	  The	  various	  aspects	  of	  each	  sub	  study	  in	  this	  thesis	  have	  been	  discussed	  within	  each	  chapter.	  What	  follows	  are	  my	  personal	  opinions	  of	  the	  benefits	  of	  the	  work	  within	  this	  thesis	  and	  areas	  where	  further	  work	  is	  required.	  	  There	   are	   a	   huge	   number	   of	   heart	   failure	   patients	  worldwide	  with	   prevalence	  increasing	  as	  survival	  from	  coronary	  disease	  improves.	  Although	  management	  of	  heart	  failure	  continues	  to	  improve	  the	  mortality	  remains	  too	  high.	  	  	  The	  development	  of	  CRT	  has	  led	  to	  a	  further	  avenue	  to	  treat	  a	  sub	  group	  of	  heart	  failure	  patients	  with	  abnormal	  ventricular	  conduction.	  However,	  there	  remain	  a	  large	  proportion	  of	  patients	  that	  undergoing	  CRT	  that	  do	  not	  RR	  or	  derive	  clinical	  benefit.	   These	   so	   called	   non-­‐responders	   have	   driven	   extensive	   research	   in	   to	  trying	  to	  understand	  why	  and	  how	  to	  improve	  these	  figures.	  Much	  of	  this	  work	  has	  focused	  on	  the	  use	  of	  echocardiographic	  derived	  indices	  of	  dyssynchrony.	  	  	  Echocardiography	  remains	  a	  corner	  stone	   in	  the	  functional	  assessment	  of	  heart	  failure	   patients,	   however	   its	   use	   in	   stratifying	   which	   patients	   are	   likely	   to	  respond	   to	   CRT	   remains	   unclear.	   There	   are	   a	   number	   of	   limitations	   to	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echocardiographic	  assessment	  of	  heart	  failure	  patients.	  1)	  Poor	  image	  quality,	  2)	  Multiple	  measures	   of	   dyssynchrony	  with	   no	   clear	   consensus	   on	  which	  method	  should	  be	  used,	  3)	  Lack	  of	  information	  on	  myocardial	  scar,	  4)	  Lack	  of	  information	  on	  anatomy	  such	  as	  coronary	  veins,	  5)	  Difficult	  to	  use	  during	  procedures.	  Many	  of	  these	  limitations	  are	  not	  found	  with	  CMR.	  	  	  It	   is	   important	   to	  understand	  how	  CMR	  can	  benefit	  our	  understanding	  of	  heart	  failure	   patients	   referred	   for	   CRT.	   At	   present	   we	   select	   patients	   based	   on	   QRS	  duration.	   It	   is	   assumed	   that	   electrical	  dyssynchrony	   translated	   into	  mechanical	  dyssynchrony	  and	  that	  correction	  of	  mechanical	  dyssynchrony	  leads	  to	  improved	  myocardial	   efficiency	   and	   response	   to	  CRT.	   Furthermore	  often	   is	   assumed	   that	  measures	   of	   dyssynchrony	   derived	   from	   strain	  will	   determine	   how	   and	  which	  patients	  will	  respond	  to	  CRT.	  	  None	  of	   these	   factors	   take	   into	  account	   structural	   information	   such	  as	  position	  and	  extent	  of	  myocardial	   scar	  and	  coronary	  venous	  anatomy.	   It	   is	   important	   to	  realise	   that	  a	  patient	  may	  appear	   to	  be	  highly	   likely	   to	   respond	  on	   the	  basis	  of	  QRS	  duration	  and	  measures	  of	  dyssynchrony,	  however,	  if	  an	  implanter	  is	  unable	  to	  position	  an	  LV	  lead	  in	  a	  good	  position	  than	  that	  patient	  will	  not	  respond.	  	  The	   benefit	   of	   CMR	   is	   that	   it	   can	   provide	   much	   of	   the	   information	   that	  echocardiographic	   imaging	   is	   unable	   to.	   Furthermore	   comparable	   indices	   of	  strain,	   muscle	   thickening	   and	   volume	   dyssynchrony	   can	   all	   be	   measured	   with	  potentially	  better	  accuracy.	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Within	   this	   thesis	   I	   have	   attempted	   to	   synthesise	   a	   novel	   framework	   for	  measuring	  global	  myocardial	  dyssynchrony	  using	  strain,	  muscle	   thickening	  and	  volume	  change.	  Using	  comparable	  indices	  to	  measure	  dyssynchrony	  has	  enabled	  a	   better	   understanding	   of	   what	   is	   being	   measured	   and	   how	   it	   can	   be	   used	   in	  patient	  selection	  for	  CRT.	  It	   is	  clear	  that	  global	  measures	  of	  strain	  do	  not	  aid	   in	  patient	   selection	   as	   the	   forces	   required	   to	   produce	   synchronous	   myocardial	  contraction	  mean	   that	   strain	  patterns	  will	   always	  appear	  dyssynchronous	  even	  in	  the	  normal	  heart.	  Using	  volume-­‐derived	  motion	  gives	  a	  far	  better	  indication	  of	  how	   coordinated	   ventricular	   contraction	   is.	   This	   thesis	   shows	   that	   a	   volume	  derived	   SDI	   is	   highly	   predictive	   of	   both	   acute	   response	   and	   remodelling	   post	  CRT.	  This	  has	  significant	  clinical	  implications.	  	  	  There	   has	   been	   a	   lot	   of	   work	   using	   haemodynamic	   data	   to	   determine	   which	  patients	  are	  likely	  to	  respond	  to	  CRT.	  With	  recent	  work	  showing	  the	  AHR	  to	  CRT	  is	  patient	  specific	  it	  was	  important	  to	  understand	  both	  the	  relationship	  between	  myocardial	  motion	   and	   acute	   response	   to	   CRT	   and	   also	   chronic	   response.	   The	  work	  in	  this	  thesis	  has	  shown	  a	  clear	  relationship	  between	  both	  acute	  response	  and	   RR.	   Also	   patients	   with	   a	   high	   volume	   SDI	   have	   a	   large	   AHR.	   This	   has	  important	  clinical	  implications	  as	  it	  validates	  the	  use	  of	  pressured	  wires	  for	  intra	  procedural	   assessment	   of	   patients	   and	   also	   the	   potential	   to	   use	   volume	  dyssynchrony	  as	  a	  way	  to	  stratify	   likelihood	  of	  response	  or	  even	  as	  a	  surrogate	  for	  the	  pressure	  wire	  assessment.	  	  	  The	   position	   and	   extent	   of	  myocardial	   scar	   is	   known	   to	   affect	   the	   response	   to	  CRT.	  The	  relationship	  of	  coronary	  veins	  to	  scar	  therefore	  has	  significance.	  As	  part	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of	  this	  thesis	  I	  developed	  a	  CMR	  method	  to	  assess	  both	  in	  a	  single	  examination.	  This	  had	  not	  previously	  been	  done	   in	  heart	   failure	  patients.	  Not	  only	  does	   this	  information	  provide	  pre-­‐procedural	   information	   to	  help	   the	   implanter,	  but	  also	  with	  the	  development	  of	  image	  segmentation	  and	  registration	  techniques	  I	  have	  been	   able	   to	   show	   how	   this	   information	   can	   be	   used	   in	   real	   time	   to	   aid	  implantation.	  The	  clinical	   implications	  are	  significant.	  These	  novel	  methods	  are	  only	   in	   their	   infancy,	   however,	   there	   is	   significant	   potential	   in	   the	   future	   to	  improve	  implant	  success	  rates.	  	  I	   have	   investigated	   the	   relationship	   between	   the	   electrical	   activation	   of	   the	  ventricle	  with	  Ensite	  mapping	  and	  how	  this	  relates	  to	  the	  mechanical	  ventricular	  motion.	   Although	   the	   method	   used	   was	   crude	   I	   showed	   that	   areas	   of	   slow	  conduction	   and	   block	   are	   related	   to	   the	   abnormal	   septal	  motion	   known	   as	   the	  septal	  flash.	  This	  part	  of	  the	  thesis	  is	  very	  important	  as	  it	  provides	  an	  explanation	  as	  to	  why	  sub	  groups	  of	  patients	  have	  a	  good	  response	  to	  CRT.	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Limitations	  of	  this	  Work	  	  All	   this	   work	   has	   been	   performed	   in	   a	   single	   centre	   with	   a	   small	   number	   of	  patients	   (n=50).	   To	   truly	   validate	   this	   work	   larger	   numbers	   of	   patients	   are	  required	  and	  this	  is	  definitely	  the	  next	  step	  to	  take	  this	  work	  further.	  Many	  of	  the	  techniques	   used	   within	   this	   thesis	   are	   experimental.	   I	   have	   shown	   that	   it	   is	  possible	   to	   use	   CMR	   images	   and	   image	   registration	   techniques	   in	   real	   time	  during	  a	  CRT	  implant.	  These	  techniques	  are	  novel	  and,	  although	  it	  would	  appear	  from	   our	   small	   patient	   group	   that	   they	   have	   potential	   to	   aid	   implant	   success	  rates,	   much	   more	   work	   is	   required	   in	   this	   area.	   Furthermore,	   although	   it	   is	  shown	   that	   it	   is	   possible	   to	   overlay	   scar	   and	   volume	   dyssynchrony	   no	  improvements	  in	  patient	  response	  rates	  were	  demonstrated.	  	  	  
The	  Future	  This	  thesis	  explores	  the	  development	  of	  many	  potential	  uses	  for	  CMR	  to	  aid	  CRT.	  There	  remains	  much	  scope	  to	  improve	  the	  image	  acquisition,	  segmentation	  and	  registration	  tools.	  During	  this	  work	  the	  CMR	  examination	  I	  used	  developed.	  One	  aspect	   of	   this	   is	   seen	   with	   the	   introduction	   of	   3D	   tagging	   into	   the	   exam	   card.	  Using	   3D	   tagging	   reduced	   acquisition	   time	   and	   improved	   tagged	   image	   quality	  making	   post	   processing	   easier	   and	   more	   reproducible.	   The	   development	   of	  better	   respiratory	  navigators	  and	  3D	   imaging	  has	  definite	  potential	   to	   improve	  CMR	   imaging	   in	   heart	   failure	   patients.	   This	   may	   progress	   the	   ability	   of	   this	  imaging	  modality	  to	  improve	  patient	  selection.	  Furthermore	  with	  new	  CMR	  fiber	  tracking	   techniques	   there	   is	   potential	   to	   gain	   better	   understanding	   of	   the	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pathological	  process	  that	  leads	  to	  LV	  failure.	  Better	  understanding	  of	  ventricular	  motion	  could	  potentially	  explain	  why	  only	  certain	  patients	  respond	  to	  CRT	  and	  could	  improve	  both	  the	  patient	  selection	  and	  response	  rates.	  	  With	   the	   development	   of	   CMR	   compatible	   pacemakers	   one	   of	   the	   major	  limitations	  with	   respect	   to	   following	   up	   patients	   post	   device	   implantation	  will	  become	  less	  of	  an	  issue.	  This	  will	  allow	  improved	  follow	  up	  particularly	  how	  CRT	  affects	  the	  measures	  of	  myocardial	  motion.	  	  With	  no	  definitive	  definition	  of	  response	  to	  CRT	  more	  work	  needs	  to	  be	  done	  on	  clarification	   of	   this.	   Although	   in	   this	   thesis	   I	   have	   used	   AHR	   and	   RR	   it	   is	  important	   to	   realize	   that	   clinical	   and	   cognitive	   improvements	   are	   equally	  important.	   The	   development	   of	   guidelines	   that	   allow	   assessment	   of	   these	  parameters	  is	  important	  for	  the	  future	  of	  further	  work	  in	  CRT.	  	   	  




General	  Conclusions	  This	   chapter	   summarizes	   the	   overall	   conclusions	   and	   suggests	   directions	   for	  future	   investigations.	   This	   thesis	   has	   demonstrated	  many	   potential	   benefits	   of	  using	  CMR	  to	  assess	  heart	  failure	  patients	  prior	  to	  CRT.	  A	  full	  assessment	  of	  heart	  failure	   patients	   is	   crucial	   to	   determine	   functional	   status	   and	   the	   aetiology	   of	  heart	  disease.	  	  	  The	  benefits	  of	  patients	  awaiting	  CRT	  having	  a	  CMR	  prior	  to	  the	  implant	  exceed	  just	   functional	   and	   aetiological	   assessment.	   The	   accurate	   assessment	   of	   global	  dyssynchrony	  with	  volume	  SDI	  is	  a	  simple	  yet	  useful	  tool	  enabling	  stratification	  of	  which	  patients	  will	  benefit	  from	  CRT.	  I	  have	  demonstrated	  there	  exists	  a	  good	  relationship	   between	   acute	   haemodynamic	   response,	   reverse	   remodelling	   and	  volume	   SDI.	   The	   use	   of	   a	   pressure	  wire	   during	   an	   implant	   is	   invasive	   (arterial	  access)	   and	  not	  without	   risk	   of	   complications.	   The	   use	   of	   the	   pressure	  wire	   to	  determine	  LV	  lead	  position	  is	  important,	  but	  this	  is	  not	  feasible	  for	  all	  implants.	  However,	   by	   using	   a	   non-­‐invasive	   assessment	   this	   has	   the	   potential	   to	   remove	  the	   potential	   of	   these	   complications	   and	   provide	   similar	   information	   to	   aid	  targeted	  LV	  lead	  implants.	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By	  developing	  an	  all	  inclusive	  CMR	  examination	  protocol,	  which	  allows	  accurate	  assessment	  of	  coronary	  veins,	  and	  myocardial	  scar,	  I	  have	  shown	  it	  is	  feasible	  to	  demonstration	   the	  relationship	  between	  potential	   target	  veins	  and	   likely	  viable	  and	  non-­‐viable	  myocardium.	  Furthermore,	  it	  is	  demonstrated	  that	  it	  is	  feasible	  in	  real	  time	  to	  use	  this	  information	  during	  implantation	  of	  the	  CRT	  device.	  	  The	   use	   of	   CMR	   is	   not	   without	   its	   limitations.	   Although	   CMR	   compatible	  pacemakers	   are	   being	   developed,	   the	   inability	   to	   do	   repeat	   scan	   post	   CRT	   is	   a	  major	  limitation.	  Ideally	  we	  require	  an	  imaging	  modality	  that	  enables	  assessment	  of	   function	   and	   mechanical	   changes	   pre	   and	   post	   implant.	   Using	  echocardiography	   to	   follow	  patients	  up	  has	  obvious	   limitations	   that	  need	   to	  be	  addressed.	  	  Although	   CMR	   techniques	   that	   assess	   dyssynchrony,	   coronary	   veins,	   and	  registration-­‐guided	   implantations	   have	   been	   developed,	   the	   studies	   herein	   are	  single	   centre	   and	   involve	   small	   numbers	   of	   patients.	   This	   work	   highlights	   the	  need	  for	  larger	  multicentre	  trials	  to	  assess	  further	  the	  ability	  of	  these	  techniques	  to	  improve	  response	  rates.	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   Ginks	   MRCP,	   BR	   Knowles	   MPhys,	   Y	   Ma	   PhD,	   A	   Shetty	  MRCP,	  GS	  Carr-­‐White	  PhD/	  FRCP,	  R	  Razavi	  MD/FRCP,	  T	  Schaeffter	  PhD,	  K	  Rhode	  PhD,	   CA	   Rinaldi	   MD/FRCP	   Real	   Time	   Overlay	   Of	   Coronary	   Vein	   Anatomy	   And	  Myocardial	   Scar	   To	   Guide	   Left	   Ventricular	   Lead	   Implantation	   In	   Cardiac	  Resynchronisation	  Therapy.	  HRS	  Denver	  12-­‐15/05/2010	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SG	   Duckett	   MRCP,	   MR	   Ginks	   MRCP,	   BR	   Knowles	   MPhys,	   Y	   Ma	   PhD,	   A	   Shetty	  MRCP,	  GS	  Carr-­‐White	  PhD/	  FRCP,	  R	  Razavi	  MD/FRCP,	  T	  Schaeffter	  PhD,	  K	  Rhode	  PhD,	  CA	  Rinaldi	  MD/FRCP,	  Advanced	  Imaging	  And	  Overlay	  Technology	  To	  Guide	  Left	   Ventricular	   Lead	   Implantation	   In	   CRT	   Patients	   With	   Previous	   Failed	  Procedures.	  HRS	  Denver	  12-­‐15/05/2010	  	  
	  
SG	   Duckett	   MRCP,	   MR	   Ginks	   MRCP,	   BR	   Knowles	   MPhys,	   Y	   Ma	   PhD,	   A	   Shetty	  MRCP,	  GS	  Carr-­‐White	  PhD/	  FRCP,	  R	  Razavi	  MD/FRCP,	  T	  Schaeffter	  PhD,	  K	  Rhode	  PhD,	  CA	  Rinaldi	  MD/FRCP	  Imaging	  fusion	  &	  overlay	  technology	  to	  guide	  LV	  lead	  implant	  in	  CRT,	  Cardisostim,	  Nice	  16-­‐18/06/2010	  	  	  
SG	   Duckett	   MRCP,	   MR	   Ginks	   MRCP,	   BR	   Knowles	   MPhys,	   A	   Shetty	   MRCP,	   S	  Kapetanakis	   MRCP,	   R	   Razavi	   MD/FRCP,	   T	   Schaeffter	   PhD,	   K	   Rhode	   PhD1,	   GS	  Carr-­‐White	  PhD/	  FRCP,	  CA	  Rinaldi	  MD/FRCP,	  CMR	  &	  3D	  Echo	  predictors	  of	  acute	  haemodynamic	  response	  to	  LV	  pacing.	  Cardisostim,	  Nice	  16-­‐18/06/2010	  	  
	  
SG	  Duckett	  MRCP,	  O.	  Camara	  PhD,	  P.	  Chinchapatnam	  PhD,	  M.	  Sermesant	  PhD,	  A.	  Pashaei	  PhD,	  M.	  Ginks	  MRCP,	  A.F.	  Frangi	  PhD,	  G.	  Carr-­‐White	  FRCP/PhD,	  R.	  Razavi	  FRCP/MD,	   B.H.	   Bijnens	   PhD,	   CA.	   Rinaldi	   FRCP/MD.	   Electromechanical	  relationship	  with	  LBBB	  &	  a	  Septal	  Flash.	  Cardisostim,	  Nice	  16-­‐18/06/2010	  	  
	  
SG	   Duckett	   MRCP,	   MR	   Ginks	   MRCP,	   BR	   Knowles	   MPhys,	   Y	   Ma	   PhD,	   A	   Shetty	  MRCP,	  GS	  Carr-­‐White	  PhD/	  FRCP,	  R	  Razavi	  MD/FRCP,	  T	  Schaeffter	  PhD,	  K	  Rhode	  PhD,	   CA	  Rinaldi	  MD/FRCP	   Predicting	   haemodynamic	   response	   to	   LV	   pacing;	   A	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comparison	   of	   Systolic	   Dyssynchrony	   Index	   derived	   from	   Cardiac	   magnetic	  resonance	  imaging	  and	  3D	  echo.	  HRS	  Denver	  12-­‐15/05/2010	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Appendix	  2	  
Ethics	  sheets	  and	  patient	  information	  	  
	   	  
St	  Thomas’	  Hospital	  Research	  Ethics	  Committee	  	  	  
PATIENT	  INFORMATION	  SHEET	  
	  
Title	  of	  Project:	  Predict	  response	  to	  CRT	  from	  echo	  and	  MRI	  data	  using	  
biophysical	  model	  
	  
Principal	  Investigator:	  Prof.	  Reza	  Razavi	  
Other	  Investigator/s	  enrolling	  patients:	  	  Dr	  S	  Duckett,	  Dr	  M	  Ginks	  
Ethics	  Committee:	  St.	  Thomas’	  Hospital	  	  	  




You	   are	   being	   invited	   to	   take	   part	   in	   a	   research	   study.	   	   Before	   you	   decide	   it	   is	  
important	   for	  you	   to	  understand	  why	   the	  research	   is	  being	  done	  and	  what	   it	  will	  
involve.	  	  Please	  take	  time	  to	  read	  the	  following	  information	  carefully.	  Talk	  to	  others	  
about	  the	  study	  if	  you	  wish.	  	  
• Part	  1	  tells	  you	  the	  purpose	  of	  this	  study	  and	  what	  will	  happen	  to	  you	  if	  you	  take	  
part.	  	  	  
• Part	  2	  gives	  you	  more	  detailed	  information	  about	  the	  conduct	  of	  the	  study.	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Ask	  us	  if	  there	  is	  anything	  that	  is	  not	  clear	  or	  if	  you	  would	  like	  more	  information.	  	  
Take	  time	  to	  decide	  whether	  or	  not	  you	  wish	  to	  take	  part.	  
	  
	  
PART	  1	  	  
Outline	  explanation	  
You	   have	   been	   recommended	   by	   your	   cardiologist	   to	   have	   cardiac	  resynchronisation	  therapy.	  This	  is	  a	  special	  kind	  of	  pacemaker	  usually	  consists	  of	  3	  electrical	   leads	  which	  are	  positioned	   in	   the	  heart	   to	   improve	  the	  efficiency	  of	  the	  heart.	  Although	  this	  treatment	  has	  been	  shown	  to	  be	  effective,	  up	  to	  30%	  of	  patients	   do	   not	   improve	   with	   this	   new	   pacemaker	   in	   terms	   of	   their	   ability	   to	  exercise	  and	  quality	  of	  life.	  
What	  is	  the	  purpose	  of	  the	  study?	  	  At	   present	   it	   is	   not	   clear	   which	   patients	   will	   respond	   to	   having	   cardiac	  resynchronisation	  therapy.	  We	  have	  designed	  this	  study	  to	  evaluate	  the	  electrical	  and	  mechanical	  function	  of	  the	  heart	  to	  see	  if	  we	  can	  discover	  measurements	  that	  will	  help	  us	  predict	  the	  patients	  that	  will	  respond.	  The	  data	  that	  we	  acquire	  will	  then	  be	  used	  to	  make	  mathematical	  models	  of	  the	  function	  of	  the	  heart	  which	  will	  help	  us	  optimise	  the	  treatment	  of	  patients	  referred	  for	  cardiac	  resynchronisation	  therapy	  in	  the	  future.	  	  
Why	  have	  I	  been	  chosen?	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You	  have	  been	  chosen	  to	  take	  part	  as	  you	  are	  eligible	  for	  this	  new	  pacemaker	  on	  the	  basis	  of	  our	  current	  evidence	  from	  large	  clinical	  trials.	  
	  
Do	  I	  have	  to	  take	  part?	  No.	  	  It	  is	  up	  to	  you	  to	  decide	  whether	  or	  not	  to	  take	  part.	   	  If	  you	  do,	  you	  will	  be	  given	  this	  information	  sheet	  to	  keep	  and	  be	  asked	  to	  sign	  a	  consent	  form.	  You	  are	  still	  free	  to	  withdraw	  at	  any	  time	  and	  do	  not	  need	  to	  give	  a	  reason.	  	  A	  decision	  to	  withdraw	  at	  any	  time,	  or	  a	  decision	  not	  to	  take	  part,	  will	  not	  affect	  the	  standard	  of	  care	  you	  receive.	  
	  
What	  will	  happen	  to	  me	  if	  I	  take	  part?	  
You	  will	  be	  given	  a	  consent	  form	  to	  sign.	  
As	  part	   of	   your	   routine	   care	  prior	   to	  having	   cardiac	   resynchronisation	   therapy	  you	  will	  be	  seen	  as	  an	  outpatient.	  You	  will	  have	  a	  questionnaire	  to	   fill	   in	  which	  takes	   10	   to	   15	   minutes,	   a	   walking	   test,	   an	   oxygen	   monitoring	   test	   and	   an	  ultrasound	  scan	  of	  your	  heart	  called	  an	  echocardiogram.	  These	  tests	  are	  routine	  and	   take	   1	   to	   2	   hrs	   to	   perform.	   They	   give	   us	   information	   on	   your	   functional	  status	  prior	  to	  your	  pacemaker.	  
On	   the	   same	  day	   you	  will	   also	   have	   a	   scan	   called	   a	  magnet	   resonance	   imaging	  scan	  (MRI),	  this	  looks	  at	  the	  heart	  giving	  us	  more	  information	  about	  its	  function	  and	  areas	  of	  localised	  scarring.	  	  The	  MRI	  scan	  involves	  lying	  still	  in	  a	  scanner	  for	  60	  to	  90	  minutes	  while	  images	  are	  taken.	  The	  MRI	  does	  not	  involve	  X	  rays	  and	  is	  part	  of	  the	  routine	  work-­‐up	  for	  the	  type	  of	  pacemaker	  you	  are	  having.	  
	   267	  
This	  will	  all	  be	  done	  prior	  to	  your	  pacemaker	  procedure.	  Once	  your	  pacemaker	  is	  inserted	  we	  would	  like	  to	  follow	  you	  up	  at	  3	  and	  6	  months	  with	  a	  repeat	  of	  the	  questionnaire,	  walking	  and	  oxygen	  monitoring	  test	  and	  ultrasound	  of	  your	  heart	  (echocardiogram).	  	  
	  
All	  the	  data	  we	  acquire	  will	  be	  used	  in	  the	  development	  of	  mathematical	  models	  that	  will	   be	   helpful	   in	   the	   future	   for	   predicting	  which	   patients	  will	   respond	   to	  cardiac	  resynhronisation	  therapy.	  
	  
How	  does	  this	  differ	  from	  “standard	  practice”	  i.e.	  routine	  care	  (if	  you	  were	  
not	  to	  take	  part	  in	  the	  study)?	  
The	   assessment	   with	   the	   questionnaire,	   walking	   test,	   oxygen	   monitoring	   and	  echocardiogram	  are	  all	   routine.	  Also	   the	  MRI	   is	  part	  of	  our	   routine	  assessment	  for	  the	  type	  of	  pacemaker	  you	  are	  receiving.	  
In	  addition	  to	  routine	  care,	  you	  would	  have:	  
2	  extra	  outpatient	  hospital	  visits	  lasting	  1	  to	  2	  hrs	  	  
	  
What	  do	  I	  have	  to	  do?	  
You	  would	  need	  to	  do	  the	  routine	  assessments,	  which	  include	  the	  questionnaire,	  walking	   test,	   oxygen	   monitoring,	   echocardiogram	   and	   MRI	   prior	   to	   your	  pacemaker.	   We	   would	   then	   need	   to	   see	   you	   at	   3	   and	   6	   months	   after	   your	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pacemaker	  has	  been	  inserted	  to	  repeat	  the	  initial	  assessments.	  (Not	  including	  the	  MRI	  scan)	  
	  
What	  is	  the	  procedure	  that	  is	  being	  tested?	  
We	  are	  assessing	   the	  electrical	  and	  mechanical	   function	  of	   the	  heart	  using	  MRI	  and	  echocardiography.	  This	  allows	  us	  to	  develop	  measures	  that	  will	  enable	  us	  to	  predict	   which	   patients	   are	   likely	   to	   respond	   to	   cardiac	   resynchronisation	  therapy.	   	   The	   data	   will	   be	   used	   to	   develop	   mathematical	   models	   of	   the	   heart	  helping	  us	  understand	  the	  function	  of	  the	  heart.	  
	  
What	  are	  the	  contraindications	  of	  taking	  part?	  	  
If	  carried	  out	  according	  to	  accepted	  standards	  and	  guidelines,	  MRI	  is	  a	  harmless	  imaging	  technique.	  We	  have	  safety	  procedures	  and	  well-­‐trained	  staff	  to	  minimise	  any	   possible	   risks	   associated	   with	   the	   procedure.	   Because	   MRI	   uses	   a	   strong	  magnet,	   it	   is	  not	  safe	   for	  some	  people	   to	  be	  scanned.	  This	   includes	  people	  who	  have	   a	   heart	   pacemaker	   or	   some	   other	   types	   of	   implanted	   device.	   You	  will	   be	  asked	  to	   fill	   in	  a	  screening	  form	  to	  make	  sure	  that	  you	  do	  not	  come	  into	  any	  of	  these	  categories.	  For	   the	  same	  reason,	   it	   is	   important	   that	  magnetic	  objects	  are	  not	  brought	  too	  close	  to	  the	  scanner.	  
	  
What	  are	  the	  possible	  disadvantages	  and	  risks	  of	  taking	  part?	  	  
The	  MRI	  scan	  may	  be	  uncomfortable,	  as	  you	  need	  to	  lie	  flat	  for	  60	  to	  90	  minutes.	  Most	  people	  tolerate	  this	  procedure	  very	  well.	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You	   will	   be	   required	   to	   have	   two	   extra	   out	   patient	   hospital	   visits	   after	   your	  pacemaker	  has	  been	  implanted.	  You	  will	  be	  reimbursed	  for	  the	  extra	  journeys.	  
	  
What	  are	  the	  possible	  benefits	  of	  taking	  part?	  
The	  main	  benefit	   is	   that	  by	  doing	   the	  study	  we	  will	  be	  able	   to	   identify	   the	  best	  site	  for	  implantation	  of	  the	  extra	  lead	  into	  your	  heart	  and	  increase	  the	  chance	  of	  the	   pacemaker	   improving	   your	   symptoms.	   You	  will	   also	   have	   closer	   follow	   up	  with	  the	  two	  extra	  hospital	  visits	  after	  the	  pacemaker	  is	  implanted.	  	  	  
What	  happens	  when	  the	  research	  study	  stops?	  You	   will	   still	   be	   routinely	   followed	   up	   in	   our	   clinic	   and	   monitored	   by	   your	  cardiologist.	  The	  results	  of	  the	  supplementary	  tests	  will	  not	  exclude	  you	  from	  any	  useful	  treatment	  approved	  for	  your	  condition.	  
What	  if	  there	  is	  a	  problem?	  Any	  complaint	  about	  the	  way	  you	  have	  been	  dealt	  with	  during	  the	  study	  or	  any	  possible	  harm	  you	  might	   suffer	  will	   be	   addressed.	  The	  detailed	   information	  on	  this	  is	  given	  in	  Part	  2.	  
Will	  my	  taking	  part	  in	  the	  study	  be	  kept	  confidential?	  	  Yes.	   All	   the	   information	   about	   your	   participation	   in	   this	   study	   will	   be	   kept	  confidential.	  	  The	  details	  are	  included	  in	  Part	  2.	  
Contact	  Details:	  Prof.	  Reza	  Razavi.	  St	  Thomas’	  Hospital,	  4th	  Floor	  Lambeth	  Wing.	  Telephone	  02071885440.	  Mobile	  phone:	  07900240841	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This	  completes	  Part	  1	  of	  the	  Information	  Sheet.	  
If	   the	   information	   in	   Part	   1	   has	   interested	   you	   and	   you	   are	   considering	  
participation,	  please	  continue	  to	  read	  the	  additional	  information	  in	  Part	  2	  
before	  making	  any	  decision.	  
	   	  




What	  if	  relevant	  new	  information	  becomes	  available?	  Sometimes	   during	   the	   course	   of	   a	   research	   project,	   new	   information	   becomes	  available	   about	   the	   procedure	   that	   is	   being	   studied.	   	   If	   this	   happens,	   your	  research	  doctor	  will	  tell	  you	  about	  it	  and	  discuss	  whether	  you	  want	  to	  or	  should	  continue	  in	  the	  study.	  
What	  will	  happen	  if	  I	  don’t	  want	  to	  carry	  on	  with	  the	  study?	  If	  you	  withdraw	  from	  the	  study,	  we	  will	  need	  to	  use	  the	  data	  collected	  up	  to	  your	  withdrawal.	   We	   will	   ask	   you	   to	   keep	   in	   contact	   with	   us	   to	   let	   us	   know	   your	  progress.	  
What	  if	  there	  is	  a	  problem?	  
Complaints:	  If	  you	  have	  a	  concern	  about	  any	  aspect	  of	  this	  study,	  you	  should	  ask	  to	   speak	  with	   the	   researchers	  who	  will	  do	   their	  best	   to	  answer	  your	  questions	  (Prof.	   Reza	  Razavi	   02071885440).	   	   Should	   you	  wish	   to	   complain	   formally,	   you	  can	  do	  this	  through	  the	  NHS	  Complaints	  Procedure.	  	  Details	  can	  be	  obtained	  from	  the	  hospital.	  
Harm:	  	  In	  the	  event	  that	  you	  are	  harmed	  during	  the	  research	  study	  there	  are	  no	  special	   compensation	   arrangements.	   	   If	   you	   are	   harmed	   and	   this	   is	   due	   to	  someone’s	   negligence	   then	   you	   may	   have	   grounds	   for	   a	   legal	   action	   for	  compensation	   against	   Guy’	   &	   St.	   Thomas’	   NHS	   Trust	   but	   you	  may	   have	   to	   pay	  your	  legal	  costs.	  The	  normal	  National	  Health	  Service	  complaints	  mechanisms	  will	  still	  be	  available	  to	  you.	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Will	  my	  taking	  part	  in	  this	  study	  be	  kept	  confidential?	  Procedures	   for	   handling,	   processing,	   storage	   and	   destruction	   of	   your	   data	   are	  compliant	  with	  the	  Data	  Protection	  Act	  1998.	  All	   information	  which	   is	   collected	   about	   you	  during	   the	   course	   of	   the	   research	  will	   be	   kept	   strictly	   confidential.	   	   Any	   information	   about	   you	  which	   leaves	   the	  hospital	   will	   have	   your	   name	   and	   address	   removed	   so	   that	   you	   cannot	   be	  recognised	  from	  it.	  Your	  data	  will	  be	  collected	  from	  the	  referral	  letter	  and	  patient	  notes,	  as	  well	  from	  your	  oral	  information;	  Data	  will	  be	  automatically	  stored	  securely,	  in	  an	  encrypted	  format;	   Authorised	   persons	   such	   as	   researchers,	   regulatory	   authorities	   and	  Research	   and	  Development	   (for	  monitoring	   of	   the	   quality	   of	   the	   research)	  will	  have	  assess	  to	  these	  data;	  Data	  will	  be	  retained	  for	  15	  years.	  Your	  own	  GP	  may	  be	  notified	  of	  your	  participation	  in	  the	  trial,	  after	  your	  consent.	  
What	  will	  happen	  to	  the	  results	  of	  the	  research	  study?	  These	   will	   be	   published	   in	   a	   research	   paper	   with	   the	   aim	   of	   advancing	   the	  knowledge	  of	  MRI	  and	  heart	   failure.	  All	  patient	   identities	  are	   treated	  as	  strictly	  confidential	  and	  anonymous	  in	  any	  publication.	  
Who	  is	  organising	  and	  funding	  the	  research?	  The	   research	   is	   organised	   by	   Prof	   Reza	   Razavi	   and	  will	   be	   partially	   funded	   by	  Kings	   College	   London.	   The	   study	   is	   being	   undertaken	   primarily	   for	   academic	  reasons.	  
Who	  has	  reviewed	  the	  study?	  The	   study	  has	  been	   independently	   reviewed	  by	   the	   St	  Thomas’	  Hospital	   Ethics	  Committee.	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A	  copy	  of	  the	  information	  sheet	  and	  a	  signed	  consent	  form	  to	  keep	  will	  be	  
given	  to	  you.	  
	  
Thank	  you	  for	  considering	  taking	  part	  or	  taking	  time	  to	  read	  this	  




Rayne	  Institute,	  KCL	  Guy's	  	  &	  St	  Thomas'	  NHS	  Trust	  St	  Thomas'	  Hospital	  Lambeth	  Palace	  Road	  London	  	  	  SE1	  7EH	  	  Tel	  :	  0207	  188	  	  1026	  Fax	  :	  0207	  188	  1011	  Study	  Number:	  09/H0802/38	  
Patient	  Identification	  Number	  for	  this	  trial:	  
	  
CONSENT	  FORM	  
Title	  of	  Project:	  Predicting	  response	  to	  cardiac	  resynchronisation	  therapy	  from	  echocardiographic	   and	   cardiac	   magnetic	   resonance	   imaging	   data	   using	  biophysical	  models	  	  Name	  of	  Researcher:	  Professor	  Reza	  Razavi	  
	   274	  
	  
	   	   	   	   	   	   	   	   	   Please	  initial	  box	  1.	   I	   confirm	   that	   I	   have	   read	   and	   understand	   the	   information	   sheet	   dated	  04/03/2009	   (version	  1)	   for	   the	   above	   study.	   I	   have	   had	   the	   opportunity	   to	  consider	   the	   information,	   ask	   questions	   and	   have	   had	   these	   answered	  satisfactorily.	  	  2.	   I	   understand	   that	   my	   participation	   is	   voluntary	   and	   that	   I	   am	   free	   to	  withdraw	   at	   any	   time,	  without	   giving	   any	   reason,	  without	  my	  medical	   care	   or	  legal	  rights	  being	  affected.	  	  3.	   	   	   I	   understand	   that	   relevant	   sections	   of	   any	   of	   my	   medical	   notes	   and	   data	  collected	   during	   the	   study	   may	   be	   looked	   at	   by	   responsible	   individuals	   from	  regulatory	  authorities	  or	   from	  the	  NHS	  Trust,	  where	   it	   is	  relevant	   to	  my	  taking	  part	  in	  this	  research.	  	  I	  give	  permission	  for	  these	  individuals	  to	  have	  access	  to	  my	  records.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  4.	   I	  agree	  to	  my	  GP	  being	  informed	  of	  my	  participation	  in	  the	  study.	  	  	  5.	  	  	  I	  agree	  to	  take	  part	  in	  the	  above	  study.	  	  _________________________	   __________________	   ________________	  Name	  of	  Patient	   Date	   Signature	  	  _________________________	   ________________	   ________________	  Name	  of	  Person	  taking	  consent	   Date	   Signature	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(if	  different	  from	  researcher)	  	  _________________________	   ________________	   ________________	  Researcher	   Date	   	   Signature	  	   When	  completed,	  1	  for	  patient;	  1	  for	  researcher	  site	  file;	  1	  (original)	  to	  be	  kept	  in	  medical	  notes	  	  
	   	  
St	  Thomas’	  Hospital	  Research	  Ethics	  Committee	  	  	  
PATIENT	  INFORMATION	  SHEET	  
	  
Title	  of	  Project:	  Biophysical	  modelling	  to	  guide	  selection	  and	  implantation	  
of	  CRT	  
	  
Principal	  Investigator:	  Prof.	  Reza	  Razavi	  
Other	  Investigator/s	  enrolling	  patients:	  	  Dr	  S	  Duckett,	  Dr	  M	  Ginks	  
Ethics	  Committee:	  St.	  Thomas’	  Hospital	  	  	  
Code	  No:	  09/H0802/37	  
	  
	  
You	   are	   being	   invited	   to	   take	   part	   in	   a	   research	   study.	   	   Before	   you	   decide	   it	   is	  
important	   for	  you	   to	  understand	  why	   the	  research	   is	  being	  done	  and	  what	   it	  will	  
involve.	  	  Please	  take	  time	  to	  read	  the	  following	  information	  carefully.	  Talk	  to	  others	  
about	  the	  study	  if	  you	  wish.	  	  
• Part	  1	  tells	  you	  the	  purpose	  of	  this	  study	  and	  what	  will	  happen	  to	  you	  if	  you	  take	  
part.	  	  	  
• Part	  2	  gives	  you	  more	  detailed	  information	  about	  the	  conduct	  of	  the	  study.	  	  
LV 
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Ask	  us	  if	  there	  is	  anything	  that	  is	  not	  clear	  or	  if	  you	  would	  like	  more	  information.	  	  
Take	  time	  to	  decide	  whether	  or	  not	  you	  wish	  to	  take	  part.	  
	  
	  
PART	  1	  	  
Outline	  explanation	  
You	   have	   been	   recommended	   by	   your	   cardiologist	   to	   have	   cardiac	  resynchronisation	  therapy.	  This	  involves	  a	  special	  pacemaker	  usually	  consists	  of	  3	  electrical	  leads	  which	  are	  positioned	  in	  the	  heart	  to	  improve	  the	  co-­‐ordination	  of	  the	  contraction	  as	  the	  heart	  beats.	  Although	  this	  treatment	  has	  been	  shown	  to	  be	  effective,	  up	  to	  30%	  of	  patients	  do	  not	   improve	  with	   this	  new	  pacemaker	   in	  terms	  of	  their	  ability	  to	  exercise	  and	  quality	  of	  life.	  
What	  is	  the	  purpose	  of	  the	  study?	  	  At	   present	   it	   is	   not	   clear	   which	   patients	   will	   respond	   to	   having	   this	   type	   of	  pacemaker.	   We	   have	   designed	   this	   study	   to	   evaluate	   the	   electrical	   and	  mechanical	  function	  of	  the	  heart	  to	  see	  if	  we	  can	  discover	  measurements	  that	  will	  help	  us	  predict	  the	  patients	  that	  will	  respond.	  The	  data	  that	  we	  acquire	  will	  then	  be	  used	  to	  make	  mathematical	  models	  of	  the	  function	  of	  the	  heart	  which	  will	  help	  us	   optimise	   the	   treatment	   of	   patients	   referred	   for	   cardiac	   resynchronisation	  therapy	  in	  the	  future.	  	  
Why	  have	  I	  been	  chosen?	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You	  have	  been	  chosen	  to	  take	  part	  since	  you	  are	  eligible	  for	  this	  new	  pacemaker	  on	  the	  basis	  of	  our	  current	  evidence	  from	  large	  clinical	  trials.	  
	  
Do	  I	  have	  to	  take	  part?	  No.	  	  It	  is	  up	  to	  you	  to	  decide	  whether	  or	  not	  to	  take	  part.	   	  If	  you	  do,	  you	  will	  be	  given	  this	  information	  sheet	  to	  keep	  and	  be	  asked	  to	  sign	  a	  consent	  form.	  You	  are	  still	  free	  to	  withdraw	  at	  any	  time	  and	  do	  not	  need	  to	  give	  a	  reason.	  	  A	  decision	  to	  withdraw	  at	  any	  time,	  or	  a	  decision	  not	  to	  take	  part,	  will	  not	  affect	  the	  standard	  of	  care	  you	  receive.	  
	  
What	  will	  happen	  to	  me	  if	  I	  take	  part?	  
You	  will	  be	  given	  a	  consent	  form	  to	  sign.	  
As	   part	   of	   your	   routine	   care	   prior	   to	   having	   the	   cardiac	   resynchronisation	  therapy	  you	  will	  be	  seen	  as	  an	  outpatient.	  You	  will	  have	  a	  questionnaire	  to	  fill	  in	  which	   takes	  10	   to	  15	  minutes,	   a	  walking	   test,	   an	  oxygen	  monitoring	   test	   and	  a	  scan	  of	  your	  heart	  called	  an	  echocardiogram.	  These	  tests	  are	  routine	  and	  take	  1	  to	  2hrs	   to	  perform.	  They	  give	  us	   information	  on	  your	   functional	  status	  prior	   to	  your	  pacemaker.	  
On	   the	   same	  day	   you	  will	   also	   have	   a	   scan	   called	   a	  magnet	   resonance	   imaging	  scan	  (MRI),	  this	  looks	  at	  the	  heart	  giving	  us	  more	  information	  about	  its	  function	  and	  areas	  of	  localised	  scarring.	  	  The	  MRI	  scan	  involves	  lying	  still	  in	  a	  tube	  for	  60	  to	   90minutes	  while	   images	   are	   taken	   before	   an	   injection	   of	   a	   substance	   called	  gadolinium	  is	  given	  to	  see	   if	   there	  are	  any	  scars	   in	  the	  heart.	  The	  MRI	  does	  not	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involve	  X	  rays	  and	  is	  part	  of	  the	  routine	  work-­‐up	  for	  the	  type	  of	  pacemaker	  you	  are	  having.	  
We	  would	  like	  to	  do	  an	  additional	  test	  called	  an	  electrophysiological	  study.	  This	  involves	  you	  coming	  in	  as	  an	  inpatient	  for	  a	  day.	  This	  procedure	  would	  be	  done	  3	  to	   7	   days	   prior	   to	   your	   pacemaker.	   This	   study	   is	   done	   in	   a	   special	   cardiac	  catheterisation	  laboratory	  which	  allows	  us	  to	  do	  a	  further	  MRI	  scan	  which	  takes	  30	  minutes	  immediately	  before	  the	  electrophysiological	  study.	  The	  benefit	  of	  this	  is	  it	  allows	  us	  to	  directly	  compare	  the	  MRI	  scan	  data	  with	  the	  electrophysiological	  invasive	  study	  data.	  	  
You	  are	  required	  to	  lie	  flat	  for	  3-­‐4	  hrs	  in	  a	  cardiac	  catheterisation	  lab.	  During	  this	  procedure	  we	  would	  use	  a	  special	  wire	  called	  a	  pressure	  wire,	  this	  passed	  either	  through	  the	  artery	  in	  your	  wrist	  or	  groin	  to	  your	  heart.	  It	  enables	  us	  to	  measure	  changes	  in	  your	  blood	  pressure.	  We	  also	  pass	  a	  tube	  called	  an	  electrical	  mapping	  catheter	   to	   your	   heart	   through	   the	   artery	   in	   your	   groin.	   The	   catheter	   and	  pressure	  wire	  are	  passed	  to	  your	  heart	  under	  X	  ray	  guidance.	  This	  allows	  us	  to	  map	   the	   electrical	   activity	   of	   the	   heart,	   also	   by	   using	   this	   catheter	   we	   can	  stimulate	   different	   areas	   of	   the	   heart	   and	   see	   how	   this	   affects	   your	   blood	  pressure.	  During	  this	  study	  we	  will	  also	  be	  performing	  another	  echocardiogram	  to	  gain	  more	  information	  about	  the	  function	  of	  the	  heart.	  	  	  
	  
This	  will	  all	  be	  done	  prior	  to	  your	  pacemaker	  procedure.	  Once	  your	  pacemaker	  is	  inserted	  we	  would	  like	  to	  follow	  you	  up	  at	  3	  and	  6	  months	  with	  a	  repeat	  of	  the	  questionnaire,	  walking	  and	  oxygen	  monitoring	  test	  and	  echocardiogram.	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All	  the	  data	  we	  acquire	  will	  be	  used	  in	  the	  development	  of	  mathematical	  models	  that	  will	   be	   helpful	   in	   the	   future	   for	   predicting	  which	   patients	  will	   respond	   to	  biventricular	  pacing.	  
	  
How	  does	  this	  differ	  from	  “standard	  practice”	  i.e.	  routine	  care	  (if	  you	  were	  
not	  to	  take	  part	  in	  the	  study)?	  
The	   assessment	   with	   the	   questionnaire,	   walking	   test,	   oxygen	   monitoring	   and	  echocardiogram	  are	  all	   routine.	  Also	   the	  MRI	   is	  part	  of	  our	   routine	  assessment	  for	  the	  type	  of	  pacemaker	  you	  are	  receiving.	  
In	  addition	  to	  routine	  care,	  you	  would	  have:	  
The	  electrophysiological	  studies	  (inpatient	  stay,	  takes	  3	  to	  4hrs)	  
2	  extra	  outpatient	  hospital	  visits	  lasting	  1	  to	  2	  hrs	  	  
	  
What	  do	  I	  have	  to	  do?	  
You	  would	  need	  to	  do	  the	  routine	  assessments,	  which	  include	  the	  questionnaire,	  walking	   test,	   oxygen	   monitoring,	   echocardiogram	   and	   MRI	   prior	   to	   your	  pacemaker.	  You	  will	  need	   to	  come	   in	   for	  a	  day	   to	  have	   the	  electrophysiological	  studies.	  We	  would	  then	  need	  to	  see	  you	  at	  3	  and	  6	  months	  after	  your	  pacemaker	  has	  been	  put	  in	  to	  repeat	  the	  initial	  assessments.	  (Not	  including	  the	  MRI	  scan	  and	  electrophysiological	  studies)	  
	  
What	  is	  the	  procedure	  that	  is	  being	  tested?	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We	  are	  assessing	  the	  electrical	  and	  mechanical	  function	  of	  the	  heart	  to	  see	  how	  that	   compares	   with	   MRI	   and	   echocardiography.	   This	   allows	   us	   to	   develop	  measures	   that	  will	   enable	  us	   to	  predict	  which	  patients	   are	   likely	   to	   respond	   to	  biventricular	  pacing.	   	  This	  date	  will	  be	  used	  to	  develop	  mathematical	  models	  of	  the	  heart	  helping	  us	  understand	  the	  function	  of	  the	  heart.	  
What	  are	  the	  side	  effects	  of	  taking	  part?	  	  
Part	  of	   the	  study	   involves	  an	   invasive	  procedure	  called	  electrophysiological	  no-­‐contact	  mapping.	  The	  electrophysiological	  study	  involves	  passing	  a	  tube	  called	  a	  catheter	   to	   your	   heart	   through	   the	   artery	   in	   your	   leg	   and	   also	   a	   wire	   again	  through	   the	   artery	   in	   your	   leg	   or	  wrist	   to	   your	  heart.	   There	   is	   the	  potential	   to	  develop	  bruising	  from	  the	  site	  that	  the	  pressure	  wire	  is	  inserted	  (wrist	  or	  groin)	  and	  also	  the	  site	  that	  the	  mapping	  catheter	  is	  inserted	  (groin).	  
The	  MRI	  scan	  can	  not	  be	  done	  under	  certain	  circumstances,	  such	  as	  if	  you	  suffer	  with	  claustrophobia	  or	  have	  previously	  had	  any	  operations	  on	  the	  brain.	  
You	   will	   be	   required	   to	   have	   two	   extra	   out	   patient	   hospital	   visits	   after	   your	  pacemaker	  has	  been	  implanted.	  
What	  are	  the	  possible	  disadvantages	  and	  risks	  of	  taking	  part?	  	  
As	   the	  electrophysiological	   study	   is	   an	   invasive	  procedure	   there	  are	   associated	  risks	  (see	  below)	  	  
-­‐	   1%	   chance	   of	   groin	   haematoma	   or	   false	   aneurysm	   as	   a	   result	   of	   arterial	  puncture,	  
−	  risk	  of	  stroke	  <	  0.1%	  
−	  infection	  /	  pulmonary	  embolus	  (clot	  on	  the	  lung)<	  1%	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−	  pericardial	  tamponade	  (development	  of	  fluid	  around	  the	  heart)	  <1%	  
	  
What	  are	  the	  possible	  benefits	  of	  taking	  part?	  
The	  main	  benefit	   is	   that	  by	  doing	   the	  study	  we	  will	  be	  able	   to	   identify	   the	  best	  site	  to	  implant	  the	  lead	  into	  your	  heart	  and	  increase	  the	  chance	  of	  the	  pacemaker	  improving	  your	  symptoms.	  You	  will	  also	  have	  closer	  follow	  up	  with	  the	  two	  extra	  hospital	  visits	  after	  the	  pacemaker	  is	  implanted.	  	  	  
What	  happens	  when	  the	  research	  study	  stops?	  You	   will	   still	   be	   routinely	   followed	   up	   in	   our	   clinic	   and	   monitored	   by	   your	  cardiologist.	  The	  results	  of	  the	  supplementary	  tests	  will	  not	  exclude	  you	  from	  any	  useful	  treatment	  approved	  for	  your	  condition.	  
What	  if	  there	  is	  a	  problem?	  Any	  complaint	  about	  the	  way	  you	  have	  been	  dealt	  with	  during	  the	  study	  or	  any	  possible	  harm	  you	  might	   suffer	  will	   be	   addressed.	  The	  detailed	   information	  on	  this	  is	  given	  in	  Part	  2.	  
Will	  my	  taking	  part	  in	  the	  study	  be	  kept	  confidential?	  	  Yes.	   All	   the	   information	   about	   your	   participation	   in	   this	   study	   will	   be	   kept	  confidential.	  	  The	  details	  are	  included	  in	  Part	  2.	  
Contact	  Details:	  Prof.	  Reza	  Razavi.	  St	  Thomas’	  Hospital,	  4th	  Floor	  Lambeth	  Wing.	  Telephone	  02071885440.	  Mobile	  phone:	  07900240841	  
This	  completes	  Part	  1	  of	  the	  Information	  Sheet.	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If	   the	   information	   in	   Part	   1	   has	   interested	   you	   and	   you	   are	   considering	  
participation,	  please	  continue	  to	  read	  the	  additional	  information	  in	  Part	  2	  
before	  making	  any	  decision.	  
	   	  




What	  if	  relevant	  new	  information	  becomes	  available?	  Sometimes	   during	   the	   course	   of	   a	   research	   project,	   new	   information	   becomes	  available	   about	   the	   procedure	   that	   is	   being	   studied.	   	   If	   this	   happens,	   your	  research	  doctor	  will	  tell	  you	  about	  it	  and	  discuss	  whether	  you	  want	  to	  or	  should	  continue	  in	  the	  study.	  
What	  will	  happen	  if	  I	  don’t	  want	  to	  carry	  on	  with	  the	  study?	  If	  you	  withdraw	  from	  the	  study,	  we	  will	  need	  to	  use	  the	  data	  collected	  up	  to	  your	  withdrawal.	   We	   will	   ask	   you	   to	   keep	   in	   contact	   with	   us	   to	   let	   us	   know	   your	  progress.	  
What	  if	  there	  is	  a	  problem?	  
Complaints:	  If	  you	  have	  a	  concern	  about	  any	  aspect	  of	  this	  study,	  you	  should	  ask	  to	   speak	  with	   the	   researchers	  who	  will	  do	   their	  best	   to	  answer	  your	  questions	  (Prof.	   Reza	  Razavi	   02071885440).	   	   Should	   you	  wish	   to	   complain	   formally,	   you	  can	  do	  this	  through	  the	  NHS	  Complaints	  Procedure.	  	  Details	  can	  be	  obtained	  from	  the	  hospital.	  
Harm:	  	  In	  the	  event	  that	  you	  are	  harmed	  during	  the	  research	  study	  there	  are	  no	  special	   compensation	   arrangements.	   	   If	   you	   are	   harmed	   and	   this	   is	   due	   to	  someone’s	   negligence	   then	   you	   may	   have	   grounds	   for	   a	   legal	   action	   for	  compensation	   against	   Guy’	   &	   St.	   Thomas’	   NHS	   Trust	   but	   you	  may	   have	   to	   pay	  your	  legal	  costs.	  The	  normal	  National	  Health	  Service	  complaints	  mechanisms	  will	  still	  be	  available	  to	  you.	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Will	  my	  taking	  part	  in	  this	  study	  be	  kept	  confidential?	  Procedures	   for	   handling,	   processing,	   storage	   and	   destruction	   of	   your	   data	   are	  compliant	  with	  the	  Data	  Protection	  Act	  1998.	  All	   information	  which	   is	   collected	   about	   you	  during	   the	   course	   of	   the	   research	  will	   be	   kept	   strictly	   confidential.	   	   Any	   information	   about	   you	  which	   leaves	   the	  hospital	   will	   have	   your	   name	   and	   address	   removed	   so	   that	   you	   cannot	   be	  recognised	  from	  it.	  Your	  data	  will	  be	  collected	  from	  the	  referral	  letter	  and	  patient	  notes,	  as	  well	  from	  your	  oral	  information;	  Data	  will	  be	  automatically	  stored	  securely,	  in	  an	  encrypted	  format;	   Authorised	   persons	   such	   as	   researchers,	   regulatory	   authorities	   and	  Research	   and	  Development	   (for	  monitoring	   of	   the	   quality	   of	   the	   research)	  will	  have	  assess	  to	  these	  data;	  Data	  will	  be	  retained	  for	  15	  years.	  Your	  own	  GP	  may	  be	  notified	  of	  your	  participation	  in	  the	  trial,	  after	  your	  consent.	  
What	  will	  happen	  to	  the	  results	  of	  the	  research	  study?	  These	   will	   be	   published	   in	   a	   research	   paper	   with	   the	   aim	   of	   advancing	   the	  knowledge	  of	  MRI	  and	  heart	   failure.	  All	  patient	   identities	  are	   treated	  as	  strictly	  confidential	  and	  anonymous	  in	  any	  publication.	  
Who	  is	  organising	  and	  funding	  the	  research?	  The	   research	   is	   organised	   by	   Prof	   Reza	   Razavi	   and	  will	   be	   partially	   funded	   by	  Kings	   College	   London.	   The	   study	   is	   being	   undertaken	   primarily	   for	   academic	  reasons.	  
Who	  has	  reviewed	  the	  study?	  The	   study	  has	  been	   independently	   reviewed	  by	   the	   St	  Thomas’	  Hospital	   Ethics	  Committee.	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A	  copy	  of	  the	  information	  sheet	  and	  a	  signed	  consent	  form	  to	  keep	  will	  be	  
given	  to	  you.	  
	  
Thank	  you	  for	  considering	  taking	  part	  or	  taking	  time	  to	  read	  this	  




Rayne	  Institute,	  KCL	  Guy's	  	  &	  St	  Thomas'	  NHS	  Trust	  St	  Thomas'	  Hospital	  Lambeth	  Palace	  Road	  London	  	  	  SE1	  7EH	  	  Tel	  :	  0207	  188	  	  1026	  Fax	  :	  0207	  188	  1011	  Study	  Number:	  09/H0802/37	  




Title	  of	  Project:	  Biophysical	  modelling	  to	  guide	  selection	  and	  implantation	  
of	  CRT	  Name	  of	  Researcher:	  Professor	  Reza	  Razavi	  	  
	   	   	   	   	   	   	   	   	   Please	  initial	  box	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1.	   I	   confirm	   that	   I	   have	   read	   and	   understand	   the	   information	   sheet	   dated	  04/03/2009	   (version	  1)	   for	   the	   above	   study.	   I	   have	   had	   the	   opportunity	   to	  consider	   the	   information,	   ask	   questions	   and	   have	   had	   these	   answered	  satisfactorily.	  	  2.	   I	   understand	   that	   my	   participation	   is	   voluntary	   and	   that	   I	   am	   free	   to	  withdraw	   at	   any	   time,	  without	   giving	   any	   reason,	  without	  my	  medical	   care	   or	  legal	  rights	  being	  affected.	  	  3.	   	   	   I	   understand	   that	   relevant	   sections	   of	   any	   of	   my	   medical	   notes	   and	   data	  collected	   during	   the	   study	   may	   be	   looked	   at	   by	   responsible	   individuals	   from	  regulatory	  authorities	  or	   from	  the	  NHS	  Trust,	  where	   it	   is	  relevant	   to	  my	  taking	  part	  in	  this	  research.	  	  I	  give	  permission	  for	  these	  individuals	  to	  have	  access	  to	  my	  records.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  4.	   I	  agree	  to	  my	  GP	  being	  informed	  of	  my	  participation	  in	  the	  study.	  	  5.	  	  	  I	  agree	  to	  take	  part	  in	  the	  above	  study.	  	  _________________________	   __________________	   ________________	  Name	  of	  Patient	   Date	   Signature	  	  	  	  _________________________	   ________________	   ________________	  Name	  of	  Person	  taking	  consent	   Date	   Signature	  (if	  different	  from	  researcher)	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  _________________________	   ________________	   ________________	  Researcher	   Date	   	   Signature	  	  	   When	  completed,	  1	  for	  patient;	  1	  for	  researcher	  site	  file;	  1	  (original)	  to	  be	  kept	  in	  medical	  notes	  	  	  
